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Abstract
The pulmonary delivery of drugs is an attractive route of administration because of
the large surface area and high permeability of the airway epithelium, the main
barrier for drug absorption. The large majority of inhaled drugs are used to manage
asthma and Chronic Obstructive Pulmonary Disorder (COPD), such as inhaled
corticosteroids and ȕ2-adrenergic receptor agonists. Local delivery of small
molecules often results in sub-optimal pharmacokinetics characterised by short
absorption times (tmax) and high systemic concentrations (Cmax). Numerous drug
delivery strategies have been attempted to increase lung retention time, including
drug encapsulation in microspheres, the use of polymeric excipients, or the
formation of low solubility drugs. So far, drug conjugation strategies have been
limited to decreasing the prodrug solubility. The non-permanent conjugation of
small molecules to a large hydrophilic polymer has not been studied for pulmonary
delivery. The rationale behind such a strategy is that small molecules are mainly
absorbed through the epithelium by passive diffusion, the absorption rates being
positively correlated to the drug lipophilicity and molecular weight.
This project has therefore been looking at the production, characterisation, in vitro
and ex vivo evaluation of polyethylene glycol (PEG)-ester conjugates for the
sustained delivery of drugs to the lung. This thesis presents the successful oxidation
and subsequent esterification of PEG of various molecular weights with
prednisolone (a corticosteroid) and salbutamol (a ȕ2-adrenergic receptor agonist).
Overall, four ester conjugates of PEG and prednisolone were studied: three
disubstituted PEG of 1000, 2000 and 3400 Da (PEG-Pred2) and one
monosubstituted PEG of 2000 Da (mPEG-Pred1). Three ester conjugates of PEG
and salbutamol were also prepared but they were unstable in buffers at pH 6.2 to
8.0, and were not studied any further. The hydrolysis rates of PEG-prednisolone
conjugates were pH dependant and the monosubstituted conjugate hydrolysed twice
as slowly as the disubstituted ones. In vitro stability was not molecular weight
dependant. Hydrolysis half lives of PEG-prednisolone conjugates were 35 and 70 h
at pH 6.2, 3 and 6 h at pH 7.4 and 1 and 2 h at pH 8.0 for mPEG-Pred1 and PEG-
Pred2 respectively. The cytotoxicity of PEG-prednisolone conjugates was assessed
using the lactate dehydrogenase membrane integrity test on the human bronchial
epithelial Calu-3 cell culture model. Conjugates of 1000 and 2000 Da were not
cytotoxic to Calu-3 cells, up to 1000 ȝM. PEG3400-Pred2 however, was cytotoxic at
concentrations above 1 ȝM and thus this compound was not studied any further.
The three remaining conjugates were stable in the presence of Calu-3 cells, with
half lives comparable to that of autohydrolysis. The local pharmacokinetics of
esters of PEG2000 and prednisolone were compared to that of prednisolone alone in
an isolated and perfused rat lung (IPRL). For the lead compound PEG-Pred2, Cmax
was reduced by a factor 3 and tmax increased by 45%, compared to prednisolone.
The apparent prednisolone absorption half life from the lung was 1 min with
prednisolone and 8 min with PEG-Pred2.
This study illustrated the feasibility of a polymeric drug conjugate strategy for
sustained release of drugs to the lung. The conjugates exhibited good in vitro
stability which was translated into improved pharmacokinetics and longer residence
time ex vivo in the IPRL. Further studies must be conducted to fully assess the role
of esterases in the pulmonary hydrolysis of the conjugates and in vivo experiments
would be necessary to verify the safety of the conjugates and efficacy of the drug.
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Salbutamol FB: Salbutamol Free Base
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THF: Tetrahydrofuran
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tmax: Time to reach maximum blood concentration
TNF-Į: Tumor Necrosis Factor alpha
TOF: Time Of Flight
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1Chapter I. General Introduction
I.1. Structure of the lung
The pulmonary delivery of drugs is a challenging pathway because the lung is a
complex organ, due to its geometry and high humidity content [1] (Fig.I.1). Weibel
described the lung as a human bronchial tree, with 23 dichotomous generations
terminated by the alveoli (respiratory sacs). The airways (trachea, bronchi and
bronchioles) are the branches of the tree and the alveoli are the leaves [2].
Fig.I.1. Schematic of the human respiratory tract, reprinted from [3]
2The main barriers for drug absorption from the lung are the epithelia (Fig.I.2):
thicker in the airway (58 ȝm) and thinner in the alveolar region (0.2 ȝm) [4, 5]. The
airway epithelium is composed of four major classes of cells: basal cells (progenitor
cells), ciliated cells, goblet cells and Clara cells. The alveolar epithelium, is
composed of type I (broad and thin) and type II (small and compact) cells.
Nonetheless, the lung is a very attractive route of administration because of its large
surface area (40-100 m2) [6] and because of its permeable epithelium [7]. Drugs
delivered via the pulmonary route are rapidly absorbed to the general circulation,
avoiding gastrointestinal absorption and first pass metabolism [8].
Fig.I.2. Schematic of the human airway epithelia, reprinted from [4]
I.2. Drug inhalation
Inhalation has been used to deliver medicines to the lung for more than 4000 years,
when people smoked the leaves of Atropa belladona to suppress cough [9].
Nowadays, the large majority of inhaled drugs are used to manage asthma and
Chronic Obstructive Pulmonary Disorder (COPD) [10].
3Asthma is a chronic lung disease characterised by loss of breath and wheezing, it is
life threatening if untreated. An asthma attack can be triggered by the environment
(e.g. dust, pollen, smoke, irritants, ...), physical activity or during the night. The
mechanisms or causes of an asthma attack are not fully understood but it seems
airway hypersensitivity causes the smooth muscle to contract, reducing the airway
diameter. According to the World Health Organisation (accessed 27 Aug 2012),
235 million people suffer from asthma worldwide.
COPD is a chronic life-threatening pulmonary disease characterised by a chronic
cough, constant difficulties to breathe, a need for air. The primary cause of the
disease is smoking which leads to a reduction in airway diameter, production of
sputum (saliva and mucus) in the lung. It is not curable but can be managed.
According to the World Health Organisation (accessed 27 Aug 2012), 64 million
people suffer from COPD worldwide.
Other lung conditions are also treated by inhaled delivery of drugs. Pneumonia can
be treated by increasing lung mucociliary clearance, using aerosolised saline
solutions, by stimulating the production of antimicrobial proteins, by delivery of
inhaled cytokines or antibiotics [11]. The delivery of antibiotics to the lung is also
used to manage cystic fibrosis [12], and particularly fight against Pseudomonas
aeruginosa and Staphylococcus aureus infections. Pseudomonas aeruginosa
infection in patients with cystic fibrosis is currently managed by administration of
nebulised antibiotics; however, there is a need for new devices and formulations of
the antibiotics to improve patient compliance [13]. Inhaled Zanamir (Relenza) is
currently used for both treatment and prophylaxis of influenza A and B. The drug
has been approved by the Food and Drug Administration (FDA) in 1999 and works
by binding to viral neuraminidase, thus inhibiting the virus ability to escape the
4infected cell and limiting the viral spread [14]. Pulmonary arterial hypertension can
be treated by treprostinil, a prostacyclin analog. For some patients, the inhalation
route of administration is more convenient compared to continuous subcutaneous or
intravenous infusions and the risk of blood stream infection and systemic exposure
are minimised [15, 16].
Despite a great potential, the lung is only marginally used to deliver drugs
systemically. Vaccines to prevent influenza [17, 18] and inhaled anaesthetics [19]
are the two main classes of therapeutics systemically delivered to the the body via
lung administration. Nicotine, a recreational drug, is rapidly delivered to the brain
after smoking tobacco [20], a human practice since the Mayans [21].
Proteins have been administered by inhalation for local delivery (e.g. Dornase alfa,
Genentech) to treat cystic fibrosis and for systemic delivery [22]. The development
of the first inhaled insulin (Exubera(c)) was a scientific success but a commercial
failure and has been discontinued after a year on the US market [23]. Inhaled
delivery of growth hormone in children has been investigated but due to low
bioavailability, it is unlikely that the product will be further developed [24].
For both systemic and local delivery of drugs to or via the lung, there is a need to
understand the fate of inhaled compounds.
5I.3. Inhaler devices to administer drugs to the lung
Aerosols are generated with a nebuliser, metered dose inhaler (MDI) or dry powder
inhaler (DPI) [5, 25]. A suspension or a solution of the active ingredient(s) is
generally nebulised as a mist by a jet or ultrasonic nebuliser [26]. The jet nebuliser
is based on the Bernoulli principle and the device produces a mist of the drug
suspension or solution using a drop in pressure at the liquid surface, generated by
the gas flow accelerated through a Venturi (Fig.I.3). The ultrasonic nebuliser uses
the vibration of a piezoelectric crystal to generate waves at the liquid surface and
produce fine aerosolised droplets (Fig.I.4).
Fig.I.3. Schematic of a jet nebuliser, adapted from [26]
Fig.I.4. Schematic of an ultrasonic nebuliser, reprinted from [26]
6Nebulisers are not easily transportable and require a long administration time; they
are mainly used by people unable to operate other devices.
A pressurised metered dose inhaler delivers aerosol of the drug in solution or
suspension in a propellant. The propellant is liquefied in the pressurised canister
and depending on the drug physicochemical properties, the active ingredient can be
dissolved or formulated as a suspension. A metered dose is dispensed and upon
actuation, the liquid is expelled from the metering chamber generating an aerosol of
the medicine (Fig.I.5). The propellant evaporates instantly due to its high vapour
pressure (and low boiling point) [27]. Ozone depleting propellants have now been
replaced by hydrofluorocarbons (HFA).
Fig.I.5. Schematic of a pressurised metered dose inhaled, reprinted from [28]
Dry powder inhalers are more recent delivery devices [29]. As the name suggests,
the drug and excipients (often lactose) are stored in the device as dry powders and
can be aerosolised by the patients breath-actuation (passive DPIs) or by
compressed air (active DPIs, e.g. Aspirair®). They can be single dose (e.g.
7Handihaler®) or multi dose (e.g. Turbuhaler®, Fig.I.6). Aerosols are often generated
by air flow turbulences created by the Venturi design of the chamber [30].
Fig.I.6. Schematic of Turbuhaler®: a multi dose, breathe-activated DPI,
reprinted from [31]
These aerosol devices usually generate particles of around 1-35 ȝm in diameter
[32], but the particle size can vary depending on the drug, the device and the user.
I.4. Deposition of drugs in the lung
The aerosolised particle aerodynamic diameter, shape and size influence the lung
deposition pattern (Fig.I.7). Overall, small particles (aerodynamic diameter < 2 ȝm)
penetrate the lung deeply and are mainly deposited in the lower respiratory tract.
Such particles can be used to systemically deliver drugs via the lung. Large
particles (aerodynamic diameter > 6ȝm) are mainly deposited in the upper airways
and they have a limited clinical efficacy. Particles of intermediate size (2 ȝm <
aerodynamic diameter < 6 ȝm) are mainly deposited in the central and small
8airway. Such particles are the most relevant for local action of drugs. Several
concomitant deposition mechanisms are taking place following inhalation of
aerosolised particles. Small particles (aerodynamic diameter < 0.5 ȝm) are mainly
deposited in the alveolar region of the airway by Brownian diffusion, random
motion. Large particles (aerodynamic diameter > 5 ȝm) are mostly deposited by
inertial impaction. Such particles are not affected by the airway airflow and due to
their size, they follow their initial trajectories (inertia) and soon impact on an
airway wall. Particles of intermediate size (1 ȝm < aerodynamic diameter < 8 ȝm),
are mostly deposited by gravitational sedimentation. Particle size and residence
time positively influence deposition by gravitational sedimentation. The particle
shape greatly influences deposition by impaction and charged particles can be
electrostatically attracted to the airway walls [33].
Fig.I.7. Influence of particle aerodynamic diameter and lung deposition,
reprinted from [5]
Ultimately, the clinical efficacy of the drug is affected by the lung deposition
pattern. For example, a study by P. Zanen et al. [34] determined the optimal particle
9size of salbutamol and ipratropium bromide dry powder to be approximately 3 ȝm.
They prepared monodisperse aerosols of 1.5, 2.8 and 5 ȝm particle size and treated
a group of patients suffering from airflow obstruction. The treatment outcome was
measured by lung function tests such as the mean forced expiratory volume in one
second (FEV1), or the maximum expiratory flow at 75/50 % of the forced vital
capacity (MEF75/50). The results indicated that out of the three particle sizes,
aerosols of 2.8 ȝm induced statistically significant better improvements in lung
function tests, with both salbutamol (20 ȝg) and ipratropium bromide (8 ȝg) [34].
The type of formulation (dry powder, solution or suspension) can influence the
dissolution rate of the drug in lung fluids, alter the pharmacokinetic profile of the
drug and ultimately modify the systemic exposure or clinical efficacy [35].
I.5. Fate of an inhaled aerosolised drug in the airways
Once deposited, the particles are solubilised in the lung fluids [3], Fig.I.8 illustrates
the fate of an inhaled aerosol deposited in the airways. In the case of a nebulised
solution, the drug is already solubilised and diffuses rapidly into the lung fluids.
Other aerosolised drugs will take longer to diffuse into the lung surface depending
on the drug solubility properties and the particle shape and composition. Large (> 6
ȝm), insoluble particles are rapidly cleared by mucocilliary clearance [36]. This
defence mechanism is the result of the synchronised movement of the cilia (located
on the apical surface of differentiated ciliated cells), and the resulting flow of
mucus is propelled out of the airway, to the oropharynx where it is swallowed or
expectorated [3]. A solubilised drug in the mucus is then available for local
metabolism. Although the lung is not as metabolically active as the liver, there are
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phase I, phase II and other enzymes in the lung. Regional distribution of these
enzymes is heterogeneous and there are differences between cell types, even within
the same airway section. There are metabolic differences between species and in
particular between human and rodents [37]. Pulmonary absorption occurs when the
drug solubilised in the mucus passes through to the epithelium and then permeates
the epithelium [38]. Hydrophobic, mucus soluble small molecules rapidly diffuse
through the epithelium by transcellular passive diffusion. It is believed that
hydrophilic compounds are transported across the lung membrane by paracellular
transport (between the cells), and the molecule charge may play a significant role in
the absorption rate [39]. In vitro studies indicate that some small molecules could
also be actively transported by so-called drug transporters. For example, the
Adenosine-5-triphosphate-binding cassette (ABC) transporters (such as P-
glycoprotein), or Organic Cation Transporters (OCT) or even peptide transporters
are thought to actively transport drugs in vitro, either as efflux transporter (i.e. back
to the apical side of the epithelium) or uptake drug transporters (i.e. from apical to
basal side) [40, 41]. ABC transporters are thought to be part of the defence
mechanisms, preventing cellular accumulation of xenobiotics. OCTs transport
positively charged molecules such as hormones, metabolites, in either direction.
Water solubility, lipophilicity and molecular weight play a significant role in the
absorption rate of small molecules that are not actively transported [42]. Thus, a
small, lipophilic, yet water soluble, molecule will cross the epithelium faster than a
large hydrophilic one. Typical inhaled small molecules up to 1000 Da are passively
absorbed through the epithelia resulting in rapid, high blood concentration [39].
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Fig.I.8. Fate of inhaled drugs in the lung
Aerosolised particles deposited (1) in the airways dissolve (2) in the mucus. Insoluble large particles may be removed from the airway by mucociliary
clearance (3). Dissolved solutes are then absorbed across epithelial cells either passively by transcellular diffusion (4a) or by paracellular transport (4b) or
actively, by drug transporters (4c). Throughout the process, drugs can be metabolised (5).
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I.6. Pharmacokinetic profiles of drugs administered by inhalation
Because of high lung absorption rates, the resulting systemic delivery of inhaled
drugs often offers a sub-optimal pharmacokinetic profile, characterised by a high
maximum blood concentration (high Cmax), that is quickly reached (short tmax). The
resulting local effects are minimised because of the short residence time of drugs in
the lung and the systemic side effects are increased because of high Cmax [43].
The therapeutic index is defined as the ratio between the desired and undesired
effects of a drug. A longer lung residence time would improve the overall
therapeutic index of inhaled drugs for local effect [44-47] and for a given dose, an
increased lung retention time would decrease the Cmax. Rosenborg et al. [47]
described for the first time in 2002 a relative therapeutic index between formoterol
and salbutamol. They measured the FEV1 as a positive outcome (desired effect) and
potassium serum concentration as a side effect after inhalation of the drugs at
different doses. They used 28 asthmatic patients and the results although not
statistically significant (maybe due to the low number of patients), illustrated the
principle of such a concept. Formoterol was 215 times more potent than salbutamol
regarding FEV1 increase (positive outcome) and 88 times more potent than
salbutamol regarding suppression of serum potassium (negative outcome). The
relative therapeutic index (ratio between positive outcome and side effect) was 2.5
in favour of formoterol [47].
The therapeutic index of inhaled corticosteroids can be clinically assessed by using
the morning Peak Expiratory Flow rate as a desired effect of the treatment and
systemic cortisol suppression as a side effect [44, 45]. The therapeutic index of a
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glucocorticoid can be improved by limiting oral bioavailability, increasing lung and
receptor affinity [46], concepts that are still the basis of new drug designs [48].
I.7. Controlled delivery of drugs administered to the lung
Extensive work has been carried out to optimise the delivery of inhaled small
molecules and macromolecules. There are three main strategies to develop
sustained release drug delivery to the airways. One can decrease the drug solubility
in mucus, slow down the cellular uptake/permeation rate through the airway
epithelium or use a sustained release formulation of the drug [49].
Fluticasone propionate, lipophilic (log P = 3.4), with low aqueous solubility (water
solubility 0.51 mg.L-1) and budesonide, less lipophilic (logP = 1.9) with higher
aqueous solubility (27.98 mg.L-1 [50]) are two inhaled corticosteroids (Fig.I.9).
Fig.I.9. Fluticasone propionate (A) and budesonide (B)
When administered to healthy patients (1000 ȝg twice daily), using dry powder
inhalers, the pharmacokinetic profiles of the two drugs were significantly different.
Budesonide had a shorter tmax (17 min) and higher Cmax (3.8 nmol) compared to
fluticasone propionate (tmax 100 min, Cmax 0.5 nmol). The fraction of the deposited
dose absorbed by the lung was higher for budesonide (flung: 32%) compared to
fluticasone propionate (flung: 12%) [51]. It was concluded that fluticasone
O
O
O
OH
OH
O
A. B.
O
O
F
O
F
OH
O
S
F
14
propionate exhibited a slower absorption due to its lower mucus solubility. The
lower availability of fluticasone propionate was explained by mucociliary clearance
extracting undissolved particles of fluticasone propionate away from the airways
[52].
Drug conjugation of compounds delivered by inhalation was attempted in the late
1970s with esters of terbutaline such as ibuterol [53] and esters of isoproterenol
such as bitolterol mesylate [54], the latter was approved by the FDA in 1984
(Fig.I.10). They were designed to reduce the drug solubility in lung fluids and
therefore, slow down the absorption rate. They also prolonged lung exposure via
increased circulation in blood after absorption by the lung. The active ȕ2-adrenergic
receptor agonist were released upon hydrolysis of the ester link in lung, blood and
other tissues. Lipid conjugation of inhaled corticosteroids was also used to modify
the dissolution rate of the drug with similar results [55].
Fig.I.10. Terbutaline (A), ibuterol (B), isoproterenol (C) and bitolterol mesylate
(D)
Sustained release formulations are based on the slow escape of drugs from a
microsphere. Liposome-based formulations of drugs administered by injection have
already been approved to treat cancer (e.g. DOXIL®, doxorubicin HCl liposomal
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formulation). Liposomes are microspheres composed of a bilayer of amphiphilic
molecules, with a hydrophilic core. They can encapsulate a wide range of
molecules, hydrophilic drugs are trapped in the liposome core, lipophilic drugs can
be located in the lipidic bilayer and nucleic acid based therapeutics at the liposome
surface (Fig.I.11). Several studies have been performed to assess the potential of
liposomal formulations of drugs for lung delivery. The results seem to be promising
since liposomes have similar properties to the lung surfactant, they are stable
suspensions, and they can target alveolar macrophages [56]. Liposomal
formulations of drugs administered as dry powder or by nebulisation improved the
pharmacokinetic profiles of drugs [57]. Tacrolimus, an immunosuppressive agent
used after lung transplantation, was formulated as a liposomal dry powder and the
resulting pharmacokinetic profile was improved after administration in rats [58].
The anaesthetic fentanyl was administered by nebulisation to a group of volunteers
as a mixture of free and liposome-encapsulated formulation. The resulting
pharmacokinetic profile was improved compared to intravenous injection of the
free drug [59]. The anticancer drugs paclitaxel and camptothecin were prepared as
liposome-based formulations and following inhalation of nebulised suspensions,
sustained release profiles in the lung were obtained [60].
Fig.I.11. Structure of an unilamellar liposome, reprinted from [56]
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Formulations of microparticles of an active ingredient and a polymer have been
used to achieve sustained delivery of drugs following inhalation. The drugs escape
from the polymer by three mechanisms: diffusion from the particle, swelling of the
polymer and then diffusion of the drug out of the polymer, or following polymer
degradation (Fig.I.12).
Fig.I.12. Drug escape from polymeric microspheres: diffusion (a), polymer
swelling followed by drug diffusion (b), or microsphere degradation (c). Reprinted
from [61]
The shading represents drug concentration, the darker, the greater the concentration
The polymers used are either natural (such as albumin, chitosan, hyaluronic acid) or
synthetic polymers (such as Poly(lactic acid) (PLA), Poly(lactic-co- glycolide acid
(PLGA), PEG) [62]. A systemic sustained delivery of a macromolecule was
achieved using chitosan encapsulated insulin delivered by inhalation. Insulin was
successfully encapsulated in chitosan microspheres and formulated as dry powder
using lactose. After delivering the formulation in vivo to rats, the resulting
hypoglycemic effect was prolonged when using the chitoasn-based formulation
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compared to insulin alone [63]. A Korean group of researchers obtained a local
sustained delivery of an anticancer small molecule using PLGA encapsulated
doxorubicin, delivered by inhalation to mice. PLGA microparticles were
successfully loaded with doxorubicin, formulated as dry powder and administered
by insufflation to anaesthetised melanoma-bearing mice. The treated group showed
significant tumour recession. Doxorubicin was detected in the lungs 14 days after
drug delivery, illustrating the prolonged lung retention of the formulation [64].
Inorganic-based microparticles have also been investigated for sustained drug
delivery of anti-inflammatory drugs. Dexamethasone phosphate was successfully
loaded into calcium pyrosphate-based fibrous microspheres. Upon intratracheal
instillation to rats, a sustained anti-inflammatory effect of 42 hours was obtained
with the formulation as opposed to the drug alone [65].
I.8. Models to study drug delivery to the lung
Aerosol properties and capabilities to deliver drugs to the lungs can be tested in
vitro. A large number of parameters can be measured to assess aerosol properties
such as aerodynamic diameter, morphology, stability, density, solubility, drug
content, zeta-potential [66]. The particle deposition pattern can be predicted using
theoretical drug deposition models and experimentally assessed with cascade
impactors. There are several mathematical models of the airways, differing in their
assumptions and simplifications. The models of the human tree (Fig.I.13), proposed
by Horsfield in 1971 are amongst the most realistic [67]. Briefly, two mathematical
models of a normal bronchial tree were designed based on physiological
measurements obtained after preparation of a human airway resin cast. The two
proposed models took into account the lung asymmetry, and are based on the lung
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dichotomous branching system: one parent branch divides into two branches
creating a new daughter branch that can divide too. Each new division gives a new
branch generation to which were associated measurements (such as airway
diameter, angle of branching) [68]. The model is still used today to predict aerosol
deposition in the human lung with modern computational mathematic.
Fig.I.13. 3D visualisation of a bronchial tree model, reprinted from [69]
Cascade impaction is the recommended (US pharmacopeia) method of assessing
aerosol aerodynamic diameter. The technique is a useful tool to simulate where not
only the aerosol but more specifically the active pharmaceutical ingredient (API) is
deposited. The general principle behind a cascade impactor is based on the tree
model, where successive branches have decreasing diameters. The aerosol passes
through nozzles of decreasing diameters, impacted particles are collected on plates
and these can then be analysed to quantify the API Fig.I.14.
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One of the most common systems is the Andersen cascade impactor, made of up to
8 stages. Mainly due to low flow rates, the next generation impactors were designed
for the pharmaceutical industry [70].
Fig.I.14. Schematic of a cascade impactor
Other in vitro systems are commonly used to assess drug activity on lung tissues.
Cell culture systems are either based on primary cell culture or cell lines or co-
cultures. Primary cell culture is the in vitro model closest to the in vivo situation
since the tissue exhibits most of the native attributes. However, cost, donor
availability and technical difficulties of working with such models often limit their
use. They are the only reliable model of the alveolar region (type I or type II
pneumocytes) since the human alveolar cell line A549 does not form tight
junctions. Several in vitro models of human respiratory epithelia have been
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developed such as the two human bronchial epithelial cell lines 16HBE14o- and
Calu-3. These models, although useful to reduce the use of animal experiments,
have to be characterised and proven to mimic the actual tissue [71]. These tissue
culture models need to display epithelium-like phenotype, to grow at an air/liquid
interface, and to behave as proper barriers, by forming functional tight junctions.
Such barrier properties are measured by Transepithelial Electrical Resistance
(TEER). Tissue cultured models have been investigated to assess drug permeability
[72] with good correlations to the in vivo situation [73]. These models have also
been extensively studied for their drug transporters such as P-glycoprotein [74],
multidrug resistance proteins [75] and drug metabolism characteristics [76, 77].
The isolated and perfused lung is an ex vivo model. The lung of an anaesthetised
animal (rat or guinea pig are the most common) is dissected, perfused with a
buffered albumin solution and ventilated through the trachea. It can be maintained
in an artificial thorax for up to three hours. Aerosols or solutions can be
administered via the trachea and the perfusate is either recirculated or not (single
pass). Permeation rate and drug absorption properties are directly determined by
measuring the amount of drug in the perfusate. The structural integrity and
functionality of the organ are maintained and the model is a close representation of
the in vivo situation. Isolated and perfused lungs are particularly useful to determine
permeation properties of drugs through the airways. Indeed, all the drug that has
crossed the epithelium is recovered in perfusate, i.e. there is no excretion or
metabolism once the drug has reached the perfusate, whereas in vivo the drug
reaches the general circulation and it can be metabolised and excreted [73, 78].
Early pharmacokinetic in vivo studies following administration of drugs to the lung
are usually conducted in rodents (often rat or mouse). The animals are sacrificed at
predetermined interva
remaining in the lung
[79].
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The lung possesses metabolic activity although lower than the liver [80] and in
particular, the capacity to metabolise esters [81, 82], so an ester link was used to
conjugate a polymer to inhaled model drugs.
Since asthma and COPD are the most common respiratory conditions, two model
drugs administered to treat these diseases were used: a corticosteroid and a ȕ2-
adrenergic receptor agonist. Inhaled corticosteroids (IC) are used locally for their
immunosuppressive and anti-inflammatory properties [83]; their mechanism of
action is complex [84] and they can result in topical (ear, nose and throat
infections) and systemic side effects (such as nausea, viral gastroenteritis, cataracts,
osteoporosis) [85]. ȕ2-adrenergic receptor agonists relax the smooth muscle and
therefore decrease airway bronchoconstriction [86]. Local (e.g. pharyngitis, rhinitis)
and systemic side effects (such as headache, tachycardia, pain, dizziness) can also
be observed [87].
Prednisolone (11ȕ,17,21-Trihydroxypregna-1,4diene-3,20-dione) as a model
corticosteroid and salbutamol sulfate (Į1-[(tert-butylamino) methyl]-4-hydroxy-m-
xylene-Į,Į-diol sulfate (2:1) salt) as model ȕ2-adrenergic receptor agonist were
chosen (Fig.I.16).
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Fig.I.16. Chemical structures of salbutamol sulfate (A) and prednisolone (B)
Salbutamol possesses four reactive groups: one primary and one secondary hydroxyl
group, one phenyl group and one amine group. Prednisolone possesses three reactive
groups: one primary, one secondary and one tertiary hydroxyl group.
Natural, synthetic and pseudo-synthetic polymers have been used to produce drug
conjugates of various molecular weights and with different linkers. Particularly,
polyethylene glycol (PEG) is the most extensively used polymer for drug
conjugation with either macromolecules or small drugs [88]. PEGylation of
proteins has been used to increase the drug circulation time and decrease the protein
immunogenicity. Several products are on the market since the first approval of
PEG-Adenosine deaminase (Adagen®) in 1990. Polymer conjugation of small
molecules is also currently investigated mainly for cancer therapies [89-91]. Enzon
Pharmaceutical and Nektar Therapeutics are two leading companies in the field of
polymer-drug conjugation. Greenwald reviewed the permanent and labile
conjugations of small and large molecular weight PEG with macromolecules and
small drugs. The conjugates improved delivery properties and therapeutic activities
of the chemotherapeutic agents [92].
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Polyethylene glycol was chosen as a polymeric drug carrier for the thesis since it
possesses reactive hydroxyl group(s) (Fig.I.17) that can be coupled to drugs, it is
commercially available in a wide range of molecular weights, and it is known to be
biocompatible, and non toxic [93]. Native PEG (terminated with two hydroxyl
groups) and monomethoxyPEG (mPEG, terminated with one hydroxyl and one
methyl group) are thought to be mainly excreted in urine, with longer body
residence time for higher molecular weight PEG [94, 95].
Fig.I.17. Chemical structures of native PEG (A) and monomethoxyPEG (B)
PEG (3350 Da) was found to be non toxic for the rat lung [96], and the lung
permeability of mPEG-Fluorescein (thiourea bond) followed a first order decay,
with a half life dependant of the polymer molecular weight up to 5 kDa. mPEG2000-
Fluorescein had a half life of 7.2 h and 99% of the dose was cleared from the
airway after 48 h [97].
The overall aim of the thesis was to evaluate the influence of PEG ester conjugates
of salbutamol and prednisolone on the local pharmacokinetic properties in the lung.
The hydrophilic polymer PEG with a molecular weight of 1000, 2000 and 3400 Da
and mPEG2000 was used.
Chapter II deals with the production, purification and characterisation of the
conjugates. In the first step, PEG hydroxyl groups were oxidised to carboxylic
acids. Then, the drugs were reacted with oxidised PEG to form PEG ester
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conjugates. The molecules were purified and characterised by Nuclear Magnetic
Resonance (NMR), Fourier Transformed Infra-Red spectroscopy (FTIR), mass
spectrometry and elemental analysis.
Chapter III illustrates the in vitro testing of the conjugates. Autohydrolysis in
simple buffers at pH 6.2, 7.4 and 8.0 was studied. Cytotoxicity of the compounds
was evaluated on Calu-3 cells, using a membrane integrity test and hydrolysis in
the presence of the cells was studied. Simulations were performed to fully describe
the hydrolysis pathways.
Chapter IV presents the ex vivo evaluation of the lead compounds, using an IPRL
model. The local pharmacokinetics of ester conjugates were studied and compared
to that of the drug alone. Simulations were also performed to measure the critical
pharmacokinetic parameters Cmax and tmax.
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Chapter II. Conjugate synthesis
II.1. Introduction
Polyethylene glycol (PEG) ester conjugation is a widely used technique to
manufacture prodrugs to treat cancer [98-100] or hypertension [101], with
antiherpetic activities [102], or for ocular delivery [103]. The conjugates hydrolyse
in the body and release the active drug. In most published studies, native PEG (i.e.
terminated by hydroxyl groups) is conjugated to a carboxyl group of the drug to
form an ester [100, 101, 103]. Inhaled corticosteroids and ȕ2-adrenergic receptor
agonists do not have carboxyl groups; therefore, the polymer carrier has to provide
the carboxyl group to be reacted with the drug hydroxyl group to form the desired
ester linkage. A common strategy is to use a spacer between PEG and the drug,
often an amino acid such as ȕ-alanine, or an activating compound such as
polyethylene glycol acetic acid N-succinimidyl ester (PEG-NHS) [92, 102, 104].
Oxidised PEG (i.e. PEG terminated by COOH) has also been directly conjugated to
proteins or drugs. MonomethoxyPEG of 2000 Da (mPEG2000) had been oxidised
into mPEGCOOH in a three step reaction that lasted 36 hours [98, 105]. A more
recent approach is to use TEMPO (2,2,6,6-Tetramethylpiperidine-1-oxyl) to turn
hydroxyl groups into carboxylic acids [106].
There are a variety of ways to produces esters. The traditional Fisher esterification
between an alcohol and a carboxylic acid is acid catalysed [107]. Nowadays, this
historical chemical route is not widely used, as more efficient ways of condensation
are available such as the use of acyl chloride that is much more reactive than
carboxylic acid, or coupling reagents such as carbodiimides, or 2-chloro-
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1methylpyridinium iodide (Mukaiyama reagent). In 1996, Greenwald, published
two studies of drugs conjugated with oxidised poly(ethylene glycol) in
dichloromethane (DCM), using the Steglich esterification [108], employing N,N-
diisopropylcarbodiimide (DIC) as coupling agent and (dimethylamine)pyridine
(DMAP) as catalyst [98, 99].
The first part of this chapter will present PEG oxidation. The second and third parts
will present esterifications of oxidised PEG with respectively prednisolone and
salbutamol.
II.2. Material and methods
II.2.1.PEG oxidation
TEMPO oxidation of monomethoxy PEG was described in 2005 by Xing-Qi Li et
al. and produced carboxymethylated PEG in high yields [109].
Scheme.II.1. TEMPO oxidation of primary hydroxyl group
TEMPO and Sodium bromide (NaBr) are used as catalysts
The same strategy was used (Scheme.II.1), with modifications, to produce oxidised
PEG. The polymers were oxidised using TEMPO as catalyst, sodium hypochlorite
(bleach solution, 13% available chlorine) and sodium bromide, in water, at pH 10
and 0°C. To improve the solubility of TEMPO, a fresh solution of the catalyst was
prepared beforehand in warm (40°C) deionised water and thoroughly mixed until
complete dissolution. An ice-cold bleach solution (adjusted to pH 10) was slowly
added to an ice-cold mixture of PEG, NaBr and TEMPO. The pH was monitored
2 NaOCl + R-CH2-OH
TEMPO, NaBr
alkaline pH, 0°C
R-COOH +2NaCl + H2O
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and maintained at 10 with addition of drops of NaOH as necessary. Table. II.1 sums
up the different typical ratios used to produce oxidised PEG of various molecular
weights. The products were then solvent extracted from the aqueous phase with
DCM and precipitated or directly dried depending on their molecular weights.
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Table. II.1. Conditions for PEG oxidations
MW: Molecular Weight
eq OH: mol equivalent to PEG OH groups
*mPEG 2000Da
PEG MW
Da
PEG TEMPO NaBr NaOCl Deionised
water
mLg mmol OH mL
[TEMPO]
M
mmol eq OH mg mmol eq OH mL mmol eq OH
1000 5 10 2.5 0.040 0.100 0.01 432 4.2 0.42 20 35 3.5 120
2000 20 20 3.52 0.057 0.200 0.01 830 8.1 0.40 35 61 3.1 150
2040* 10 4.9 1.21 0.04 0.040 0.01 239 2.3 0.48 14 25 5.1 50
3395 34 20 5.28 0.037 0.200 0.01 833 8.1 0.41 35 61 3.1 150
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II.2.2.PEG-prednisolone
Prednisolone (Fig.II.1) is a corticosteroid that possesses one primary hydroxyl
group, likely to be the most reactive toward esterification. The molecule also has a
secondary and a tertiary hydroxyl group, which are less reactive. Its molecular
weight is 360.44 Da, it is a white crystalline powder insoluble in water and slightly
soluble in methanol and non polar organic solvents.
Fig.II.1. Prednisolone
II.2.2.2. Acyl chloride
The first esterification route investigated consisted of a two step synthesis starting
with chlorination of oxidised PEG to turn the free carboxylic acids into a highly
reactive acyl chloride, using thionyl chloride (SOCl2), Scheme.II.2. PEG acyl
chloride was then reacted with prednisolone in the presence of a tertiary amine
base, acting as an HCl scavenger, thus accelerating the reaction (Table. II.2). The
reaction was followed by NMR. The purification of the products was carried out by
silica gel chromatography, filtration over silica, solvent extraction and precipitation.
The choice of solvents was selected by Thin Layer Chromatography (TLC) and
rationalised by the Hansen Solubility Parameters (HSP) of the solvent mixtures
used.
O
O
CH3
OH
H
H
OHCH3
H
OH
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Scheme.II.2. PEG-prednisolone through acyl chloride route
The first set of reactions concerned the production of PEG-prednisolone ester of
various molecular weights using a standard methodology for acyl chloride
preparation and esterification (Table. II.2). Particularly, PP11 and PP14 illustrate
the conjugation of PEG3400COOH and prednisolone and the development of a
purification methodology. PP08, PP16 and PP13 illustrate the production of
respectively mPEG2000COOH, PEG2000COOH and PEG1000COOH and prednisolone
and their purification (Table. II.3). Schematics of the purification strategies are
presented in Fig.II.2, they consisted of filtrations over silica, precipitations, cation
exchange and silica gel chromatography.
The second set of reactions (using PEG3400COOH) dealt with optimisation of the
chemical reactions. Pyridine (pKa 5.25) was used instead of triethylamine (pKa
10.75) as it is a weaker amine base (PP17). The way the three reactants (PEG acyl
chloride, prednisolone, and pyridine) were mixed together was investigated in
PP20/PP21. The ratio of prednisolone was tested in PP22/PP23. A lower excess of
thionyl chloride (10×) was used in PP26/PP27 to produce PEG acyl chlorides.
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Table. II.2. Experimental conditions for the use of thionyl chloride for esterification of PEGCOOH and prednisolone
Batch PEG type
PEGCOOH Prednisolone Thionyl chloride
Triethylamine /
Pyridine
Solvents, temperature
Time
min
[COOH] mmol/L / COOH / COOH / COOH
PP11
PEG3400
40 1.4 27.5 2.6 75 mL of dry THF, 50 mL of dry DCM, 40°C 1200
PP14 30 1.4 28.1 2.4 70 mL of dry THF, 30 mL of dry DCM, 40°C 1580
PP08 mPEG2000 34 1.4 28.2 2.7 25 mL of dry THF, 25 mL of dry DCM, 40°C 1260
PP16 PEG2000 30 1.5 45.8 3.1 60 mL of dry THF, 40 mL of dry DCM, 45°C 1105
PP13 PEG1000 38 1.4 22.5 2.6 40 mL of dry THF, 25 mL of dry DCM, 40°C 1600
PP17
PEG3400
30 1.8 34.7 11.5 20 mL of dry THF, 20 mL of dry DCM, 45°C 1010
PP20 15 1.5 69.8 2.1 15 mL of dry THF, 22.5 mL of dry DCM, 45°C 1410
PP21 14 1.4 69.8 2.1 20 mL of dry THF, 22.5 mL of dry DCM, 45°C 1380
PP22 26 2.1 69.3 12.5 15 mL of dry THF, 8 mL of dry DCM, 50°C 100
PP23 26 1.0 69.3 12.5 15 mL of dry THF, 8 mL of dry DCM, 50°C 100
PP25 24 1.0 10.5 19.0 15 mL of dry THF, 10 mL of dry DCM, 40°C 1245
PP26 20 2.1 10.5 19.0 15 mL of dry THF, 15 mL of dry DCM, 40°C 1185
THF: tetrahydrofuran
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Table. II.3. Purification steps for PEG-prednisolone of various molecular weights
Product PEG type Crude product Purification 1 Purification 2
PP11
PEG3400
Filtration,
evaporation
of solvents
PP11BS1
S.F: EAÆ [PP11SFA-D]
DCM/MeOH 90/10Æ [PP11SFE-K] -
PP14 PP14S1
S.F: ether/EA 50/50 [PP14SF1-3]
THF/DCM 40/60 [PP14SF4-7] precipitation
ether Æ PP14SF4p
THF/DCM 50/50 [PP14SF8-9] precipitation
ether
[PP14SF4-9p]: cation exchange in acetone
overnightÆ PP14SFDC1S
PP08 mPEG2000
Precipitation in
ether PP08P2
Cation exchange in THF/DCM, overnightÆ
PP08DC2, precipitation cyclohexane
S.F: Ether/EA 90/10 A
DCM/MeOH 80/20Æ PP08DC2DF1B
PP16 PEG2000 PP16S1 HCl wash (15 mL at 0.5M) Æ PP16HCl
S.F: Ether/EA 50/50
Column: 1- THF/EA 50/50
2- THFÆ SGA precipitated in etherÆ
PP16SGAp
PP13 PEG1000 PP13S1
Cation exchange in acetone, overnight, then in
DCM, 2hÆ PP13DC2
S.F: Ether/EA 90/10 [A]
DCM/MeOH 80/20Æ [PP13DC2DFB]
S.F: silica filtration, TEA: triethylamine, EA: ethyl acetate, THF: tetrahydrofuran, DCM: dichloromethane, MeOH: methanol. Column: silica gel chromatography.
separation of prednisolone and PEG-TEA, separation of TEAH
+
Cl
-
Intermediate samples names are in italic e.g. PP11SFA is the first fraction collected after
Silica filtration of PP11BS1
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Fig.II.2. Purification
chloride and prednisol
EA: Ethyl acetate, DCM
HCl wash, SF: Silica filtr
Esters of PEG and pr
route but due to low
overall yields were poor
route. The use of a coupl
steps for PEG-prednisolone products resul
one conjugation
: Dichloromethane, MeOH: Methanol, THF: Te
ation, CX: Cation exchange
ednisolone were successfully prepared via
conversion rates and the need for extensive
and these results called for a more effic
ing reagent was therefore investigated.
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II.2.2.3. Mukaiyama reagent
In 1977, T. Mukaiyama published a new method for the preparation of carboxylic
esters, and described the use of 2-chloro-1-methylpyridinium iodide (Mukaiyama
reagent) to conjugate a wide range of carboxylic acids and alcohols, in the presence
of tertiary amine base, in a wide range of solvents such as ether, dichloromethane,
tetrahydrofuran, acetonitrile, 1,2-dimethoxyethane, pyridine and toluene [110]. In
1998, Greenwald compared the coupling of PEG diacid and camptothecin with DIC
and Mukaiyama reagent [104]. The use of the Mukaiyama reagent led to 90% of
diester whereas the use of DIC yielded to a mixture of mono and diester.
In this work, the use of Mukaiyama reagent to conjugate oxidised PEG and
prednisolone (Scheme.II.3) was investigated using triethylamine as amine base, in
DCM and THF. Several ratios of the three components, initially based on previous
publications [104, 110], were investigated to optimise the reaction (Table. II.4),
followed by NMR.
Once the conditions were optimised with PEG3400, other PEG molecular weights
were used using the optimised conditions (Table. II.5).
Scheme.II.3. PEG-prednisolone via Mukaiyama reagent route
Purification of the products was carried out according to the PEG molecular weight:
PEG3400 and mPEG2000 afforded products that recrystallised in isopropanol.
Conjugates obtained with PEG2000 and PEG1000 were purified by silica gel
chromatography.
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Table. II.4. Experimental optimisation of the use of Mukaiyama reagent for esterification of PEG3400 and prednisolone
Table. II.5. Experimental conditions for the production of PEG-prednisolone ester of various molecular weights
Batch
Oxidised PEG Prednisolone
Mukaiyama
reagent
Triethylamine
Solvents, temperature
Time
min
Type
[COOH]
mmol/L
/ COOH / COOH / COOH
PP33 PEG1000 57 1.4 3.0 5.9 50 mL of dry THF, 20 mL of dry DCM, 50°C 4320
PP28 mPEG2000 49 1.4 3.1 6.3 20 mL of dry THF, 20 mL of dry DCM, 40°C 4110
PP32 PEG2000 50 1.4 3.0 6.1 20 mL of dry THF, 20 mL of dry DCM, 40°C 4245
PP31 PEG3400 40 1.4 3.1 6.1 20 mL of dry THF, 30 mL of dry DCM, 40°C 4380
Batch
PEG3400(COOH)2 Prednisolone
Mukaiyama
reagent
Triethylamine
Solvents, temperature
Time
min
[COOH] mmol/L / COOH / COOH / COOH
PP04 5 1.3 1.3 3.5 45 mL of dry DCM, 45°C 250
PP01 6 1.2 1.3 2.6 70 mL of dry THF, 50°C 2440
PP24 15 1.5 1.5 4.3 10 mL of dry THF, 30 mL of dry DCM, 50°C 1250
PP27 13 1.5 3.0 6.1 12 mL of dry THF, 32 mL of dry DCM, 50°C 2460
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II.2.3.PEG-salbutamol
Salbutamol (Fig.II.3) is a ȕ2-adrenergic receptor agonist, sold as a salt of
salbutamol sulfate of molecular weight 576.71 Da. It is a white crystalline powder.
The molecule which possesses one primary hydroxyl group, which is the most
reactive. It also has one secondary and one tertiary (phenol) hydroxyl group, less
reactive. The amine group, being nucleophilic as well as a base, is likely to react
during esterification to form an amide bond.
Fig.II.3. Salbutamol sulfate
Ijzerman et al. characterised the ionisation scheme of salbutamol (Fig.II.4) and
calculated the macroscopic pKa values of amine (pKa1= 9.07) and phenol
(pKa2=10.37) groups, in aqueous solutions [111] [112].
Fig.II.4. Ionisation scheme of salbutamol
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II.2.3.2. Modification of salbutamol
Commercially available salbutamol is usually sold as the salt salbutamol sulfate,
which is soluble in water and slightly soluble in alcohol, both unsuitable solvents
for esterification purposes. Therefore, we produced a free base form of salbutamol
to improve the drug solubility in non polar organic solvents, by isolating the neutral
form of the molecule (Scheme.II.4). This was achieved by solubilising salbutamol
sulfate in water and increasing the pH of the solution to deprotonate the amine
group. Then, the water was removed and salbutamol free base was recovered in
THF. In salbutamol free base, the amine is deprotonated and the nitrogen carries a
free electron pair, likely to react in place of the hydroxyl group through amidation.
Scheme.II.4. Production of salbutamol free base
To improve the drug solubility in non polar organic solvents while maintaining the
protonation of the amine group, a new salt of salbutamol was produced by mixing
protonated dodecyl sulfonic acid (pKa = 2.3 [113]) and salbutamol free base to
produce salbutamol dodecyl sulfate (salbutamol DS), Scheme.II.5.
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Scheme.II.5. Production of salbutamol dodecyl sulfate
The alkyl chain of salbutamol DS aids in solubilising the new salbutamol salt in
non polar organic solvents while the protonated amine was prevented from
interfering in the esterification reaction.
II.2.3.3. Esterification of oxidised PEG and salbutamol DS
The experimental design space of the experiments conducted to optimise the
reaction conditions of esterification of oxidised PEG and salbutamol was defined
by the variation of three parameters:
 the type of salbutamol employed (salbutamol sulfate, free base, dodecyl
sulfate)
 the synthesis route (coupling reagent such as Mukaiyama reagent, N,N'-
dicyclohexylcarbodiimide (DCC), or direct esterification through acyl chloride)
 the tertiary amine base used (triethylamine, DMAP, pyridine, 2,6 lutidine), of
different pKa and steric hindrance
Upon optimisation, the acyl chloride route using 2,6 lutidine as tertiary amine base
was employed to produce esters of oxidised mPEG2000, PEG2000, PEG3400 and
salbutamol dodecyl sulfate (Scheme.II.6). The experimental conditions are
summarised in Table. II.6.
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Scheme.II.6. Production of PEG-salbutamol ester conjugates
Table. II.6. Optimised conditions for PEG-salbutamol ester conjugation
Oxidised PEG SOCl2
Salbutamol
DS
2,6
lutidine Solvents,
temperature
Time
min
Type
[COOH]
mmol/L
/ COOH / COOH / COOH
mPEG2000 19 6.3 2.4 5.6
22 mL of dry THF, 11
mL of dry DCM, 50°C
42
PEG2000 20 5.3 2.2 5.2
44 mL of dry THF, 20
mL of dry DCM, 50°C
45
PEG3400 20 5.5 2.3 5.4
44 mL of dry THF, 20
mL of dry DCM, 50°C
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Purification of the conjugates was performed by anion exchange to eliminate
dodecyl sulfonate ions (replaced by chloride ions), excess salbutamol was washed
with dilute HCl and the purified product precipitated in diethyl ether to remove the
excess 2,6 lutidine (Scheme.II.7). Two dimensions NMR, FTIR and elemental
analysis were conducted to determine the conjugates chemical structure and purity.
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Scheme.II.7. Schematic of PEG-salbutamol ester conjugate purification
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II.2.4.Analytical techniques
II.2.4.1. Acid titration
Oxidised products were analysed by acid titration. A known amount of dried
oxidised PEG (e.g. 569.62 mg of oxidised PEG3400) was dissolved in
approximately 50 mL of deionised water. Total carboxylic acid content was
titrated against sodium hydroxide by measuring the pH of the solution with
addition of sodium hydroxide (200 ʅL of 0.1 M solution or 0.03 M closer to
equivalence). The amount of carboxylic acid in solution was equal to the
amount of sodium hydroxide added to get to the equivalence point, determined
as the inflection point in the graph of pH vs amount of NaOH. Excel software
was used to calculate
ο௣ுοே௔ைு (slope of the plot pH vs NaOH, approximation of
the first derivative of the function pH = f(NaOH)) and to determine its
maximum, defining the equivalence point.
II.2.4.2. Infra Red spectroscopy
Infra Red spectrometry was performed by grinding 2 mg of product with 200
mg of potassium bromide (spectroscopic grade) using an agate mortar and
pestle. FTIR spectra were then acquired using a Nicolet 380 FTIR spectrometer
(Thermo Fisher, Waltham, MA, USA), and spectra were processed by
OMINIC software (Thermo Fisher).
II.2.4.3. Nuclear Magnetic Resonance spectrometry
For NMR analyses, the sample (20 mg for 1H NMR, 50 mg for 13C NMR) was
dissolved in deuterated solvent (methanol MeOD, chloroform CDCl3,
deuterium oxide D2O or dymethyl sulfoxide DMSOd6). One Dimensional
Nuclear Magnetic Resonance (1D NMR) spectra were acquired on a Bruker
DPX300, or a Bruker DPX400, using the standard pulse sequence zg 30, 0.1 s
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relaxation delay, 2.9846 s acquisition time, 16 or 64 scans. Two Dimensional
NMR spectra were acquired on a Bruker AV(III)400 NMR spectrometer.
Heteronuclear Multiple Quantum Coherence (HMQC, showing one-bond
correlations from 1H to 13C nuclei), using the inv4gptp pulse sequence, 8
transients, acquisition times (0.2540, 0,0305 1H, 13C). Heteronuclear Multiple
Bond Coherence (HMBC, showing over 2 or 3 bonds correlations from 1H to
13C nuclei), spectra were recorded using Bruker hmbcetgpl2nd pulse sequence,
16 transients, acquisition time (0.5079, 0,0221 1H, 13C). Spectra were then
processed using ACD Labs software v12.
II.2.4.4. Reaction completion follow up
To follow the reaction progress, approximately 500 µL of the reaction mixture
was sampled under inert atmosphere and the solvents evaporated to dryness
using a rotary evaporator. The crude solid was resuspended in deuterated NMR
solvent and spectra were acquired and processed.
II.2.4.5. Mass spectrometry
For mass spectrometry measurement, samples were prepared in MeOH at 10
ng.L-1 and analyses were conducted using ESI (Electrospray Ionisation) with a
Bruker MicroTOF (in-house analytical service) or an API 4000 (Applied
Biosystem) mass spectrometer or Matrix-Assisted Laser Desorption/Ionisation
(MALDI) using a Bruker Ultraflex III and measuring Time Of Flight (TOF).
II.2.4.6. Elemental analysis
For elemental microanalysis, 2 mg of product were used to measure C, N and
H content using an in-house analytical service (CE-440 Elemental Analyzer
from Exeter Analytical).
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II.3. Results
II.3.1.PEG oxidation
The TEMPO mediated oxidation of polyethylene glycol of various molecular
weights was successfully carried out and the oxidised polymers were
characterised by Infra Red spectroscopy, acid titration and NMR. The
following describes in detail the analysis of oxidised PEG3400. The same
characterisation was carried out for PEG of other molecular weights and after
optimisation, 100% oxidation could be achieved consistently for all molecular
weights. PEG oxidation results for all molecular weights are combined in
Table. II.8. Supportive information for oxidised PEG1000, PEG2000 and
mPEG2000, such as, IR spectra, acid titration and NMR are available in
Appendix 1.
Infra Red spectroscopy: A carbonyl stretch at 1745 cm-1 appeared in the Infra
red spectrum of oxidised PEG3400 when compared to native PEG (Fig.II.5),
whereas the rest of the spectrum conformed to that of the starting material.
Fig.II.5. Infra Red Spectrum of unmodified and oxidised PEG3400
 PEG3400OH, PEG3400COOH
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Acid titration: During acid titration of 569.62 mg of oxidised PEG with sodium
hydroxide, the equivalence point was reached after addition of 322 ʅmol of
NaOH (Fig.II.6). Fully oxidised PEG has gained 2 oxygen atoms (16 Da) and
lost 4 protons (1 Da) compared to native PEG. Therefore, the molecular weight
of oxidised PEG3400 was:
(II.1) Mn(PEGCOOH)=Mn(PEG)+2×16-4×1
(II.2) Mn (PEGCOOH) = 3395 + 28
(II.3) Mn(PEGCOOH) = 3423 Da
The starting number of moles of PEG3400 was 166 ʅmol (ହ଺ଽ.଺ଶ௠௚ଷସଶଷ஽௔ ) and
therefore the number of carboxylic acid per molecule of PEG was 1.94
(
ଷଶଶ ఓ௠௢௟ଵ଺଺ ఓ௠௢௟).
Fig.II.6. Acid titration for PEG3400COOH
-i- pH, 'pH/'NaOH
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NMR spectroscopy: A new signal at 4.12 ppm appeared on the proton NMR of
oxidised PEG. Considering a molecular weight of 3423 Da, the number of PEG
unit was calculated and thus the total number of protons for the signal in
position 1 (Fig.II.7). A general formula for oxidised PEG was
C4H6O5(C2H4O)n, and the molecular weight can be calculated according to the
number of PEG units n and the atomic mass of each of its atom (ma(atom)):
(II.4) Mn (PEGCOOH) = 4 ma(C)+6 ma(H)+5 ma(O)+n (2 ma(C)+4
ma(H)+ma(O))
3423 = ((4×12.011+6×1.008+5×15.999) + n×(2×12.011+4×1.011+15.999))
3423 = 134.09 + n×44.05
n = 74.66.
With an average of 74.66 units per molecule of PEG, the average number of
protons in position 1 was 299 (4×74.66). This number of protons was then used
as a reference to integrate the signals in NMR spectra and therefore
integrations for other signals gave the number of protons per molecule of PEG.
Two dimensional NMR studies in MeOD were conducted on oxidised PEG and
the assignment of the spectra allowed the deduction of the following structure
(Fig.II.7):
Fig.II.7. Position numbering of PEG
Different numbers refer to different proton environments and letters refer to different
carbon environments
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Oxidised PEG3400
1H NMR (400 MHz, methanol-d4) G 4.12 (s, 4H), 3.64 (br. s.,
299H). The proton NMR spectrum of oxidised PEG was characterised by a
broad signal for 299 protons in position 1 (G 3.64 (br. s., 299H)) and the
appearance of a signal for 3.79 protons in position 2 (G 4.12 (s, 4H)) (Fig.II.8).
On average, 1.90 carboxylic acid groups per PEG were calculated, this is
consistent with acid titration results and within the margin of error for complete
oxidation.
Fig.II.8. Proton NMR spectrum for oxidised PEG3400
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in MeOD
The HMQC spectrum (showing one bond correlation between 1H and 13C) of
oxidised PEG displayed the values for carbon chemical shifts in positions A
and B. Where the signal 1/B was positioned, the ordinate value gave the
chemical shift for the carbon atom in position B (71.2 ppm), directly bonded to
the protons in position 1. The correlation 2/A gave the value for the carbon
atom in position A (69.2 ppm), directly bonded to protons in position 2
(Fig.II.9).
PEG3400COOH.esp
9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
0
0.25
0.50
0.75
1.00
N
o
rm
a
liz
e
d
In
te
n
s
it
y
299.003.79
METHANOL-d4
M02(s)
M01(br. s.)
4
.1
2
PEG3400COOH.esp
4.00 3.75 3.50
Chemical Shift (ppm)
0
0.025
0.050
0.075
N
o
rm
a
liz
e
d
In
te
n
s
it
y
299.003.79
M02(s)
M01(br. s.)
4
.1
2
1
2
1
2
49
Fig.II.9. 2D HMQC spectrum for oxidised PEG
Spectra acquired on a Bruker AV(III)400 spectrometer in MeOD
The HMBC spectrum (showing multiple correlation between 1H and 13C) of
oxidised PEG showed the correlations 1/A and 2/B.
The correlation 2/C produced a typical carbonyl chemical shift for carbon in
position C (172.3 ppm) (Fig.II.10).
Fig.II.10. 2D HMBC spectrum for oxidised PEG
Spectra acquired on a Bruker AV(III)400 spectrometer in MeOD
The structure of oxidised PEG3400 was therefore confirmed by NMR, and the
findings for NMR study are in Table. II.7.
5.5 5.0 4.5 4.0 3.5 3.0 2.5
F2 Chemical Shift (ppm)
0
20
40
60
80
100
120
140
F
1
C
h
e
m
ic
a
l
S
h
if
t
(p
p
m
)
1/B
4.150 4.125 4.100 4.075
F2 Chemical Shift (ppm)
64
66
68
70
72
74
F
1
C
h
e
m
ic
a
l
S
h
if
t
(p
p
m
)
2/A
5.5 5.0 4.5 4.0 3.5 3.0 2.5
F2 Chemical Shift (ppm)
0
50
100
150
200
F
1
C
h
e
m
ic
a
l
S
h
if
t
(p
p
m
)
1/B
2/B
2/C
1 bond artefact
50
Table. II.7. Full assignment of 2D NMR spectra of oxidised PEG.
# Atom
Chemical shift
(ppm)
Type Integral
1
H
3.64 s 299
2 4.12 s 3.79
A
C
69.2
NA NAB 71.2
C 172.3
Spectra were recorded in MeOD, using an AV(III)400 Bruker spectrometer. s: singlet,
d: doublet, dd: doublet of doublets, m: multiplet, br: broad, NA: Not Applicable.
Oxidised PEG of other molecular weights were analysed likewise and Table.
II.8 combines the results of PEG oxidations for various molecular weights.
PEG1000: The IR spectrum showed a carbonyl stretch at 1743 cm
-1 with the rest
of the spectrum conformed to PEG (Appendix 1, Fig.VI.1). 1H NMR (400
MHz, chloroform-d) G 4.16 (s, 4H), 3.65 (s, 81H) (Appendix 1, Fig.VI.2). The
molecular weight of oxidised PEG1000 was calculated with equation (II.1) and
the general formula for PEG C4H6O5(C2H4O)n to give 1028 Da. The number of
PEG units, n was calculated with equation (II.4). There was an average of n =
20.29 units of PEG (
ଵ଴ଶ଼ିଵଷସ.଴ଽସସ.଴ହ ) in PEG1000COOH, which gave 81 protons (4 ×
20.29) for the signal in position 1 (G 3.65 (s, 81H)). With this reference set, the
integral for the signal in position 2 was measured at 3.91 protons (G 4.16 (s,
4H)), or 1.96 mol of carboxylic acid per mol of polymer. Acid titration was
conducted on 257.8 mg of oxidised PEG1000 (250.8 ʅmol) and the equivalence
point was reached after addition of 500 ʅmol of NaOH (Appendix 1, Fig.VI.3).
The number of carboxylic acids per mol of PEG was therefore 1.99 (
ହ଴଴ଶହ଴.଼),
confirming the total oxidation of PEG1000.
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PEG2000: The IR spectrum showed a carbonyl stretch at 1743 cm
-1 with the rest
of the spectrum conformed to PEG (Appendix 1, Fig.VI.1). 1H NMR (400
MHz, chlorofom-d) G 4.07 (s, 4H), 3.58 (br. s., 172H), Appendix 1, Fig.VI.4.
The molecular weight of oxidised PEG2000 was calculated with equation (II.1)
and the general formula for PEG C4H6O5(C2H4O)n to give 2028 Da. The
number of PEG units, n was calculated with equation (II.4). There was an
average of n = 43 units of PEG (
ଶ଴ଶ଼ିଵଷସ.଴ଽସସ.଴ହ ) in PEG2000COOH, which gave 172
protons (4 × 43) for the signal in position 1 (G 3.58 (br. s., 172H)). With this
reference set, the integral for the signal in position 2 was measured at 4.15
protons (G 4.07 (s, 4H)), or 2.08 mol of carboxylic acid per mol of polymer.
Acid titration was conducted on 264.97 mg of oxidised PEG2000 (130.7 ʅmol)
and the equivalence point was reached after addition of 280 ʅmol of NaOH
(Appendix 1, Fig.VI.5). The number of carboxylic acids per mol of PEG
was therefore 2.14 (
ଶ଼଴ଵଷ଴.଻), confirming the total oxidation of PEG2000.
mPEG2000: The IR spectrum showed a carbonyl stretch at 1742 cm
-1 with the
rest of the spectrum conformed to that of mPEG (Appendix 1, Fig.VI.6).
Fig.II.11. Proton numbering of mPEG
1H NMR for mPEG2000COOH: (400 MHz, chloroform-d) G 4.08 (s, 2H), 3.58
(s, 178H), 3.32 (s, 3H) (Appendix 1, Fig.VI.7). The actual molecular weight of
n
O
CH3
O
O
OH
1
2
3
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mPEG2000COOH (Fig.II.11) was calculated with the
1HNMR spectrum. The
integration for the methyl group in position 3 was used as a reference and set at
3 protons (G 3.32 (s, 3H)). The total number of protons for the main PEG unit
chain in position 1 was measured at 178.34 protons (G 3.58 (s, 178H)). The
number of carboxylic acid groups per molecule of mPEG was 1.24 since
the integration for the signal of position 2 gave 2.47 protons (G 4.08 (s, 2H)).
The general formula for mPEG was C3H6O3(C2H4O)n, with n = 44.59 (
ଵ଻଼.ଷସସ )
on average for mPEG2000COOH. The molecular weight of oxidised mPEG2000
was therefore:
(II.5) Mn = 3 ma(C)+6 ma(H)+3 ma(O)+n (2 ma(C)+4 ma(H)+ma(O))
(II.6) Mn = (3×12.011+6×1.008+3×15.999) +
44.59×(2×12.011+4×1.011+15.999)
(II.7) Mn (mPEG2000COOH) = 2054 Da
Acid titration was conducted on 252.89 mg of oxidised mPEG2000 (123.1 ʅmol)
and the equivalence point was reached after addition of 137 ʅmol of NaOH
(Appendix 1, Fig.VI.8). The number of carboxylic acids per mol of PEG
was therefore 1.11 (
ଵଷ଻ଵଶଷ.ଵ), confirming the total oxidation of mPEG2000.
Table. II.8. Results for PEG oxidation
*mPEG 2000 Da, yield after purification
PEG MW (Da)
COOH/PEG FTIR Yield
%NMR Acid titration cm
-1
1000 1.96 1.99 1743 45
2000 2.08 2.14 1743 87
2000* 1.24 1.11 1742 76
3400 1.90 1.9 1745 93
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Summary
All products were 100% oxidised, and the synthetic yields were influenced by
the polymer molecular weights. The recovery for mPEG2000, PEG2000 and 3400
Da was greater than 75%, while it was 45% for PEG1000(Table. II.8). The
physical properties of PEG were clearly molecular weight dependent. PEG1000
was a white waxy paste that melted at 37-40°C whereas with increasing
molecular weighs, the polymers became more powder-like and less waxy,
PEG3400 melted at 54-58°C. Aqueous and organic solubility were also
molecular weight dependant, water solubility decreasing with increasing
molecular weight. PEG3400 was efficiently extracted from the aqueous phase
and crystallised, yielding a good recovery. PEG1000 was not efficiently solvent
extracted, it was not crystalline, giving poor recovery. The recovery was
ranked as follows: PEG3400 > PEG2000 > PEG1000.
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II.3.2.PEG-prednisolone
II.3.2.1. Analysis of prednisolone.
Carbon atoms of prednisolone were lettered and protons numbered for
reference in the NMR analysis (Fig.II.12). The reader must be aware that the
numbering and lettering system referred respectively to protons and carbons of
the molecules and this nomenclature is different to the position numbering
proposed by the International Union of Pure and Applied Chemistry (IUPAC)
[114]. The following assignment was performed with the use of 1HNMR, 2D
HMQC and 2D HMBC (Fig.II.13, Fig.II.14, Fig.II.15). The proton and carbon
chemical shifts were combined in Table. II.9.
a.
b.
c.
Fig.II.12. Proton numbering (a), carbon lettering (b) of prednisolone used in
the thesis, position numbering (c) of prednisolone according the IUPAC
nomenclature
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Fig.II.13. 1HNMR of prednisolone and signal assignment
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in MeOD
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Fig.II.14. 2D HMQC of prednisolone and correlation assignment
Spectra acquired on a Bruker AV(III)400 spectrometer in MeOD
Signals for carbon atoms in positions O to U were not assigned using HMQC.
The 2D HMBC granted the full assignment of these signals (Fig.II.15).
In this spectrum, seven carbon signals, not seen in HMQC spectrum, appeared
at 44.7, 47.1, 88.8, 158.6, 173.3, 187.5 and 211.4 ppm, corresponding to the
chemical shifts for the unassigned positions O to U. Using the proton signal to
which they were correlated, it was possible to fully assign the chemical shifts
for prednisolone (Table. II.9), and the results conformed to the supplier
specifications (Sigma) and a previous NMR assignment performed in
deuterated chloroform by Rachwal et al. [115].
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Fig.II.15. 2D HMBC of prednisolone
Spectra acquired on a Bruker AV(III)400 spectrometer in MeOD
The NMR analysis of prednisolone gave a rather complex set of spectra to
analyse, especially 1H-NMR and HMBC. The study of prednisolone NMR
spectra was nonetheless essential in order to analyse the products of
esterification between oxidised PEG and prednisolone. The hydroxyl groups of
prednisolone has been particularly scrutinised with an emphasis on the primary
hydroxyl group of the molecule which was the more likely to react to form an
ester bond. Particularly, any changes in the signal for positions 11/K (for
primary hydroxyl group), 12/L (for secondary hydroxyl group) and P (for
tertiary hydroxyl group) were monitored. Integrity of the rest of the structure
was assessed by tracking any changes in the remaining parts of the spectrum.
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Table. II.9. Prednisolone full assignment of proton and carbon chemical shifts
Proton position Chemical shift (ppm) Carbon position Chemical shift (ppm)
1 0.91 A 16.3
2 1.01 B 55.9
3 1.13 / 2.13 C 34.1
4 1.41 / 1.78 D 23.4
5 1.44 / 2.71 E 33.1
6 1.49 F 20.1
7 1.60 / 2.00 G 39.2
8 1.73 H 51.4
9 2.16 I 31.2
10 2.36 / 2.65 J 31.7
11 4.25 / 4.61 K 66.2
12 4.40 L 69.3
13 6.00 M 121.1
14 6.24 N 126.5
15 7.46 O 47.1
P 88.8
Q 211.4
R 187.5
S 173.3
T 44.7
U 158.6
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II.3.2.2. Reaction with PEG acyl chloride
PP11: NMR analysis of the crude product PP11 was conducted as follow:
The usual NMR solvent traces were observed: THF ((1.87, m, 11.49 H) and
(3.72, m, merged with PEG signal 1)), and DCM (5.51 ppm, s).
Triethylammonium chloride signals were also present ((1.32 ppm, t, J=7.3 Hz,
25H) and (3.21, q, J=7.3 Hz, 14H) and (3.35, q, J=7.3 Hz, 2H)), Fig.II.17.
In the region 3.1-5.3 ppm, the peak for PEG signal 1 was broad with satellite
peaks and set at 299 protons (PEG chain (CH2-CH2-O)n). The signal at 4.30
ppm (2) was directly correlated to a carbon at 67.6 ppm (A,Fig.II.18) and
along the molecule to B (70.1 ppm) and to C shifted to 170.6 ppm (Fig.II.19).
The doublet of doublets at 5.05 ppm (J = 17.57, 56.97 Hz, 2.7 H),
corresponded to prednisolone position 11 when conjugated to PEG as it was
correlated to position K at 67.9 ppm (Fig.II.18) and Q (205.2 ppm) and PEG
position C (170.6 ppm) (Fig.II.19). This correlation 11/C was a definite proof
that PEG and prednisolone were conjugated via an ester link. There were 1.39
mol of conjugated prednisolone per mol of PEG (PEG-CH2-CO-O-Pred, į 4.3,
(s, 2.78 H)). The other signals conformed to unreacted prednisolone: signals for
position 11 (Pred-CO-CH2-OH, 4.43 ppm (dd, J = 19.07, 147.57 Hz, 1.83 H))
and 12 (4.43 ppm, m, 2.51 H).
The other signal for PEG position 2 was shifted to 3.95 ppm and therefore
likely to be related to a deprotonated form of oxidised PEG (PEG-CH2-COO
-, į
3.95 ppm). The integration value could not be used as the signal was merged
with one of PEG unit satellite signal.
A third form of oxidised PEG was present in the mixture. The foreign singlet i
at 4.69 ppm (PEG-CH2-N
+-(CH2-CH3)3, s, 0.59 H) was directly bonded to a
60
carbon a at 83.9 ppm (Fig.II.18) and along the molecule to carbon atoms b
(49.9 ppm) and e (71.1 ppm) (Fig.II.19). The signal b was also correlated to a
proton signal in position ii (3.38 ppm), close to triethylamine, in both HMBC
and HMQC spectra. The proton signal ii was correlated further along the
molecule to a, confirming a link with proton signal i and to carbon signal c
(5.8ppm). This signal c was found on HMQC as being directly bonded to
triethylamine signal iii (Fig.II.18), which in turn was linked to b in HMBC
spectrum (Fig.II.19).
Fig.II.16. Different forms of PEG present in crude PP11
1.PEG-triethylammoium, 2. deprotonated PEG, 3. PEG-prednisolone
1.
3.
2.
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Fig.II.17. 1HNMR for crude PP11
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in MeOD
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Fig.II.18. HMQC for crude PP11
Spectra acquired on a Bruker AV(III)400 spectrometer in MeOD
Fig.II.19. HMBC for crude PP11
Spectra acquired on a Bruker AV(III)400 spectrometer in MeOD
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In conclusion, crude PP11 was a mixture of triethylammonium chloride,
unconjugated PEGCOO- (0.3 mol), PEG-prednisolone ester (1.4 mol), PEG-
triethylamonium (0.3 mol), and unreacted prednisolone (Fig.II.16).
PP11SFAD: after clearing the NMR spectrum of the solvent traces (Fig.II.20),
the analysis revealed that this fraction contained only unreacted prednisolone,
no trace of PEG or triethylamine.
Fig.II.20. 1HNMR spectrum for PP11SFAD
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in MeOD
PP11SFEK: According to NMR spectroscopy (Fig.II.21), there was no free
prednisolone in this fraction, only a mixture of 0.19 mol of PEGCOOH (į 4.10,
s, 0.37 H, PEG-CH2COOH), 1.52 mol of PEG-prednisolone (į 4.30, s, 3.04 H,
PEG-CH2-CO-Pred) and 0.21 mol of PEG-triethylammonium (į 4.68, s, 0.42
H, PEG-CH2-N
+-(CH2-CH3)3).
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Fig.II.21. 1HNMR spectrum for PP11SFEK
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in MeOD
This simple filtration over silica allowed separating prednisolone (eluted with
ethyl acetate) from the rest of the mixture but triethylammonium chloride and
PEG-triethylammonium were still contaminating the sample PP11SFEK
(eluted with DCM/MeOH 90/10 v/v).
f_bay.PP11SFEK.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
Chemical Shift (ppm)
0
0.005
0.010
0.015
0.020
0.025
0.030
0.035
0.040
0.045
0.050
0.055
N
o
rm
a
liz
e
d
In
te
n
s
it
y
4.911.603.19300.663.040.422.741.831.781.69
METHANOL-d4
DCM
THF
THF
Triethylammonium HClWater
Triethylammonium HCl
0
.9
3
1
.0
3
1
.5
0
1
.7
8
2
.1
7
2
.3
9
2
.6
6
3
.3
4
3
.3
6
3
.6
4
3
.8
2
4
.1
0
4
.3
0
4
.4
3
4
.4
3
4
.6
8
4
.9
6
5
.0
1
5
.1
1
5
.1
5
6
.0
1
6
.2
4
6
.2
4
6
.2
7
6
.2
7
7
.4
7
7
.4
9
f_bay.PP11SFEK.esp
5.0 4.5 4.0 3.5
Chemical Shift (ppm)
0
0.005
0.010
0.015
0.020
0.025
0.030
0.035
0.040
0.045
N
o
rm
a
liz
e
d
In
te
n
s
it
y
300.660.373.041.640.422.74
METHANOL-d4
THF
Water
Triethylammonium HCl
3
.3
4
3
.3
6
3
.6
4
3
.8
2
4
.1
0
4
.3
0
4
.4
3
4
.4
3
4
.6
8
4
.9
65
.0
1
5
.1
1
5
.1
5
1
6
1
2'
15 14 13
11'
i ii
1
2
2'
12
65
PP14: 1HNMR analysis (Appendix 2, Fig.VI.9) of the crude product revealed a
similar mixture as obtained for PP11, there were 1.32 mol of PEG-
prednisolone (į 4.30, s, 2.64 H, PEG-CH2-CO-O-Pred), 0.29 mol of
PEGCOOH (į 4.00, s, 0.57 H, PEG-CH2-COO-), 0.38 mol of PEG-
triethylammonium (PEG-CH2-N
+(CH2-CH3)3), 3.24 mol of triethylammonium
chloride (į 3.21, q, 19.41 H, +N-(CH2-CH3)3) and 1.5 mol of free prednisolone.
PP14SF1P: 1HNMR analysis revealed the fraction contained only prednisolone
(Appendix 2, Fig.VI.10).
PP14SF4P contained PEG that was 100% conjugated to prednisolone (į 4.30,
s, 4H, PEGCH2-COO-Pred) and 1.2 mol of triethylammonium chloride (į 3.21,
q, 6.9 H, N+(CH2-CH3)3) and (į 1.32, t, 10.7 H, N+(CH2-CH3)3). This fraction
was free of unreacted prednisolone and PEG-triethylammonium (Appendix 2,
Fig.VI.11).
Similarly to PP11, the filtration over silica allowed separating prednisolone in
the first fractions (diethyl ether/ethyl acetate 50/50 v/v) and recovering PEG-
prednisolone and triethylammonium chloride in the last fractions (eluted with
THF/DCM 40/60 v/v). The less polar solvent mixture afforded a good
separation of free prednisolone from the mixture. The undesired
triethylammonium chloride was successfully removed by cation exchange and
in PP14SFDC, there was no trace of the contaminants, the sample contained
pure PEG3400-prednisolone2 (Appendix 2, Fig.VI.12).
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PP08P2 (esterification of mPEG2000COOH) contained 0.15 mol of mPEG-
triethylammonium, 0.10 mol of unreacted mPEG and 0.80 mol of mPEG-
prednisolone. The mixture was also contaminated with 1.16 mol of
triethylammonium chloride (Appendix 2, Fig.VI.13). Cation exchange was
effective in removing triethylammonium base contaminants from the mixture
as PP08DC2 was free of PEG-triethylammonium and contained only 0.11 mol
of triethylammonium chloride (Appendix 2, Fig.VI.14). After filtration over
silica, the product (PP08DC2DF1B) was virtually free of contaminants and
consisted in 0.94 mol of mPEG-prednisolone, and 0.05 mol of unreacted
mPEGCOOH. The amount of triethylammonium chloride was 0.02 mol
(Appendix 2, Fig.VI.15).
PP16S1 (esterification of PEG2000COOH) was a mixture similar to the previous
experiments and contained 0.10 mol of unreacted PEG, 0.63 mol of PEG-
triethylammonium, 1.22 mol of PEG-prednisolone, 1.86 mol of free
prednisolone and 2.38 mol of triethylammonium chloride (Appendix 2,
Fig.VI.16). The mixture washed with HCl (PP16HCl) contained less
triethylammonium chloride (0.77 mol) and less PEG-triethylammonium, the
proportion for the other species was similar to the crude product (Appendix 2,
Fig.VI.17). After silica filtration, silica gel chromatography and precipitation
PP16SGAp was pure PEG-prednisolone (Appendix 2, Fig.VI.18).
PP13S1 (esterification of PEG1000COOH) was a mixture of 1.14 mol of PEG-
prednisolone, 0.12 mol of unreacted oxidised PEG, 0.77 mol of PEG-
triethylammonium. The sample also contained 1.89 mol of triethylammonium
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chloride and 2.05 mol of free prednisolone (Appendix 2,Fig.VI.19). Similarly
to PP08 purification, cation exchange allowed the removal of
triethylammonium chloride (PP13DC2) and PEG triethylammonium chloride
proportion was lowered to 0.11 mol (Appendix 2,Fig.VI.20). Silica filtration
allowed once again the removal of free prednisolone and the recovery of
purified PEG-prednisolone. The final product PP13DC2DFB contained 0.14
mol of unreacted PEG, 0.09 mol of PEG-triethylammonium and 1.72 mol of
PEG-prednisolone (Appendix 2Fig.VI.21) and the overall yield was 25%.
The previous procedure: acyl chloride and esterification with triethylamine was
optimised to get pure PEG-prednisolone. However, this chemical route and
subsequent purification process was not satisfactorily efficient and afforded
yields so low that it was difficult to accurately determine them. These low
yields were explained by several reasons:
x The succession of purification steps: the more steps, the lower the yield.
eg 3 steps at 85% gives a theoretical 61.4% yield (100 × 0.853)
x The low conjugation rates: 80% for mPEG (PP08) and 61% on average
for PEG (PP14, PP16 and PP13).
Therefore there was a need to improve the chemistry of the reaction to reduce
undesired conjugation between PEG and the tertiary amine base triethylamine.
By doing so, the aim was to facilitate the recovery and decrease the number of
purification steps but also to improve the synthetic yield and increase the
proportion of conjugated PEG-prednisolone in the crude mixture. The
following experiments dealt with the optimisation of a better esterification
procedure, starting with the use of pyridine, a weaker amine base (pKa 5.25)
than triethylamine (pKa 10.75).
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PP17S2 was analysed by 2D NMR and similarly to PP11, the study of 1HNMR
(Fig.II.23), HMQC and HMBC revealed that PEG was conjugated to pyridine
(0.35 mol), and prednisolone (1.39 mol) with a fraction unreacted (0.35 mol).
Some pyridine (4.35 mol) and free prednisolone (2.40 mol) also remained.
According to 2D NMR, several chemical products were present in the crude
product PP17S2 (Fig.II.22).
Fig.II.22. Chemical structures of PP17 mixture products
1. PEG-pyridinium, 2. unreacted oxidised PEG, 3. PEG-prednisolone, 4. pyridine
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Fig.II.23. 1HNMR of PP17S2
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in CDCl3
The study of both HMQC and HMBC spectra afforded the determination of the
relevant proton and carbon signals (Table. II.10). The correlation 11/C
(HMBC) confirmed the conjugation between PEG and prednisolone and the
correlation 2/ A illustrated the conjugation between PEG and pyridine.
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Table. II.10. Proton and carbon signals of PP17S2 crude product
Proton position Chemical shift (ppm) Carbon position Chemical shift (ppm)
1 8.69 A 146.2 *
2 7.58 B 125.3 *
3 8.01 C 140.0 *
1 9.45 A 143.6 *
2 8.17 B 127.9 *
3 8.58 C 146.2 *
1 3.62 B 70.5 *
2 4.14 A 68.6 *
C 171.9 **
2 4.26 A 68.2 *
C 170.1 **
2 6.29 A 88.5 *
11 4.26/4.65 K 67.7 *
Q 212.4 **
11 5.03 K 68.6 *
Q 204.8 **
* Determined using HMQC correlation with corresponding proton signal, **
determined using HMBC correlation
In conclusion, there was no difference between the two types of amine bases
used. The cross-reaction between PEG and the amine base took place with both
triethylamine and pyridine.
PP20/21: Despite the relative low proportion of pyridine used (2.1/COOH),
both crude products had the same relative amount of undesired PEG-
pyridinium (0.68-0.69 mol) (Appendix 2, Fig.VI.22 and Fig.VI.23). The
proportion of PEG-prednisolone in PP20S2 (1.08 mol) and in PP21S2 (0.91
mol) were similar. In conclusion, the type of addition did not change the
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relative amount of PEG-pyridinium in the crude product neither did it change
the proportion of the desired ester.
PP22/PP23: The two reactions ended up with a similar mixture of PEG-
prednisolone (1.08, 1.04 mol resp.), unreacted PEG (0.17, 0.18 mol resp.) and
PEG-pyridinium (0.76, 0.80 mol resp.). Here the relative amount of
prednisolone did not influence the final conjugation efficiency and the
proportion of PEG-pyridinium was still high (Appendix 2, Fig.VI.24,
Fig.VI.25).
PP25/PP26: When decreasing the relative amount of thionyl chloride used to
produce PEG acyl chloride, there was no decarboxylation of PEGCOOH taking
place and the crude products were free of PEG-pyridinium. In PP25S2,
produced with one prednisolone per acyl chloride, there were 1.28 mol of PEG-
prednisolone (and 0.75 mol of unreacted PEG) (Appendix 2, Fig.VI.26). In
PP26S1, produced with two molecules of prednisolone per acyl chloride, there
were 1.38 mol of PEG-prednisolone (and 0.63 mol of unreacted PEG)
(Appendix 2, Fig.VI.27). The lower excess of thionyl chloride used in these
reactions had the beneficial effect to avoid decarboxylation of oxidised PEG
but it also increased the relative amount of unreacted PEG.
Table. II.11 summarises the compositions of the crude and purified products
obtained after esterification of oxidised PEG of various molecular weights and
prednisolone using thionyl chloride. Table. II.12 illustrates the compositions of
the crude mixtures obtained after esterification of oxidised PEG 3400 and
prednisolone using acyl chloride at different ratios.
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Table. II.11. PEG-prednisolone crude mixture and purified product compositions according to NMR for various PEG molecular weights
Signal
Product
PEG type
Unreacted
PEGCOOH /
PEGCOO
-
PEG-TEA
PEG-
prednisolone
TEA HCl
Free
prednisolone
&H2 (PEG unit)
#2 (4.14 ppm)
(4.00 ppm)
#i (4.68 ppm) #2 (4.30 ppm) (1.32 ppm)
#13
(6.00 ppm)
#1 (3.63 ppm)
PP11SB1
PEG3400
0.32 0.30 1.39 2.77 1.41 299+11.49(THF)
PP11SFEK 0.19 0.21 1.52 283 0 299+1.66(THF)
PP14S1 0.29 0.38 1.32 3.71 1.48 299+16(THF)
PP14SF4P 0 0 1.99 1.19 0 299
PP14SFDC 0 0 2.0 0.11 0 299
PP08P2
mPEG2000
0.10 0.15 0.80 1.16 0.67 178
PP08DC2 0.06 0 0.87 0.11 0.45 178
PP08DC2DF1B 0.05 0 0.94 0.02 0 178
PP16S1
PEG2000
0.10 0.63 1.22 2.38 1.86 172
PP16HCl 0.17 0.49 1.27 0.77 1.73 172+4.60(THF)
PP16SGAp 0 0 2.17 0 0 172
PP13S1
PEG1000
0.12 0.77 1.14 1.89 2.05 81+18.28(THF)
PP13DC2 0.15 0.11 1.64 0 3.42 81+1.57(THF)
PP13DC2DFB 0.14 0.09 1.72 0 0 81+1.47(THF)
The number of moles of each species is calculated relative to one mole of PEG. One mole of PEG is used as reference using the appropriate number of
protons for PEG signal in position 1. (e.g. 299H for PEG3400, 172H for PEG2000, 178H for mPEG2000 or 81H for PEG1000).
1
HNMR spectra recorded in MeOD
or CDCl3
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Table. II.12. PEG-prednisolone crude mixture composition according to NMR for PEG3400
Signal
Product
PEG type
Unreacted
PEGCOOH
PEG-pyridine PEG-
prednisolone
Pyridine
Free
prednisolone
&H2 (PEG unit)
#2 (4.14 ppm)
#2 (6.05 ppm)
(6.29 ppm)
#2 (4.26 ppm) aromatic
#13
(5.98 ppm)
#1 (3.62 ppm)
PP17S2
PEG3400
0.35 0.35 2.40 4.35 1.39 299
PP20S1 0.29 0.69 2.40 18.5 1.08 299+10.54(THF)
PP21S2 0.43 0.68 2.08 13.8 0.91 299+8.58(THF)
PP22S2 0.17 0.76 3.01 4.34 1.08 299
PP23S2 0.18 0.80 1.01 2.6 1.04 299
PP25S1 0.75 0 1.58 5.56 1.28 299
PP26S1 0.63 0 2.49 5.93 1.38 299
The number of moles of each species is calculated relative to one mole of PEG. One mole of PEG is used as reference using 299 protons for PEG3400 unit
signal in position 1.
1
HNMR spectra recorded in MeOD or CDCl3
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Discussion
For the previous reactions, the relative amount of thionyl chloride used to generate
PEG acyl chloride was 10, 30 or 70 times excess (relative to carboxylic acid). The
resulting amount of PEG-amine produced as a result was respectively 0, 0.30 and
0.75 mol per mol of PEG. There was therefore a linear relationship (Fig.II.24)
between the amount of acyl chloride and the resulting decarboxylation of oxidised
PEG and the ensuing production of PEG-amine (Fig.II.24).
Fig.II.24. Relationship between acyl chloride excess and relative amount of
PEG3400-amine
In this system, the balance between the production of sufficient acyl chloride to get
maximum conjugation and excessive acyl chloride leading to PEGCOOH
decarboxylation could not result in complete PEG conjugation to prednisolone
while avoiding PEG decarboxylation.
Despite the 69% conversion in PP26, and the possibility of purifying the products
to a satisfactory grade (PP14, PP08, PP16 and PP13), these results called for a
better, more efficient route to produce PEG-prednisolone ester conjugates. The use
of coupling reagent 2-chloro-1-methyl pyridinium iodide (Mukaiyama reagent) was
investigated to overcome these difficulties as discussed in the following section.
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II.3.2.3. Mukaiyama reagent
The use of Mukaiyama reagent was investigated using DCM, THF, and then a
mixture of the two solvents, and varying ratios of prednisolone and tertiary amine
base. PP04 was produced by reacting oxidised PEG2000 and prednisolone with
Mukaiyama reagent and triethylamine, in DCM at 40°C. After 250 min, a first
sample (PP04S1) was withdrawn and analysed by 2D NMR. The full assignments
of the corresponding spectra are detailed below and the same methodology was
used to deduce the reaction completion for the following reactions (PP01, PP24,
PP27).
a. Experimental optimisations
PP04: For one mole of mPEG2000, the crude product PP04S1 contained 0.67 mol of
ester of PEG-prednisolone, unreacted oxidised PEG (0.35 mol), and 1.23 mol of
reacted Mukaiyama reagent (1-methylpyridin-2(1H)-one). There was also some
unreacted prednisolone (0.43 mol) and triethylammonium HCl (2.73 mol)
(Fig.II.25). According to NMR spectra (Fig.II.26, Fig.II.27, Fig.II.28), the
following chemical entities were present in the crude product PP04S1 (Fig.II.25).
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Fig.II.25. Chemical structures of PP04 mixture products
1. Oxidised PEG. 2. Unreacted prednisolone, 3. PEG-prednisolone, 4. Reacted Mukaiyama
reagent.
Proton and carbon chemical shifts of the crude mixture are presented in 0.
Fig.II.26. 1HNMR spectrum of PP04S1
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in CDCl3
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Fig.II.27. HMQC of PP04S1
Spectra acquired on a Bruker AV(III)400 spectrometer in CDCl3
Fig.II.28. HMBC of PP04S1
Spectra acquired on a Bruker AV(III)400 spectrometer in CDCl3
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Table. II.13. Proton and carbon signals of PP04S1 crude products
Proton position Chemical shift (ppm) Carbon position Chemical shift (ppm)
1 3.52 A 37.6 *
F 138.1 **
2 6.14 B 106.1 *
3 6.53 C 120.8 *
4 7.33 D 139.7 *
5 7.30 E 138.4 *
F 162.9 **
1 3.61 B 70.3 *
2 4.00 A 68.9 *
C 174.6 **
3 3.35 D 58.6 *
2 4.26 A 68.2 *
C 170.1 **
11 4.65 / 4.25 K 67.2 *
13 5.97 M 122.4 *
14 6.22 N 127.6 *
15 7.28 U 150.4 *
11 5.02 K 68.2 *
* Determined using HMQC correlation with corresponding proton signal, ** determined
using HMBC correlation
After 250 min of reaction, 67% of the starting carboxyl groups were conjugated to
prednisolone, and the coupling reagent was entirely consumed.
PP01: When conducted in THF, using oxidised PEG3400, the reaction yielded
comparable results: Mukaiyama reagent was entirely consumed, and the
conjugation efficiency was 63.5% after 2440 min (Appendix 3, Fig.VI.28).
PP24: After 60 min (PP24S1), according to 1HNMR of the crude product
(Appendix 3, Fig.VI.29), 50% of the carboxyl groups were conjugated to
79
prednisolone. The reaction was not finished since 0.45 mol of unreacted
Mukaiyama reagent was detected, (e.g. signal at 8.31 ppm). The reaction was
complete (no trace of coupling reagent) after 1250 min (PP24S2) and resulted
(Appendix 3, Fig.VI.30) in the conjugation of 1.67 of an original 2 mol of carboxyl
groups conjugated to prednisolone (83.5%). The increasing amount of
prednisolone, Mukaiyama reagent and triethylamine significantly improved the
synthetic yield. Since the Mukaiyama reagent was entirely consumed at the end of
the reaction and the conjugation was not complete, one could assume that the
coupling reagent was limiting the reaction completion. The starting relative amount
of Mukaiyama reagent was therefore doubled in the following experiment.
PP27: The first sample was withdrawn after 1000 min (PP27S1) and the synthetic
yield was 91.5% (Appendix 3, Fig.VI.31). After 2460 min, the reaction was
complete and every PEG carboxyl group was conjugated to prednisolone
(Appendix 3, Fig.VI.32). A small amount of unreacted Mukaiyama reagent was left
(0.8 mol) while 3.76 mol of Mukaiyama reagent had reacted. Triethylammonium
chloride (11.28 mol) and unreacted prednisolone (0.92 mol) were also present in the
crude product. After silica gel chromatography, the fraction recovered in THF
(PP27FB) contained 0.72 mol of reacted Mukaiyama reagent and 1.19 mol of
butylated hydroxytoluene (BHT) from evaporated THF as contaminant (Appendix
3, Fig.VI.33). When recrystallised from isopropanol, the product PP27C1 was a
pure ester conjugate of PEG3400-Pred2 (Fig.II.29).
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Fig.II.29. 1HNMR for PP27C1
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in MeOD
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b. Production and purification of mPEG2000-prednisolone using optimised
conditions
PP28: Oxidised mPEG2000 was successfully conjugated to prednisolone after 4110
min of reaction. The crude product PP28S1 (Appendix 3, Fig.VI.34) was
contaminated by reacted and unreacted Mukaiyama reagent (1.47 and 0.23 mol
respectively), triethylammonium chloride (2.63 mol) and unreacted prednisolone
(0.22 mol). After crystallisation from propan-2-ol, and successive washes in diethyl
ether, ethanol, and diethyl ether, the product PP28C1 was obtained free of
contamination (Fig.II.30). In the purified product, 0.99 mol of prednisolone was
conjugated (per mol of mPEG2000).
The product purity was confirmed by elemental analysis since the measured relative
weight amounts of carbon, nitrogen and hydrogen agreed with calculated values
(Table. II.14).
FTIR confirmed the presence of prednisolone with the characteristic prednisolone
peaks (1659 cm-1, 1614 cm-1, 1419 cm-1), but also the ester link with the carbonyl
shifting from 1747 cm-1 in the oxidised PEG to 1761 cm-1 in the ester (Fig.II.31).
The carbonyl stretch of prednisolone at 1707 cm-1 was shifted to 1726 cm-1 after
conjugation, which conformed to the spectrum of prednisolone acetate [116].
Mass spectrometry analysis was performed and a mass difference of 342 Da
(between oxidised mPEG2000 and PP28C1) was measured, confirming the product
molecular formula (Fig.II.32). Briefly, the mass spectrum for mPEG2000COOH
showed several overlapping mass distribution patterns. The maximum intensity was
obtained for 635.5 atomic mass units (amu), the surrounding peaks were separated
by 14.7 amu on average. Since PEG monomer weights 44 Da, the maximum peak
82
at 635.5 amu corresponded to mPEGCOOH triply charged (
ସସଵସ.଻ = 3). Under the
same ionisation conditions, the triply charged signal of PP28C1 was measured at
749.7 mass units. The mass difference of the triply charged species was therefore
114.2 amu (749.7-635.5). Assuming the two compounds did ionise in the same way
and produced the same ionic complexes, the mass difference between
mPEG2000COOH and PP28C1 was 342.6 Da (3 × 114.2) compared to the
theoretical mass difference being 342.4 Da (addition of prednisolone at 360.4 Da
and loss of water at 18 Da). The synthetic yield was 58% (II.4.2.2).
83
Fig.II.30. 1HNMR of purified PP28C1
Spectrum acquired on a Bruker AV(III)500, 16 scans, in MeOD
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Fig.II.31. FTIR spectra of prednisolone, oxidised mPEG2000, PP28C1
 Prednisolone,  mPEG2000COOH,  PP28C1 (mPEG2000-prednisolone)
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Fig.II.32. Mass spectra of mPEG2000COOH (left) and mPEG-prednisolone (right)
The maximum signal for triply charged mPEGCOOH was at 635.5 atomic mass units. Under the same ionisation conditions, the maximum triply charged
signal for mPEG-prednisolone was 749.7 amu. The mass difference of the triply charged species was therefore 114.2 amu (749.7-635.5). Assuming the two
compounds did ionise in the same way and produced the same ionic complexes, the mass difference between mEG2000COOH and mPEG-prednisolone was
342.6 Da (3 × 114.2) compared to the theoretical mass difference being 342.4 Da (addition of prednisolone at 360.4 Da and loss of water at 18 Da).
635.5
749.7
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c. Production and purification of PEG-prednisolone esters of other molecular
weights
Conjugates of oxidised PEG1000, PEG2000 and PEG3400 were obtained and
characterised in exactly the same manner as described above for the mPEG2000
(PP28). FTIR spectra for all PEG-prednisolone ester conjugates are displayed in
Fig.II.33. Table. II.14 sums up NMR, mass spectrometry results, elemental analyses
and synthetic yields for PEG-prednisolone ester conjugates. Proton NMR of the
purified products and detailed calculation of mass spectrometry analyses are
available in Appendix 3, Fig.VI.35 to Fig.VI.40.
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Fig.II.33. FTIR spectra of PEG-prednisolone conjugates
PEG1000-Pred2, PEG2000-Pred2, mPEG2000-Pred, PEG3400-Pred2
88
Table. II.14. PEG-prednisolone ester conjugate analyses
Product Type Formula
Average MW NMR Elemental analysis Mass spectrometry
Synthetic
yield
(II.4.2.2)
Da
mol of Pred
/ mol of PEG
Measured
%
Theoretical
%
0HDVXUHGǻmass
Da
7KHRUHWLFDOǻmass
Da
%
PP33w3 PEG1000-Pred2 C86H138O33 1700
1.91
(Fig.VI.35)
% C: 58.3
% H: 8.1
% N: -0.3
% C: 57.0
% H: 8.7
% N: 0
684.2
(Fig.VI.36)
684.9 69
PP32D PEG2000-Pred2 C136H238O58 2801
2.07
(Fig.VI.37)
% C: 57.1
% H: 8.0
% N: 0
% C: 58.3
% H: 8.5
% N: 0
685.5
(Fig.VI.38)
684.9 60
PP28C1 mPEG2000-Pred C116H216O53 2459
0.99
(Fig.II.30)
% C: 56.3
% H: 8.8
% N: -0.1
% C: 56.5
% H: 8.8
% N: 0
342.6
(Fig.II.32)
342.4 58
PP31P2 PEG3400-Pred2 C194H354O87 4079
1.94
(Fig.VI.39)
% C: 55.9
% H: 8.1
% N: 0.2
% C: 57.0
% H: 8.7
% N: 0
685.3
(Fig.VI.40)
684.9 75
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Summary
Esters of oxidised PEG and prednisolone of different molecular weights were
produced using a coupling reagent. They were then purified and characterised by
2D NMR, FTIR, elemental analysis and mass spectrometry. The synthetic yields
varied upon the molecular weight and the subsequent purification procedure.
PEG1000-Pred2 ฀w฀a฀s฀ ฀a฀n฀ ฀o฀i฀l฀y฀ ฀b฀r฀o฀w฀n฀ ฀p฀r฀o฀d฀u฀c฀t฀,฀ ฀r฀e฀c฀o฀v฀e฀r฀e฀d฀ ฀i฀n฀ ฀g฀o฀o฀d฀ ฀y฀i฀e฀l฀d฀ ฀(Ș฀=฀6฀9฀%฀)฀ ฀b฀y฀ 
silica gel chromatography whereas PEG3400-Pred2 was an off white powder
recrystallised from isopropanol, in good yield ฀(Ș฀=฀7฀5฀%฀)฀.฀ ฀T฀h฀e฀ ฀two conjugates of
2000 Da possessed intermediate physical properties. mPEG2000-Pred was a light-
฀b฀r฀o฀w฀n฀ ฀p฀o฀w฀d฀e฀r฀,฀ ฀r฀e฀c฀o฀v฀e฀r฀e฀d฀ ฀f฀r฀o฀m฀ ฀c฀r฀y฀s฀t฀a฀l฀l฀i฀s฀a฀t฀i฀o฀n฀ ฀i฀n฀ ฀i฀s฀o฀p฀r฀o฀p฀a฀n฀o฀l฀ ฀(Ș฀=฀5฀8฀%฀)฀ ฀a฀n฀d฀ ฀P฀E฀G2000-
Pred2 ฀w฀a฀s฀ ฀a฀ ฀w฀a฀x฀y฀ ฀p฀a฀s฀t฀e฀,฀ ฀r฀e฀c฀o฀v฀e฀r฀e฀d฀ ฀b฀y฀ ฀s฀i฀l฀i฀c฀a฀ ฀g฀e฀l฀ ฀c฀h฀r฀o฀m฀a฀t฀o฀g฀r฀a฀p฀h฀y฀ ฀(Ș฀=฀6฀0฀%฀)฀.This
method was an improvement compared to the acyl chloride route since the
conversion rates were higher, there was no side reaction and the purifications
required less steps, affording much better synthetic yields of the purified ester of
PEG and prednisolone.
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II.3.3.PEG-salbutamol
II.3.3.1. Modification of salbutamol
Salbutamol free base: the resulting powder was obtained in good yields (86%) and
was confirmed (by NMR) to be a free base form of salbutamol. The solubility
properties of salbutamol free base in organic solvents were improved compared to
salbutamol sulphate since salbutamol free base was soluble in THF and dioxane
whereas salbutamol sulfate was soluble in more polar solvents such as water,
DMSO, alcohols. The precipitate recovered by filtration of the THF solution was
confirmed to be sodium sulphate (Fig.II.35), extracted from salbutamol sulphate
solution by sodium hydroxide, to give the free base form of salbutamol. Analysis of
2D NMR of salbutamol sulfate and salbutamol free base was conducted and the
results are displayed in Table. II.15. Fig.II.34 illustrates the position numbering of
salbutamol and dodecyl sulfonic acid.
Salbutamol dodecyl sulfate: the resulting powder was obtained in good yields
(88%) and was confirmed to be salbutamol dodecyl sulfate (Fig.II.35). Solubility in
organic solvents was maintained and the amine group was protonated since the
signals in positions 8 and 9 were closer to those of salbutamol sulfate. The ratio
dodecyl sulfonic acid/salbutamol was 1/1 (Table. II.15).
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Fig.II.34. Position numbering of salbutamol and dodecyl sulfonic acid
The full assignments of 2D NMR spectra are available in Appendix 4, Fig.VI.41,
Fig.VI.42, and Fig.VI.43 for respectively salbutamol sulfate, salbutamol free base
and salbutamol dodecyl sulfate.
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Table. II.15. NMR analysis of the different forms of salbutamol
Salbutamol sulfate Salbutamol free base Salbutamol dodecyl sulfate
# Type H shift (ppm) නࡴ C shift (ppm) Type H shift (ppm) නࡴ C shift (ppm) Type H shift (ppm) නࡴ C shift (ppm) #
11 s 1.19 9 26.48 s 1.01 9 29.10 s 1.29 9 25.18 11
10 NA 53.97 NA 49.48 NA 56.67 10
9 m 2.75 2 49.34 m 2.53 2 51.11 m 2.89 2 48.33 9
8 dd 4.68 1 70.19 dd 4.38 1 72.80 dd 4.75 1 69.54 8
7 s 4.47 2 58.45 s 4.47 2 59.10 d 4.50 2 58.45 7
6 d 6.73 1 114.55 d 6.66 1 114.55 d 6.77 1 114.88 6
5 dd 7.06 1 125.33 dd 6.96 1 125.32 dd 7.10 1 125.64 5
4 NA 133.19 NA 134.10 NA 132.28 4
3 s 7.31 1 125.65 d 7.22 1 125.33 d 7.36 1 125.65 3
2
NA
128.69
NA
128.24
NA
128.69 2
1 153.91 154.34 154.34 1
t 3.67 2 65.95 a
m 1.47 2 29.41 b
t 0.87 3 14.09 c
s 1.24 18
25.50 d
22.53 e
31.37 f
29.15 g
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Fig.II.35. FTIR spectra of salbutamol sulfate, salbutamol free base, salbutamol
dodecyl sulfate and sodium sulfate
 salbutamol sulfate,  salbutamol free base,  salbutamol dodecyl sulfate,  sodium
sulfate
II.3.3.2. PEG-salbutamol esters
a. Esterification
The conjugation of oxidised PEG and salbutamol was the most efficient through the
acyl chloride route and the use of salbutamol dodecyl sulfate. A relatively short
reaction time was necessary since the product seemed to degrade if the reaction was
prolonged for too long.
The choice of the tertiary amine base was therefore of primary importance since it
needs to scavenge the hydrochloric acid formed upon conjugation and push the
reaction toward completion (Scheme.II.8). Therefore, the higher the pKa of the
base, the better. However, it was necessary that the tertiary amine base had a pKa
lower that the pKa of the salbutamol amine group (pKa2 = 10.37), in order to keep
it protonated. Triethylamine has a pKa (10.72) [117] which is higher than
salbutamol and therefore deprotonated the amine group of the drug. Pyridine and
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2,6 lutidine have lower pKa values (5.17 and 6.71 respectively) [117] and some
conjugation was obtained with both amine bases. The reaction kinetic seemed to be
faster with 2,6 lutidine, probably because of its higher pKa. A compromise was
found in 2,6 lutidine, a tertiary amine base with a pKa high enough to quickly
precipitate HCl and low enough to leave salbutamol protonated.
Scheme.II.8. Mechanism of PEG-salbutamol esterification via acyl chloride
b. Purification
The following paragraph illustrates the strategy employed to purify PS62 (PEG2000
salbutamol ester). The same methodology was used to purify the two other
conjugates (PEG3400-salbutamol and mPEG2000-salbutamol).
The crude product PS62S2 contained 2,6 lutidine, free salbutamol, and dodecyl
sulfonate as contaminant (Appendix 4, Fig.VI.44). The first purification step
consisted of anion exchange to replace the dodecyl sulfonate with chloride ions.
After passage through the resin, 90% of the dodecyl sulfonate had been removed in
the product PS62 IRACl1 (Appendix 4, Fig.VI.45), with salbutamol still conjugated
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to PEG. The second purification step consisted in washing away the excess of
salbutamol. A dilute solution of HCl was thoroughly mixed with a solution of the
product solubilised in DCM/CHCl3 and water-soluble salbutamol chloride was
washed away in the aqueous phase. The product PS62X1 (Appendix 4, Fig.VI.46)
was freed of solvent traces (DCM, CHCl3, 2,6 lutidine) and traces of remaining
dodecyl sulfonic acid by precipitation in diethyl ether to yield a yellow solid. Table.
II.16 summarises the product composition throughout purification.
Table. II.16. PS62 contaminant composition throughout purification
Contaminant
Product
mol of contaminant / mol of PEG2000
dodecyl sulfonate 2,6 lutidine free salbutamol
PS62S2 5.0 8.8 2.8
PS62IRACl1 0.5 4.9 2.3
PS62X1 0.5 3.3 0
PS62Y1 0 0 0
The purified product PS62Y1 appeared to be composed of a mixture of PEG ester
of salbutamol and unreacted carboxyl groups (NMR in MeOD). On average, for
one mole of PEG2000 (-O-CH2-CH2-O-, į 3.63, 192 H), there was 0.45 mol of
unconjugated oxidised PEG (PEG-CH2-COO
-, į 4.00, 0.90 H), 1.35 mol of PEG
(PEG-CH2-CO-O-Salbu, į 4.20, 2.31 H) conjugated to the primary hydroxyl group
of salbutamol (Salbu-CH2-O-CO-PEG, į 5.22, 2.34 H), 0.20 mol of which was
conjugated to the secondary hydroxyl group of salbutamol as well (PEG-CH2-CO-
O-Salbu, į 4.17, 0.40 H and Salbu-CH-O-CO-PEG, į 4.98, 0.23 H). Two
dimensional NMR confirmed the structure of PEG2000-Salbu1.35 (Appendix 4,
Fig.VI.47).
96
The results obtained for PEG2000, PEG3400 and mPEG2000 salbutamol ester
conjugates are displayed in Table. II.17 and illustrated in Fig.II.36. Proton NMR
spectra of purified PEG3400-salbutamol ester and mPEG-salbutamol ester are given
in Appendix 4, respectively Fig.VI.48 and Fig.VI.49.
The average number of salbutamol per PEG was calculated as
(II.8) ݊ = ܤ െ ஼ଶ
A general formula PEG-Salbun was generated and used to calculate the average
molecular weight and elemental mass composition.
Table. II.17. PEG-salbutamol ester conjugates characterised by NMR
Type
MW
Da
average number
of PEG unit
Ɨ
mol conjugated to
primary
OH group
B
secondary
OH group
C
free
COOH
D
PEG2000-Salbu1.25 2573 48 1.36 0.20 0.45
PEG3400-Salbu1.53 3987 78.5 1.62 0.17 0.20
mPEG2000-Salbu0.85 2336 46 0.88 0.05 0.16
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Fig.II.36. Schematic of PEG-salbutamol ester mixtures determined by NMR
A. mPEG-salbutamol ester conjugation mixture, B. PEG-salbutamol ester conjugation
mixture
The purified products were analysed by FTIR (Fig.II.37) and presented spectra
typical of oxidised PEG while the signal for the ฀c฀a฀r฀b฀o฀n฀y฀l฀ ฀s฀t฀r฀e฀t฀c฀h฀ ฀(Ȟ(C=O)) was
shifted to slightly higher wavenumbers from 1745cm-1 to 1747-1749 cm-1. Two
typical signals for salbutamol at 1616 and 1202 cm-1 (Ȟ฀(฀C฀=฀C฀)฀ ฀a฀n฀d฀ ฀p฀h฀e฀n฀y฀l฀ ฀r฀i฀n฀g฀ 
vibration, respectively [118]) were found in the conjugates but not in oxidised PEG,
illustrating the presence of salbutamol in the conjugates.
Elemental analysis confirmed the presence of nitrogen (from salbutamol) in the
right proportions (Table. II.18), further confirming the obtained product
composition.
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Table. II.18. Elemental analysis of PEG-salbutamol ester conjugates
Type MW (Da) Calculated % Measured %
PEG2000-Salbu1.25 2573
C 54.31 53.7
H 8.74 8.58
N 0.68 1
PEG3400-Salbu1.53 3987
C 54.50 53.59
H 8.86 8.74
N 0.54 0.45
mPEG2000-Salbu0.85 2336
C 54.54 53.90
H 8.93 8.78
N 0.51 0.46
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Fig.II.37. FTIR spectra of salbutamol sulfate, oxidised PEG, PEG-salbutamol conjugates
 Salbutamol sulfate,  PEGCOOH,  PEG1000-Salbu2,  PEG2000-Salbu2,  mPEG2000-Salbu
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Summary
Direct esterification of oxidised PEG and salbutamol sulfate was inefficient due to
the poor drug solubility in organic solvents. Solubility was improved by producing
a free base form of salbutamol, which was soluble in THF but the conjugation
efficiency was not improved due to the salbutamol amine group competing with the
primary hydroxyl group to potentially form undesirable amide bonds. The
production of salbutamol dodecyl sulfate had the benefit to maintain organic
solvent solubility with the fatty chain of dodecyl sulfonate (C12) and the protonation
of salbutamol amine group which was accordingly not nucleophilic. It was
necessary to maintain the amine group protonated and the tertiary amine base used
to accelerate the esterification was carefully selected. Esterification with
Mukaiyama reagent, salbutamol dodecyl sulfate and 2,6-lutidine proceeded too
slowly and there was a competition between esterification and hydrolysis of the
product, resulting in partial esterifications (data not shown).
As a comparison, ester conjugates of oxidised PEG2000, mPEG2000 and PEG3400
were also produced via the acyl chloride route, purified by anion exchange and
characterised by 2D NMR, FTIR and elemental analysis. There was no
decarboxylation since the excess of thionyl chloride was limited to 6.3 (relative to
PEG carboxylic acid groups). The reactions were less efficient (77.5-90%
conjugation) than with prednisolone and some conjugation to the secondary
hydroxyl group occurred. Nonetheless, products of sufficient purity were obtained
in good yields (56-59%).
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II.4. Experimental
II.4.1.TEMPO oxidation of Polyethylene glycols
PEG 1000, PEG 2000, PEG 3400, deuterated NMR solvents, spectroscopic grade
potassium bromide and sodium hypochlorite solution were purchased from Sigma
Aldrich, (MO, USA), mPEG 2000 was purchased from Alfa Aesar (Heysham, UK),
TEMPO was a Fluka product (Buchs, Switzerland). Fisher scientific
(Loughborough, UK) provided concentrated hydrochloric acid and sodium
hydroxide. Sodium bromide was purchased from Riedel-de Haën (Sleeze,
Germany). Unless stated otherwise, organic solvents were of laboratory grade,
purchased from Fisher scientific.
PEG3400: A TEMPO solution (37 mM) was freshly prepared by dissolving TEMPO
(43.36 mg, 0.28 mmol) in warm deionised water (7.5 mL) and thoroughly mixing
until complete dissolution. In a 250 mL beaker, PEG3400 (33.95 g, 10 mmol of PEG,
20 mmol of hydroxyl group) and sodium bromide (833.0 mg, 8.1 mmol) were
dissolved in deionised water (150 mL). TEMPO solution (5.275 mL, 0.20 mmol)
was then added to the mixture and the pH was adjusted to 10 with sodium
hydroxide solution (0.5 M). The solution was then placed on an ice-water bath and
the temperature dropped to 2°C and maintained at that temperature during the
reaction. Cold aqueous sodium hypochlorite solution (35 mL, 13% available
chlorine, pH adjusted to 10 with 2M HCl) was then slowly added in aliquots over
more than 24 minutes whilst the pH was maintained at 10 by dropwise addition of
cold NaOH (0.5 M) solution when required. The mixture was then left to complete
the reaction for 300 min, and was subsequently slowly warmed up to 17°C. Excess
sodium hypochlorite was quenched with ethanol (25 mL) and the pH was adjusted
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to three with aqueous HCl (2 M). Oxidised PEG was then extracted with DCM,
dried over MgSO4, filtered and concentrated using a rotary evaporator. The product
was then precipitated in diethyl ether, collected by vacuum filtration and dried to
constant mass in a vacuum desiccator to yield 31.89 g ฀o฀f฀ ฀a฀ ฀w฀h฀i฀t฀e฀ ฀p฀o฀w฀d฀e฀r฀ ฀(Ș฀ ฀=฀ ฀9฀3฀%฀).
฀I฀R฀ ฀(฀K฀B฀r฀ ฀d฀i฀s฀c฀)฀:฀ Ȟmax 530, 843, 962, 1122, 1242, 1281, 1344, 1468, 1745, 2897 cm-1.
1H-NMR (400 MHz, methanol-d4) G 4.12 (s, 4H, PEG-(CH2-COOH)2), 3.64 (br. s.,
299H, PEG backbone).
PEG1000: The same procedure as for oxidation of PEG3400 was employed. Briefly, a
fresh TEMPO solution (40 mM) was prepared by solubilising TEMPO (93.59 mg,
0.60 mmol) in warm deionised water (15 mL). PEG1000 (5 g, 10 mmol of OH) was
oxidised using fresh TEMPO solution (2.5 mL, 0.10 mmol), NaBr (431.5 mg, 4.19
mmol) and 20 mL (35 mmol) of aqueous sodium hypochlorite solution (13%
available chlorine, pH adjusted to 10 with 2M HCl). The mixture was left to react
overnight and after acidification, oxidised PEG1000 was extracted three times with
DCM (60 mL), concentrated and precipitated in n-hexane (200 mL). It was then left
to dry to constant weight in a vacuum desiccator to yield 2.33 g of a white oily
product (Ș฀ ฀=฀ 45%). ฀I฀R฀ ฀(฀K฀B฀r฀ ฀d฀i฀s฀c฀)฀:฀ Ȟmax 845, 955, 1103, 1248, 1348, 1462, 1743,
2874 cm-1. 1H NMR (400 MHz, chloroform-d) G 4.16 (s, 4H, PEG-(CH2-COOH)2),
3.65 (s, 81H, PEG backbone).
PEG2000: The same procedure as for oxidation of PEG3400 was employed. Briefly, a
fresh TEMPO solution (56 mM) was prepared by dissolving TEMPO (86.88 mg,
0.56 mmol) in warm deionised water (10 mL). PEG2000 (20 g, 20 mmol of OH)
were oxidised using the freshly prepared TEMPO solution (3.5 mL, 0.2 mmol),
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NaBr (829.7 mg, 8.1 mmol) and 35 mL (61 mmol) of aqueous sodium hypochlorite
solution (13% available chlorine, pH adjusted to 10 with 2M HCl). The mixture
was left to react overnight and after acidification, oxidised PEG2000 was extracted
three times with DCM (75 mL), concentrated and precipitated in diethyl ether (800
mL). It was then left to dry to constant weight in a vacuum desiccator to yield 17.73
g of a white powder (Ș฀ ฀=฀ 87%). ฀I฀R฀ ฀(฀K฀B฀r฀ ฀d฀i฀s฀c฀)฀:฀ Ȟmax 528, 843, 962, 1107, 1242,
1279, 1342, 1468, 1743, 2879 cm-1. 1H NMR (400 MHz, chlorofom-d) G 4.07 (s,
4H, PEG-(CH2-COOH)2), 3.58 (br. s., 172H, PEG backbone).
mPEG2000: The same procedure as for oxidation of PEG3400 was employed. Briefly,
a fresh TEMPO solution (41 mM) was prepared by dissolving TEMPO (70.6 mg,
0.45 mmol) in warm deionised water (11 mL). Ten grams of mPEG2000 (4.9 mmol
of OH) were oxidised using fresh TEMPO solution (1.2 mL, 0.05 mmol), NaBr
(239.4 mg, 2.3 mmol) and 14.4 mL (25 mmol) of aqueous sodium hypochlorite
solution (13% available chlorine, pH adjusted to 10 with 2M HCl). The mixture
was left to react overnight and after acidification, oxidised mPEG2000 was extracted
three times with DCM (75 mL), concentrated and precipitated in diethyl ether (300
mL). It was then left to dry to constant weight in a vacuum desiccator to yield 7.66
g of a white waxy powder (Ș฀ ฀=฀ 76%). ฀I฀R฀ ฀(฀K฀B฀r฀ ฀d฀i฀s฀c฀)฀:฀ Ȟmax 530, 843, 964, 1117,
1244, 1281, 1344, 1468, 1654, 1742, 2893 cm-1. 1H-NMR (400 MHz, chloroform-
d) G 4.08 (s, 2H, PEG-CH2-COOH), 3.58 (s, 178H, PEG backbone), 3.32 (s, 3H,
terminal methoxy).
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II.4.2.Esterification of PEG and prednisolone
For all esterification reactions, the glassware was dried by flame drying. Dry
conditions were used to conduct the reactions. Solutions and suspensions were
transferred with a cannula and transferred volumes replaced with Argon (supplied
by BOC, UK). The solid reagents were stored in a vacuum desiccator and further
dried prior to reaction by creating a high vacuum (less than 13 Pa) in the reaction
vessel for at least 180 min. The liquid reagents were supplied dry and stored over
molecular sieves.
Amberlite IRA 200 (C)Na+ was purchased from Alfa Aesar, prednisolone, dry
triethylamine were purchased from Sigma, thionyl chloride was a Fluka product.
Dry DCM, dry THF were purchased from ACROS organics (Geel, Belgium).
Cation exchange resin preparation. The resin was washed in deionised water until
the eluent was clear, and the beads were drained by vacuum filtration using a
Venturi device.
Mukaiyama reagent was purchased from Fluka, dry pyridine was purchased from
Acros organics.
II.4.2.1. Acyl chloride
PP11: Oxidised PEG3400 (8.56 g, 5.0 mmol of COOH) was placed in a two-neck
100 mL round bottom flask mounted with a condenser. The polymer was then
solubilised in dry DCM (50 mL) and thionyl chloride (10 mL) was added with a
glass pipette, under an argon flux. The reaction was stirred overnight at 40°C. The
heating was stopped and solvent and excess of thionyl chloride were evaporated to
dryness by vacuum distillation to yield an off-white solid. In a 250 mL round
bottom flask, dry prednisolone (2522 mg, 7.0 mmol) was poured over a flow of
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argon and dissolved in dry THF (75 mL). Triethylamine (1.8 mL, 13 mmol) was
added to the prednisolone solution with a syringe. PEG acyl chloride was
solubilised in dry DCM (40 mL) and slowly added to the stirred solution of
prednisolone and triethylamine over 15 minutes at room temperature. The
temperature was then set to 40°C. The reaction was stopped after 1200 minutes by
switching the heating and stirring off. The solution was then filtered and the solvent
was evaporated off. The crude product PP11BS1 was analysed by NMR. A small
fraction of the product was resuspended in DCM and mixed with silica gel and the
solvent was removed by rotary evaporation. The dry silica gel was then transferred
onto a paper filter and washed with ethyl acetate (fractions A to D) until no more
fluorescence was detected in the eluent (checked by TLC). The silica was then
washed with DCM/MeOH 90/10 v/v (fractions E to K) until no fluorescence was
detected in the eluent. Fractions E to K were pooled together and evaporated to
dryness for NMR analysis (PP11SFEK).
PP14: The reaction was carried out in the same way as for PP11. Briefly, oxidised
PEG3400 (5.04 g, 2.9 mmol of COOH) was chlorinated overnight with thinoyl
chloride (6.0 mL, 83 mmol) in DCM (20 mL). After drying, PEG acyl chloride
dissolved in dry DCM (30 mL) was added to a solution of prednisolone (1.47 g, 4.1
mmol) and triethylamine (1 mL, 7.2 mmol) in dry THF (70 mL). The reaction was
carried out for 1580 min at 40°C and after completion, the mixture was filtered and
the solvent evaporated to dryness to give PP14S1, which was analysed by NMR.
PP14S1 was then solubilised in DCM (200 mL). Dry silica gel (24g) was added to
half of the PP14S1 solution, thoroughly stirred to let the product to adsorb on silica,
and the solvent was subsequently removed by rotary evaporation. The dry silica
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was transferred onto a filter and washed with diethyl ether/ethyl acetate 50/50 v/v
(fractions 1-3). THF/DCM 40/60 v/v was then used and 500 mL fractions were
collected for NMR analysis (fractions 4-7). Finally, THF/DCM 50/50 v/v was used
for the last two fractions (8 and 9). The fractions were concentrated and
individually precipitated in diethyl ether. PP14SF4P was analysed by NMR. The
precipitated fractions 4 to 9 were pooled together, solubilised in acetone (100 mL)
and mixed overnight at 250 rpm with prepared cation exchange resin (57 g). The
suspension was then filtered, the beads washed 3 times with acetone (100 mL), the
solvent evaporated to dryness and the product PP14SFDC1S analysed by NMR.
PP08: The reaction was carried out in the same way as for PP11. Briefly, oxidised
mPEG2000 (3.5 g, 1.7 mmol of COOH) was chlorinated overnight with thionyl
chloride (3.5 mL, 48.2 mmol) in DCM (30 mL). After drying, PEG acyl chloride in
dry DCM (25 mL) was added to a solution of prednisolone (876.7 mg, 2.4 mmol)
and triethylamine (650 ʅL, 4.7 mmol) in dry THF (25 mL). The reaction was
carried out for 1260 min at 40°C and after completion, the mixture was filtered and
the solvent evaporated to dryness. The product was then resuspended in DCM (13
mL) and precipitated in diethyl ether (200 mL) to give 3781 mg of PP08P2,
analysed by NMR. A small fraction of PP08P2 (255 mg) was then solubilised in
DCM (8 mL) and the flask washed with two times six millilitres of THF. To this
stirred solution was added the prepared cation exchange resin (1.80 g), previously
washed twice with 50 mL of THF/DCM (60/40 v/v) and left overnight. The
suspension was filtered, washed with DCM and the solvents were evaporated. The
product PP08DC2 was analysed by NMR and then solubilised in DCM (8 mL) and
precipitated in cyclohexane (80 mL) to yield 106 mg of precipitated product that
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was then solubilised again in DCM (15 mL) and adsorbed on dry silica (454.5 mg).
The solvent was then removed by rotary evaporation. The silica was transferred
onto a paper filter and washed with 100 mL of diethyl ether/ethyl acetate (90/10
v/v) (fraction 1) and 100 mL of DCM/MeOH (80/20 v/v) (fraction 2). The second
fraction was evaporated to dryness to give PP08DC2DF1B, analysed by NMR.
PP16: The reaction was carried out in the same way as for PP11. Briefly, oxidised
PEG2000 (3.05 g, 3.0 mmol of COOH) was chlorinated overnight with thinoyl
chloride (10.0 mL, 140 mmol) in DCM (10 mL). After drying, PEG acyl chloride
dissolved in dry DCM (40 mL) was added to a solution of prednisolone (1.59 g, 4.4
mmol) and triethylamine (1.3 mL, 9.3 mmol) in dry THF (60 mL). The reaction
was carried out for 1105 min at 45°C and after completion, the mixture was filtered
and the solvent evaporated to dryness to give PP16S1, analysed by NMR. PP14S1
was solubilised in DCM (50 mL) and washed with 15 mL of 0.5 M HCl. The
organic phase was collected and dried over MgSO4. The solvent was evaporated to
dryness and PP16HCl analysed by NMR. PP16HCl was solubilised in DCM (50
mL), adsorbed on dry silica (5.1 g) and DCM was removed by rotary evaporation.
The silica was transferred onto a paper filter and washed with one litre of diethyl
ether/ethyl acetate (50/50 v/v). A silica gel chromatography column was loaded
with the treated silica (bed height 17 cm, 120 mL) and THF/ethyl acetate (50/50
v/v). The column was subsequently washed with 200 mL of the packing solvent
mixture, then 160 mL of THF. The PP16SGA fraction was collected, evaporated to
dryness, solubilised in DCM (15 mL), and precipitated in diethyl ether (200 mL) to
yield an off white paste (PP16SGAp), analysed by NMR.
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PP13: The reaction was carried out in the same way as for PP11. Briefly, oxidised
PEG1000 (1.57 g, 3.1 mmol of COOH) was chlorinated overnight with thinoyl
chloride (5.0 mL, 69 mmol) in DCM (30 mL). After drying, PEG acyl chloride
dissolved in dry DCM (25 mL) was added to a solution of prednisolone (1.51 g, 4.2
mmol) and triethylamine (1.1 mL, 7.9 mmol) in dry THF (40 mL). The reaction
was carried out for 1600 min at 40°C and after completion, the mixture was filtered
and the solvent evaporated off to dryness to give PP13S1, analysed by NMR. The
product was solubilised in acetone (100 mL) and mixed with prepared cation
exchange resin (19 g), and washed with acetone (250 mL). The ion exchange was
carried out overnight over gentle mixing. The suspension was filtered, the resin
rinsed six times with DCM (25 mL), the solvents evaporated to dryness to give an
oily product PP13DC1. The product was then solubilised in DCM (50 mL) and
cation exchanged with 10 g of prepared resin (washed with 300 mL of acetone and
25 mL of DCM) for 120 min. The suspension was filtered, the resin washed with
DCM (100 mL) and the solvent evaporated to dryness to give 1.22 g of PP13DC2
(analysed by NMR). The product was suspended in DCM (70 mL), adsorbed on dry
silica (6 g), the solvent removed and the silica transferred onto a paper filter. The
silica was washed with 4 times 350 mL of ethyl acetate/diethyl ether (10/90 v/v) to
give fraction A, then 350 mL of DCM/MeOH (80/20 v/v) were used to give
fraction B. The solvents were removed by rotary evaporation to yield 699.2 g of dry
product PP13DC2DFB฀,฀ ฀a฀n฀a฀l฀y฀s฀e฀d฀ ฀b฀y฀ ฀N฀M฀R฀ ฀(Ș฀ ฀=฀ ฀2฀8฀%฀)฀.฀ 
PP17: Dry PEG3400COOH (2.04 g, 1.2 mmol of COOH) was poured into a two-
necked 100 mL round bottom flask, mounted with a condenser, flushed with argon
and solubilised in DCM (15 mL). Thionyl chloride (3.0 mL, 41 mmol) was added
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and the temperature was increased to 45°C. After 240 min, the solvent and excess
of thionyl chloride were removed by vacuum distillation to yield a white solid. In a
two-necked 100 mL round bottom flask, mounted with a condenser, prednisolone
(764.0 mg, 2.1 mmol) was added to THF (20 mL). Dry pyridine (1.1 mL, 13.7
mmol) was added in the stirred solution of prednisolone. PEG acyl chloride was
solubilised in DCM (20 mL) and slowly transferred into the prednisolone/pyridine
solution over seven minutes. The temperature was increased to 45°C and the
reaction was carried out for 1010 minutes. PP17S2 was obtained by evaporation of
solvents.
PP22/PP23: Oxidised PEG3400 (2.04 g, 0.6 mmol PEG, 1.2 mmol of carboxylic
acid) were poured, under Argon, into a two-necked 100 mL round bottom flask
mounted with a condenser. After drying, the polymer was solubilised in dry DCM
(15 mL). Thionyl chloride (6.0 mL, 83 mmol) was then added with a syringe and
the temperature was increased and maintained at 45°C under stirring. The mixture
was left to react for 215 min. The solvents were then evaporated off by vacuum
distillation and a yellowish solid was obtained. The solid was resuspended in dry
DCM (16 mL) and transferred into a sealed 50 mL measuring cylinder, flushed with
Argon beforehand. The flask was further washed with dry THF (10 mL) and the
solution added into the measuring cylinder.
PP22: prednisolone (448.6 mg, 1.24 mmol) was poured into a two necked 50 mL
round bottom flask mounted with a condenser and flushed with Argon for more
than 15 minutes after drying. Prednisolone was solubilised in exactly 10 mL of dry
THF and stirred. Dry pyridine (600 ȝL, 7.46 mmol) was added with a syringe under
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argon. Thirteen millilitres of the PEG acyl chloride solution (0.3 mmol of PEG,
0.15 mmol of acyl chloride) were then slowly added into the prednisolone/pyridine
solution over 5 minutes. The temperature was then increased and maintained at
50°C under constant stirring. After 120 min, a sample (500 µL) was taken under
argon, the solvent evaporated, the crude product resuspended in deuterated
methanol and analysed by NMR (PP22S1) and the reaction was continued for 1000
min. The solvents were then evaporated off by rotary evaporation and the product
PP22S2 analysed by NMR.
PP23: prednisolone (216.7 mg, 0.63 mmol) was used following the same procedure
as for PP22.
PP20/PP21: PEG3400 acyl chloride was produced according to the same procedure
as for PP22/PP23. Briefly, PEG3400 diacid (2.03 g, 0.59 mmol of PEG, 1.18 mmol
of carboxylic acid) was reacted with thionyl chloride (6.0 mL, 83 mmol) for 240
min at 45°C. The product was then solubilised in dry DCM (45 mL).
PP20: prednisolone (314.0 mg, 0.87 mmol) was solubilised in dry THF (15 mL).
Dry pyridine (100 ȝL, 1.24 mmol) was added and 22.5 mL of PEG acyl chloride
solution (0.30 mmol of PEG, 0.59 mmol of acyl chloride) was then slowly added to
the mixture over 40 minutes, under stirring. The temperature was subsequently
increased and maintained at 45°C. After 30 minutes, a sample was taken and
analysed by NMR (PP20S1) and the reaction was continued for 1410 min when the
solvents were evaporated to dryness to give PP20S2, analysed by NMR.
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PP21: prednisolone (309.3 mg, 0.86 mmol) was solubilised in dry THF (20 mL),
and 22.5 mL of PEG acyl chloride solution (0.30 mmol of PEG, 0.59 mmol of acyl
chloride) added all at once. Dry pyridine (100ȝL) was mixed with dry DCM and
slowly added to the mixture over 40 minutes while stirring. The temperature was
then increased and maintained at 45°C. After 45 minutes, a sample was taken and
analysed by NMR (PP21S1) and the reaction was continued for an additional 1380
min when the solvents were evaporated to dryness to give PP21S2 and analysed by
NMR.
PP25/PP26: PEG3400 acyl chloride was produced according to the same procedure
as for PP22/PP23. Briefly, PEG3400 diacid (2.02 g, 0.59 mmol of PEG, 1.18 mmol
of carboxylic acid) was reacted with thionyl chloride (900 µL, 12.4 mmol) for 180
min at 30°C. The product was then solubilised in dry DCM (30 mL).
PP25: prednisolone (221.4 mg, 0.62 mmol) was solubilised in dry THF (15 mL).
Dry pyridine (900 ȝL, 11.2 mmol) was added, followed by 15 mL of PEG acyl
chloride solution (0.30 mmol of PEG, 0.59 mmol of acyl chloride), under stirring,
over 10 minutes. The temperature was then increased and maintained at 40°C for
1245 min. The solvents were evaporated by rotary evaporation and PP25S1
analysed by NMR.
PP26: prednisolone (441.7 mg, 1.23 mmol) was solubilised in dry THF (15 mL).
Dry pyridine (900 ȝL, 11.2 mmol) was added, followed by 15 mL of PEG acyl
chloride solution (0.30 mmol of PEG, 0.59 mmol of acyl chloride) under stirring
and over 10 minutes. The temperature was then increased and maintained at 40°C
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for 1185 min. The solvents were evaporated by rotary evaporation and PP26S1
analysed by NMR.
II.4.2.2. Mukaiyama reagent
PP04: prednisolone (112.5 mg, 0.31 mmol) and Mukaiyama reagent (82.85 mg,
0.32 mmol) were added in a 100 mL two necked round bottom flask mounted with
a condenser. The flask was flushed with argon after drying and the products
suspended in dry DCM (40 mL), under stirring. In a two necked 50 mL round
bottom flask, oxidised mPEG2000 (501.2 mg, 0.24 mmol of carboxylic acid) was
solubilised in dry DCM (20 mL). The PEG solution was then transferred under
argon to the stirred suspension of prednisolone and Mukaiyama reagent at room
temperature, over 5 minutes. Triethylamine (125 ȝL, 0.86 mmol) was added with a
syringe. The temperature was then increased and maintained at 40°C. A first
sample (PP04S1) was withdrawn after 250 min, the solvent evaporated off and
analysed by NMR. The reaction was stopped after 1310 min (PP02S2).
PP01: oxidised PEG3400 (700.3 mg, 0.20 mmol of PEG, 0.41 mmol of carboxylic
acid) and prednisolone (180.7 mg, 0.50 mmol) were poured in a two necked 100
mL round bottom flask mounted with a condenser. After drying, dry THF (60 mL)
was added under stirring and the temperature was increased to 40°C. Dry
triethylamine (150 ȝL, 1.08 mmol) was then added with a syringe. Mukaiyama
reagent was placed in a two necked 50 mL round bottom flask and suspended in dry
THF (10 mL). Mukaiyama suspension was then transferred into the
PEG/prednisolone/triethylamine suspension and the temperature was increased and
maintained at 50°C. A first sample was taken after 1270 min (PP01S1) and a
second sample after 2440 min (PP1S2).
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PP24: prednisolone (309.2 mg, 0.86 mmol) and Mukaiyama reagent (226.1 mg,
0.88 mmol) were added in a 100 mL argon-flushed two necked round bottom flask
mounted with a condenser. The products were suspended in dry THF (10 mL) and
dry DCM (10 mL), under stirring and 350 µL of dry triethylamine (2.5 mmol) were
added with a syringe. In a 2 neck 50 mL round bottom flask, 1009 mg of oxidised
PEG3400 (0.29 mmol of PEG, 0.59 mmol of carboxylic acid) were solubilised in 20
mL of dry DCM. PEG solution was slowly added to Mukaiyama
reagent/prednisolone/triethylamine solution over 12 min and the temperature was
increased to 50°C. A sample was taken after 60 min (PS24S1) and the reaction was
continued for 1250 min (PS24S2).
PP27: The procedure used for PP24 was employed. Briefly, prednisolone (318.7
mg, 0.88 mmol), Mukaiyama reagent (451.9 mg, 1.77 mmol) and 500 µL of dry
triethylamine (3.59 mmol) were suspended in a mixture of dry DCM (12 mL) and
dry THF (12 mL). PEG solution (1001 mg, 0.59 mmol of carboxylic acid) was
slowly added to the mixture. A first sample was withdrawn after 1000 min
(PP27S1) and the reaction carried out for a total of 2460 min (PP27S2) at 50°C.
PP33: oxidised PEG1000 (2050 mg , 3.99 mmol of carboxylic acid) was placed in a
two necked 100 mL round bottom flask under high vacuum (less than 13 Pa) for
more than 300 min. Dry Mukaiyama reagent (3035 mg, 11.88 mmol) and dry
prednisolone (1983 mg , 5.50 mmol) were poured in a two necked 100 mL round
bottom flask mounted with a condenser and the flask was then maintained under
high vacuum (less than 13 Pa) for more than 300 min. Oxidised PEG was
solubilised in dry DCM (15 mL). Prednisolone and Mukaiyama reagent were
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suspended in dry THF (50 mL) and dry triethylamine (3.3 mL, 24 mmol) was
added. PEG solution was slowly transferred to the suspension at room temperature
over 10 minutes under stirring. The flask that contained PEG was rinsed with dry
DCM (5 mL) and transferred to the reaction mixture. Temperature was then
maintained at 40°C for 4320 min. Heating and stirring were stopped, the solution
filtered and solvents evaporated to dryness.
The dry residue was solubilised in acetonitrile (12 mL) and loaded into a
chromatography column packed with silica gel in acetonitrile (25 cm bed height,
200 mL). The column was washed with 5 column volumes of acetonitrile until no
more product was visibly coming out of the column (TLC plate revealed by UV
light). Tetrahydrofuran was then used to recover the ester conjugate (2 column
volumes). After evaporation of THF, the product was resuspended in DCM (15
mL) and precipitated in diethyl ether (200 mL) to yield a viscous dark yellow syrup
that stuck to the beaker walls (PP33w1). The product was then taken up in DCM
(15 mL) and precipitated in 200 mL of pentane (PP33w2). A third precipitation in
diethyl ether afforded a yellow paste that was resuspended in a minimum amount of
methanol, transferred to a glass vial and dried until constant weight (PP33w3) to
afford 2330 ฀m฀g฀ ฀o฀f฀ ฀p฀u฀r฀e฀ ฀p฀r฀o฀d฀u฀c฀t฀ ฀(Ș฀ ฀=฀ ฀6฀9฀%฀). Elemental analysis: measured C 58.3%
H 8.1% N -0.3%, calculated C 57%, H 8.7%, N 0%. ฀I฀R฀ ฀(฀K฀B฀r฀ ฀d฀i฀s฀c฀)฀:฀ Ȟmax 847, 949,
1113, 1246, 1292, 1350, 1450, 1659, 1724, 1761, 2870 cm-1. Selection of
significant 1H-NMR signals (400 MHz, methanol-d4) G 7.50 (d, J = 9.90 Hz, 1H),
6.28 (dd, J = 1.90, 10.00 Hz, 1H), 6.03 (s, 2H), prednisolone alkene protons, 4.94 -
5.21 (m, 4H), prednisolone-C=O-CH2-O-C=O-PEG), 4.33 (s, 4H), PEG-CH2-C=O-
O-Pred, 3.66 (s, 81H), PEG backbone.
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PP28: the same production procedure as for PP33 was employed. Briefly, oxidised
mPEG2000 (4007 mg , 1.95 mmol of carboxylic acid) dissolved in dry DCM (20
mL) was slowly added to a suspension of prednisolone (1001 mg, 2.78 mmol),
Mukaiyama reagent (1557 mg, 6.10 mmol) and triethylamine (1.7 mL, 12 mmol) in
dry THF (20 mL). The mixture was allowed to react for 4110 min at 40°C. Heating
and stirring were stopped, the solution filtered and solvents evaporated to dryness.
The dry residue was solubilised in warm propan-2-ol and left to crystallise
overnight to afford yellow crystals. The crystals were then filtered and washed with
diethyl ether/propan-2-ol (75/25 v/v) and cold diethyl ether. The crystals were then
dried until constant weight in a vacuum desiccator and afforded 2816 mg of pure
฀p฀r฀o฀d฀u฀c฀t฀ ฀(Ș฀ ฀=฀ 58%). Elemental analysis: measured C 56.3% H 8.8% N -0.1%,
calculated C 56.5%, H 8.8%, N 0%. ฀I฀R฀ ฀(฀K฀B฀r฀ ฀d฀i฀s฀c฀)฀:฀ Ȟmax 843, 962, 1113, 1242,
1283, 1344, 1468, 1659, 1761, 2893 cm-1. Selection of significant 1H-NMR signals
(500 MHz, methanol-d4) G 7.48 (d, J = 9.93 Hz, 1H), 6.26 (dd, J = 1.89, 10.09 Hz,
1H), 6.01 (s, 1H), prednisolone alkene protons, 4.99-5.12 (m, 2H), prednisolone-
C=O-CH2-O-C=O-PEG), 4.31 (s, 2H), PEG-CH2-C=O-O-Pred, 3.63 (s, 184H),
PEG backbone, 3.36 (s, 3H), methoxy PEG.
PP32: the same production procedure as for PP33 was employed. Briefly, oxidised
PEG2000 (2013 mg , 2.0 mmol of carboxylic acid) dissolved in dry DCM (20 mL)
were slowly added to a suspension of prednisolone (997.4 mg, 2.77 mmol),
Mukaiyama reagent (1512 mg, 5.92 mmol) and triethylamine (1.7 mL, 12 mmol) in
dry THF (20 mL). The mixture was allowed to react for 4245 min. Heating and
stirring were stopped, the solution filtered and solvents evaporated to dryness.
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The dry residue was solubilised in acetonitrile (10 mL) and loaded into a
chromatography column packed with silica gel in acetonitrile (24 cm bed height,
170 mL). The column was washed with 4 column volumes of acetonitrile until no
more product was visibly coming out of the column (TLC plate revealed by UV
light). Tetrahydrofuran was then used to recover the ester conjugate (6 column
volumes). After evaporation of THF, the product was resuspended in DCM (12
mL) and precipitated in ice cold diethyl ether (200 mL), washed with ice cold
diethyl ether, and filtered to yield a pale yellow solid that melted rapidly at room
temperature. The product was transferred to a glass vial and dried until constant
weight (PP32C2) and afforded 1699 mg of pure PEG-prednisolone ฀(Ș฀ ฀=฀ ฀6฀0฀%฀).
Elemental analysis: measured C 57.1% H 8.0% N 0%, calculated C 58.3%, H 8.5%,
฀N฀ ฀0฀%฀.฀ ฀I฀R฀ ฀(฀K฀B฀r฀ ฀d฀i฀s฀c฀)฀:฀ Ȟmax 849, 953, 1117, 1253, 1302, 1354, 1471, 1659, 1726,
1761, 2883 cm-1. Selection of significant 1H-NMR signals (400 MHz, methanol-
d4)G 7.48 (d, J = 9.90 Hz, 2H), 6.25 (dd, J = 1.90, 10.10 Hz, 2H), 6.01 (s, 2H),
prednisolone alkene protons, 4.91 - 5.21 (m, 4H), prednisolone-C=O-CH2-O-C=O-
PEG), 4.30 (s, 4H), PEG-CH2-C=O-O-Pred, 3.63 (s, 180H), PEG backbone.
PP31: the same production procedure as for PP33 was employed. Briefly, oxidised
PEG3400 (3405 mg, 2.0 mmol of carboxylic acid) dissolved in dry DCM (30 mL)
were slowly added to a suspension of prednisolone (1002 mg, 2.78 mmol),
Mukaiyama reagent (1561 mg, 6.11 mmol) and triethylamine (1.7 mL, 12 mmol) in
dry THF (20 mL). The mixture was allowed to react for 4380 min. Heating and
stirring were stopped, the solution filtered and solvents evaporated to dryness.
The dry residue was solubilised in warm propan-2-ol and left to crystallise
overnight to afford off-white crystals. The crystals were then filtered and washed
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with diethyl ether/propan-2-ol (75/25 v/v) and solubilised in DCM (14 mL) to be
precipitated in diethyl ether (200 mL). The crystals were then filtered by vacuum
filtration on a filter paper, collected and dried in a vacuum desiccator until constant
weight. The reaction afforded 3030 mg of pure product (Ș฀ ฀=฀ ฀7฀5฀%). Elemental
analysis: measured C 55.9% H 8.1% N 0.2%, calculated C 57.0%, H 8.7%, N 0%.
฀I฀R฀ ฀(฀K฀B฀r฀ ฀d฀i฀s฀c฀)฀:฀ Ȟmax 843, 964, 1116, 1242, 1282, 1344, 1468, 1661, 1728, 1765,
2891 cm-1. Selection of significant 1H-NMR signals (500 MHz, methanol-d4)G 7.48
(d, J = 10.09 Hz, 2H), 6.26 (dd, J = 1.89, 10.09 Hz, 2H), 6.01 (s, 2H), prednisolone
alkene protons, 4.93 - 5.18 (m, 4H), prednisolone-C=O-CH2-O-C=O-PEG), 4.31 (s,
4H), PEG-CH2-C=O-O-Pred, 3.63 (s, 299H), PEG backbone.
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II.4.3.Esterification of PEG and salbutamol
Salbutamol sulfate and Amberlite IRA Cl- were purchased from Alfa Aesar, dry
2,6-lutidine was an Aldrich product, sodium dodecyl sulfate was purchased from
Melford (Ipswich, UK).
Salbutamol FB: salbutamol sulfate (2192 mg, 7.6 mmol) was dissolved in deionised
water (75 mL). The pH was adjusted to 9.72 using sodium hydroxide solution (2.5
M). Water was evaporated off in a rotary evaporator set at 60°C, mounted with a
splash guard to avoid condensing water refluxing back in the flask. The residue was
resuspended in THF (50 mL), the solution filtered, the filtrant resuspended twice
more in THF (50 mL) and subsequently filtered. The organic solution was
concentrated to 30 mL and salbutamol free base was precipitated in n-hexane (200
mL) as a white crystalline powder. The precipitate was recovered by gravitation
filtration and left to dry in a vacuum oven until constant weight (1572 ฀m฀g฀,฀ Ș฀ ฀=฀ 
86%). 1H NMR (400 MHz, METHANOL-d4) G 7.24 (d, J = 2.26 Hz, 1H), 7.05 -
7.12 (m, 1H), 6.73 (d, J = 8.03 Hz, 1H), 4.65 (s, 2H), 4.58 - 4.63 (m, 1H), 2.55 -
2.89 (m, 2H), 1.11 (s, 9H). ฀I฀R฀ ฀(฀K฀B฀r฀ ฀d฀i฀s฀c฀)฀:฀ Ȟmax 613, 719, 819, 1038, 1078, 1269,
1338, 1502, 1606, 2964 cm-1.
Salbutamol dodecyl sulfate: salbutamol free base (1335 mg, 5.58 mmol) was
dissolved in deionised water (125 mL), and 36.43 mL (5.58 mmol) of dodecyl
sulfonic acid solution at 0.1531 M (3091 mg of sodium dodecyl sulfate (SDS)
(10.72 mmol) adjusted to pH 1.5 in 70 mL) were added under stirring. The solution
lost its pale yellow colour and a white precipitate rapidly appeared. The solution
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was filtered through a paper filter using a Ventrui vacuum system and the
precipitate was dried using high vacuum until constant weight (2483 ฀m฀g฀,฀ Ș฀ ฀=฀ ฀8฀8฀%฀)฀.
1H NMR (400 MHz, DMSO-d6) G 7.22 (d, J = 1.76 Hz, 1H), 6.96 (dd, J = 2.13,
8.16 Hz, 1H), 6.66 (d, J = 8.28 Hz, 1H), 4.47 (s, 2H), 4.38 (dd, J = 5.27, 7.28 Hz,
1H), 2.52 - 2.58 (m, 2H), 1.01 (s, 9H). ฀I฀R฀ ฀(฀K฀B฀r฀ ฀d฀i฀s฀c฀)฀:฀ Ȟmax 594, 812, 993, 1202,
1258, 1385, 1618, 2853, 2922 cm-1.
PS62: oxidised PEG2000 (1309 mg, 1.29 mmol of COOH) was poured in a 100 mL
two necked round bottom flask. Salbutamol dodecyl sulfate (1406 mg, 2.78 mmol)
was placed in a 100 mL two necked bottom flask mounted with a condenser. Both
flasks were connected to high vacuum (less than 13 Pa) overnight to dry the
products. PEG was solubilised in dry DCM (20 mL) under stirring and thionyl
chloride (500 ȝL, 6.88 mmol) was injected with a syringe. The reaction was
allowed to proceed for 240 min. Heating was stopped and after cooling down, the
solvent and excess thionyl chloride were evaporated off. Salbutamol dodecyl
sulfate was solubilised in dry THF (44 mL) and heated to 50°C, under stirring. Dry
2,6 lutidine (780 ȝL, 6.70 mmol) was added with a syringe. PEG acyl chloride was
solubilised in dry DCM (20 mL) and added in aliquots to the salbutamol/lutidine
solution. After 45 min, heating and stirring were stopped, the solvent evaporated to
dryness and the dry residue analysed by NMR (PS62S2). The product was
suspended in 20 mL of MeOH and passed through an anion exchange column
(resin: IRA Cl- equilibrated in MeOH, column 25.5 cm length by 24 mm internal
diameter (ID)). The solvent was evaporated using a rotary evaporator at 40°C, the
dry residue PS62IRACl1 analysed by NMR. The product was solubilised in DCM
(80 mL) and chloroform (20 mL) and washed with 20 mL of dilute HCl solution (1
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drop of 0.02 M HCl in one litre of deionised water). The organic layer was
recovered and dried over MgSO4, filtered and the solvents evaporated off
(PS62X1). The product was finally solubilised in 10 mL, then another 3 mL of
DCM and precipitated in a mixture of 150 mL of diethyl ether and 15 mL of n-
hexane. The purified product was filtered using a Ventrui vacuum system and
washed with diethyl ether/propan-2-ol (50/50 v/v) to yield a white powder that
melted rapidly at room temperature. PS62Y1 was left to dry until constant weight
in a vacuum oven (943 mg, Ș฀ ฀=฀ ฀5฀7฀%). Elemental analysis: measured C 53.70%,
8.58H %, N 1%, calculated C 54.31%, H 8.74%, N 0.68%. ฀I฀R฀ ฀(฀K฀B฀r฀ ฀d฀i฀s฀c฀)฀:฀ Ȟmax 837,
951, 1097, 1250, 1350, 1454, 1616, 1749, 2870 cm-1.
PS57: the same methodology as for PS 62 was used to produce an ester of oxidised
mPEG2000 and salbutamol. Briefly, oxidised mPEG2000 (1264 mg, 0.62 mmol) was
reacted with thionyl chloride (280 ȝL, 3.86 mmol). PEG acyl chloride was then
reacted with a mixture of salbutamol dodecyl sulfate (742.5 mg, 1.47 mmol) and
2,6 lutidine (400 ȝL, 3.43 mmol) for 44 min at 50°C. The crude product PS57S2
was purified by anion exchange (IRACl- in MeOH, 21 cm length, 24 mm ID),
followed by a dilute HCl wash, and precipitation in diethyl ether to yield a brown
฀p฀o฀w฀d฀e฀r฀ ฀(Ș฀ ฀=฀ ฀5฀9฀%฀)฀.Elemental analysis: measured C 53.90%, 8.78H %, N 0.46%,
calculated C 54.54%, H 8.93%, N 0.51%. ฀I฀R฀ ฀(฀K฀B฀r฀ ฀d฀i฀s฀c฀)฀:฀ Ȟmax 843, 964, 1117, 1282,
1344, 1467, 1616, 1749, 2893 cm-1.
PS60: The same methodology as for PS62 was used to produce an ester of oxidised
PEG3400 and salbutamol. Briefly, oxidised PEG3400 (2138 mg, 1.25 mmol of
COOH) was reacted with thionyl chloride (500 ȝL, 6.88 mmol). PEG acyl chloride
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was then reacted with a mixture of salbutamol dodecyl sulfate (1424 mg, 2.82
mmol) and 2,6 lutidine (780 ȝL, 6.70 mmol) for 37 min at 50°C. The crude product
PS60S2 was purified by anion exchange (IRACl- in MeOH, 21 cm length, 24 mm
ID), followed by a dilute HCl wash, and precipitation in diethyl ether to yield a
฀w฀h฀i฀t฀e฀ ฀p฀o฀w฀d฀e฀r฀ ฀(Ș฀ ฀=฀ ฀5฀6฀%฀)฀.Elemental analysis: measured C 53.59%, 8.74H %, N
0.45%, calculated C 54.50%, H 8.86%, N 0.54%. ฀I฀R฀ ฀(฀K฀B฀r฀ ฀d฀i฀s฀c฀)฀:฀ Ȟmax 841, 951,
1103, 1248, 1346, 1466, 1616, 1747, 2874 cm-1.
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II.5. Conclusion
PEG of various molecular weights (1000, 2000, 3400 Da) and end groups (mPEG
of PEG) were quantitatively oxidised and the primary hydroxyl groups turned into
carboxylic acids. Esters of oxidised PEG and prednisolone and salbutamol were
produced, purified and characterised. Overall, four prednisolone conjugates were
produced (PEG1000-Pred2, PEG2000-Pred2, mPEG2000-Pred, PEG3400-Pred2) and three
salbutamol conjugates (PEG2000-Salbu1.25, mPEG2000-Salbu0.85, PEG3400-Salbu1.53).
The synthesis of PEG-prednisolone ester conjugates produced fully conjugated
polymeric prodrugs whereas PEG-salbutamol was more troublesome and only
partial conjugations were achieved. The two conjugation and purification methods
were highly reproducible and were repeated for several PEG molecular weights.
The conjugates were obtained in high purity and sufficient amounts (gram scale)
were produced for in vitro and ex vivo testing.
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Chapter III. In vitro testing
III.1. Introduction
In vitro testing of pharmaceutics has always played a critical role in the drug
development process but with pressure from authorities to reduce the use of
animals, in vitro testing has become increasingly important and new models of
tissue, organ, or disease are published regularly [119]. The conjugates were
therefore tested in vitro to evaluate their aqueous stability and cytotoxicity. The aim
of this chapter is to evaluate the behaviour of the conjugates in vitro, in systems of
increasing complexity.
Firstly, aqueous stability of the conjugates was assessed in buffers at different pHs.
The pH range was biologically relevant and covered the naturally occurring pH in
the lung, according to published literature. The pH of exhaled breath condensate of
healthy non smokers was measured at 7.43, 7.41 for asthmatic non smokers and
6.91 for asthmatic smokers [120], the pH was also lower (7.16) in patient with
COPD [121]. In another study, exhaled breath condensates of healthy subjects had a
pH of 6.08 [122]. Hunt measured the pH of exhaled airway vapours and obtained
values of 7.65 and 5.23 for healthy subjects or individuals admitted to the hospital
with acute asthma respectively [123]. In a fifth study, exhaled breath condensate of
healthy individuals exhibited a pH of 8.27 and no difference was observed with
patients suffering from COPD or asthma. Subjects with a cold, however, had a
significantly lower pH value of exhaled breath condensate (7.56) [124]. Overall,
there is a great variability in published pH values for exhaled breath condensate.
Since there is no consensus on the pH value of lung fluids, a pH range (6.2 to 8.0)
124
rather than the usual in vitro assessment at pH 7.4 (blood pH) was chosen in this
study to account for this variability.
The human bronchial epithelial cell line Calu-3 is a well established model of the
human airways [72, 125]. The cells can be cultured in submerged conditions or at
an air-liquid interface and both conditions are suitable models for the human airway
epithelium [126] despite small morphological differences [77] [127]. Calu-3 cells
have been used to study the transepithelial transport of drugs [128] [129], to
characterise aerosols in the airways [130] or to measure local pharmacokinetic and
metabolism of drugs [131] [132]. The Calu-3 cell line was therefore used as an in
vitro model of the human airway epithelium in this study.
Cytotoxicity of the conjugates was then assessed using a measure of Lactate
Dehydrogenase release from cells. Cell metabolism or cell membrane integrity are
commonly used to assess cytotoxicity of a compound [133]. In the case of lung
delivery, cell membrane integrity appeared to be of primary interest since the lung
epithelium plays the role of a barrier and any variation in cell permeability would
dramatically modify the epithelium absorption properties. The choice was also
based on previous experiences in the laboratory and the ease of experimental
procedure.
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III.2. Material and methods
III.2.1.HPLC methodologies
For both drugs, the High Performance Liquid Chromatography (HPLC) system
used for quantitative analyses was an Agilent 1050 series, equipped with a 21-
position autosampler rack and an on-line degasser (Waldbronn, Germany),
controlled by Chemstation software (rev A 08.03, Agilent). Ultrapure water was
used throughout the analyses (18.2 Mȍ.cm-1 at 25°C, delivered by a PureLab type
of water purifier from ELGA, Marlow, UK). HPLC grade methanol, SDS, and
analytical grade 85% phosphoric acid were purchased from Fisher scientific,
prednisolone and triethylamine were purchased from Sigma and salbutamol sulfate
was purchased from Alfa Aesar.
Stock solutions of drugs and conjugates were prepared in methanol. These solutions
were serially diluted in methanol using positive displacement pipettes and analysed
by HPLC. The peak area vs concentration was plotted and linear regression
performed to assess the limits of quantification for each molecule. Known amounts
of compounds were dissolved in buffers and analysed by HPLC to validate the
method. Stock solutions and calibration solutions were stored for up to 2 months at
-20°C.
III.2.1.1. Prednisolone
Prednisolone and prednisolone conjugates were analysed using a Gemini reverse
phase C18 stationary phase (Phenomenex, Macclesfield, UK), 100 × 3 mm, 3 µm
particle size. The mobile phase was a gradient of methanol in water from 65 to 90%
organic in aqueous (Fig.III.1) at 0.5 mL.min-1 and 10 µL of sample were injected.
The column was maintained at 40°C and the detector set at 242 nm.
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Fig.III.1. Gradient for HPLC analyses of prednisolone and prednisolone
conjugates
Calibration solutions were prepared as a mixture of conjugate and prednisolone and
the correlation between signal peak area for the two molecules and corresponding
concentration was used to determine the calibration curve. Stock solutions of the
conjugates and of prednisolone were prepared in methanol, according to Table.
III.1. An example of solutions preparation for calibration of PP33 (PEG1000-Pred2)
is given in Table. III.2, the solution preparation tables for the other conjugates are
in Appendix 5, Table. VI.1 to Table. VI.3. Briefly, 64 ȝL of stock solutions of
prednisolone and of the conjugate were mixed together with 172 ȝL of methanol to
make up solution TA. Solution T1 was produced by diluting TA (32 ȝL) in
methanol (168 ȝL). Two fold dilutions in methanol were then serially prepared
(solutions R2 to R9).
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Table. III.1. Stock solutions of prednisolone and prednisolone conjugates
Compound Type
MW Weight
Volume
of MeOH
[Conjugate] [Pred]
Da mg ȝL mM mM
prednisolone free drug 360.45 9.32 862 NA 29.9
PP33 PEG1000-Pred2 1700 19.76 775 15.0 30.0
PP28 mPEG2000-Pred1 2459 37.74 477 32.2 32.2
PP29 PEG2000-Pred2 2801 35.68 849 15.0 30.0
PP31 PEG3400-Pred2 4079 29.18 477 15.0 30.0
Table. III.2. Calibration solution preparation for P33
Solution
Volume of
Pred stock
Volume of
PP33 stock
Volume of
methanol
[Conjugate] [Prednisolone]
ȝL ȝL ȝL mM mM
Pred-
PP33 TA
64 64 172 3.20 6.40
Solution
Volume of Pred-PP28 TA
Volume of
methanol
[conjugate] [prednisolone]
ȝL ȝL mM mM
Pred-
PP33 T1
32 168 0.51 1.02
Solution
Volume of
standard
Volume of
methanol
[Conjugate] [Prednisolone]
ȝL ȝL ȝM ȝM
Pred-
PP33 R2
200 ȝL of R1 200 255.97 511.94
Pred-
PP33 R3
200 ȝL of R2 200 127.98 255.97
Pred-
PP33 R4
200 ȝL of R3 200 63.99 127.98
Pred-
PP33 R5
200 ȝL of R4 200 32.00 63.99
Pred-
PP33 R6
200 ȝL of R5 200 16.00 32.00
Pred-
PP33 R7
200 ȝL of R6 200 8.00 16.00
Pred-
PP33 R8
200 ȝL of R7 200 4.00 8.00
Pred-
PP33 R9
200 ȝL of R8 200 2.00 4.00
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III.2.1.2. Salbutamol
Salbutamol and salbutamol conjugates were analysed using a Supelcosil reverse
phase C18 stationary phase (Sigma), 150 × 4.6 mm, 5 µm particle size, monitored at
225 nm. The mobile phase was a gradient of methanol in aqueous buffer from 60 to
90% organic in aqueous (Fig.III.2) at 2 mL.min-1 and 20 µL of sample were
injected. The column was maintained at 40°C. To prepare 1L of buffer, 1.44 g of
SDS were dissolved in 980 mL of ultrapure water, 8 mL of phosphoric acid (85%)
were added and the mobile phase pH was adjusted to 2.5 with triethylamine (11
mL).
Fig.III.2. Gradient for HPLC analyses of salbutamol and salbutamol conjugates
Stock solutions were prepared in methanol according to Table. III.3, and calibration
solutions were prepared by serially diluting the stock solutions in methanol
(Appendix 6, Table. VI.4, Table. VI.5, Table. VI.6). After HPLC analysis, the
correlation between signal peak area and concentration was used to determine the
calibration curve.
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Table. III.3. Stock solutions of salbutamol and salbutamol conjugates
Compound Type
MW Weight
Volume of
MeOH
[conjugate] [Salbu]
Da mg ȝL mM mM
Salbutamol
sulfate
free drug 576.71 3.94 455 NA 30.0
PS57
mPEG2000-
Pred1
2336 76.74 930 35.3 30.0
PS60
PEG3400-
Pred2
3987 44.11 590 18.8 28.7
III.2.2.Hydrolysis in simple buffers
III.2.2.1. Buffer preparation
Sodium phosphate salts were purchased from Sigma, other salts from Fisher
Scientific.
Buffers were prepared at pH 6.2, 7.4, 8.0 and 9.0. Mc Ilvaine buffers [134] covered
the range 6.2 to 7.4 and phosphate buffers covered the range 7.4 to 9.0. KCl was
used to maintain a constant ionic strength of 0.5.
McIlvaine buffers of 0.5 ionic strength were prepared according to published
literature [135]. Briefly, a solution of 0.2 M Na2HPO4 was prepared by dissolving
1.42 g of dry disodium hydrogen phosphate in 50 mL of deionised water. A
solution of citric acid at 0.1 M was prepared by dissolving 10.51 g of dry citric acid
in 500 mL of deionised water. Appropriate volume of citric acid and disodium
hydrogen phosphate solutions were then mixed and KCl added to adjust ionic
strength to 0.5 (Table. III.4). The pH was then adjusted with drops of HCl or NaOH
2 M.
Table. III.4. Recipe for Mc Ilvaine buffers
pH 0.2 M Na2HPO4 0.1 M citric acid Total volume
KCl to get ȝ =
0.5
mL mL mL mg
6.2 33.05 16.95 50 530
7.4 45.425 4.575 50 24
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Phosphate buffers at pH 7.4, 8.0 and 9.0 were prepared according to equation
(III.1), using a pKa value of 7.21 for phosphate [136]. The complete recipe for
phosphate buffer preparation is displayed in Table. III.5, the calculations were
based on acid base reaction for phosphate:
(III.1) ݌ܪ = ݌ܭܽ + ݈݋݃ [ே௔మு௉ைర]
[ே௔ுమ௉ைర]
A solution of 0.1 M NaH2PO4 was prepared by dissolving 2.84 g of salt in 200 mL
of deionised water. 0.1 M Na2HPO4 solution was prepared by dissolving 600 mg of
salt in 50 mL of deionised water. Appropriate volumes of the two buffers were
mixed together, required amount of KCl added and pH adjusted with drops of HCl
2M or NaOH 2M. The ionic strength, ʅ was calculated as follows:
(III.2) ʅ = ଵଶσ ܿ௜ݖ௜ଶ௡௜ୀଵ
Where ci is the molar concentration of an ion of charge zi.
e.g. For phosphate buffer at pH 7.4:
ʅ = ଵଶ ([NaH2PO4]×(+1)2 + [NaH2PO4]×(-1)2 + 2 [Na2HPO4]×(+1)2 + [Na2HPO4]×(-2)2)
ʅ = ଵଶ (ଵଽ.଺ଶ௠௅×଴.ଵெହ଴௠௅ ×(1+1)+ ଷ଴.ଷ଼௠௅×଴.ଵெହ଴௠௅ ×(2×1+4))
ʅ = ଵଶ (0.03924×2 + 0.06076×6)
ʅ = 0.22152
The ionic strength was adjusted by adding KCl, which contribution was calculated
as ʅKCl = ଵଶ ([KCl]×(-1)2 + [KCl]×(+1)2)
ʅ KCl = [KCl]
The required concentration of KCl needed for e.g. phosphate buffer at pH 7.4 is
therefore 0.5  0.22 = 0.28 M. The number of moles of KCl in 50 mL of buffer is
0.05×0.28 = 0.014 moles (1.04 g).
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Table. III.5. Recipe for Phosphate buffers
pH
NaH2PO4 0.1 M Na2HPO4 0.1 M V
µ
KCl to get
µ = 0.5
mL mL mL M g
7.4 19.62 30.38 50 0.22 0.28 1.04
8 6.98 43.02 50 0.27 0.23 0.85
9 0.80 49.20 50 0.30 0.20 0.76
The buffers were filtered through 0.2 ȝm polyethersulfone filter (Sartorius), stored
in the fridge and used within a month. Several batches of buffers were prepared
during the course of the studies.
III.2.2.2. PEG-prednisolone
For practical reasons due to the different hydrolysis rates, three protocols were
employed for hydrolysis studies. The general procedure consisted of preparing a
concentrated stock solution (Table. III.7) of conjugate in MeOH (30 mM in
prednisolone) and at time 0, adding a small amount of methanolic stock solution to
pre-warmed buffer at 37°C. A 70 ʅL sample was taken at predetermined intervals
and directly analysed by HPLC. Each study was done in triplicate. PP29 (PEG2000-
Pred2) hydrolysis was used to test the continuity of the buffer range and hydrolysis
was measured at pH 7.4 with the two buffer types.
x Protocol 1: In a glass vial with a magnetic stirrer, placed in a temperature-
controlled oil bath, 3.5 mL of buffer was thermally equilibrated for more than 15
min. At time 0, 50 ʅL of stock solution in MeOH was added and samples were
withdrawn regularly and directly analysed by HPLC. This protocol was followed
for the first trials but the heating system (oil bath) was a bit messy and was later
replaced by the use of a heat block.
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x Protocol 2: One mL of buffer was transferred in a 1.5 mL centrifugation tube
and placed to warm up at 37°C on a heat block for at least 15 min. To this solution
was added 14.3 ȝL of conjugate stock solution in MeOH at time 0 (working
concentration 423 ʅM in prednisolone). The tube was vortexed and left with no
more agitation at 37°C. A 70 ʅL sample was regularly taken and directly analysed
by HPLC. This protocol was used for hydrolyses at pH 7.4, 8.0 and 9.0.
x Protocol 3: At time 0, 14.3 ʅL of methanolic stock solution was added to 1
mL of pre-heated McIlvaine buffer at pH 6.2. The solution was then rapidly
aliquoted in 70 ʅL individual scintillation vials, and placed in a temperature-
controlled cabinet, at 37°C, 5% CO2. The vials were then frozen at -80°C at regular
intervals. They were all directly analysed by HPLC at once upon thawing. This
protocol was used for hydrolysis studies at pH 6.2.
The following design of experiment (DoE) was used to measure the hydrolysis rates
of PEG-prednisolone conjugates in simple buffers, each condition was performed in
triplicates (Table. III.6):
Table. III.6. DoE for PEG-Pred hydrolysis study
Conjugate Type
pH
6.2*
pH
7.4*
pH 7.4** pH 8.0** pH 9.0**
PP33
PEG1000-
Pred2
P3 P2 - P2 -
PP28 mPEG-Pred P3 P2 - P2 -
PP29
PEG2000-
Pred2
P1 P3 P2 P2 P2 P1 P2
PP31
PEG3400-
Pred2
P3 P2 - P2 -
* Mc Ilvaine buffer, ʅ=0.5. ** Phosphate buffer, ʅ=0.5. P1/2/3: Protocol 1/2/3
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Table. III.7. Stock solutions for PEG-prednisolone hydrolysis studies
Conjugate
MW
Da
Mass of
conjugate
mg
Volume of
methanol ʅL
[Conjugate]
mM
Corresponding
[prednisolone] mM
PP33 1700 35.68 849 15 30
PP28 2459 37.74 509 30 30
PP29 2801 19.76 775 15 30
PP31 1700 29.18 477 15 30
III.2.2.3. PEG-salbutamol
Protocol 2 was used to assess the stability of PEG-salbutamol conjugates in buffers:
the hydrolysis was conducted at different temperatures (in the fridge at 8°C, at
room temperature, or 37°C). Samples were directly analysed by HPLC.
III.2.3.Cytotoxicity assay with Calu-3 cells
III.2.3.1. Cell culture
Human bronchial epithelial cells Calu-3 obtained from the American Type Culture
Collection were maintained in Dulbeccos Modified Eagle's medium: nutrient
mixture F-12 Ham (1:1) (Sigma) supplemented with 10% Foetal Bovine Serum
(FBS), 100 UI.mL-1 penicillin and 100 ȝg.mL-1 streptomycin (Invitrogen), 2 mM
glutamine (Invitrogen) and 1% v/v non-essential amino acids (100×, Invitrogen) at
37°C in a 5% CO2 atmosphere. The cells were used between passage 20 and 40.
When reaching approximately 90% confluence, the cells were split and 1/3 was
used to seed a new 75 cm2 cell culture flask.
For cytotoxicity experiments, Calu-3 cells were seeded on a 96 well plate (Corning
Costar) at 1u105 cells.cm-2 and grown for 24 hours in maintenance medium until
confluence.
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III.2.3.2. Solution preparation
A stock solution of prednisolone in ethanol was prepared by dissolving 5.28 mg of
prednisolone in 293 ʅL of ethanol (50 mM). This stock solution was then diluted
(1/2) in serum free medium (Pred CA). Solution Pred CB was obtained by diluting
Pred CA 50 fold in serum-free medium and the next dilutions were performed in
serum-free medium containing 1 % ethanol, according to Table. III.8, so that the
concentration in ethanol was maintained at 1% in the working solutions.
Table. III.8. Solution preparation for prednisolone cytotoxicity assay
Solution
Volume of
standard ȝL
Volume of medium
ȝL
[Prednisolone]
ȝM % EtOH
Pred CA 100 ʅL of stock 100 ʅL of medium 25000 50
Pred CB 80 ʅL of CA 3920 ʅL of medium 500 1
Pred CC 1700 ʅL of CB 1700 ʅL of medium* 250 1
Pred CD 1300 ʅL of CB 1950 ʅL of medium* 100 1
Pred CE 1250 ʅL of CB 1250 ʅL of medium* 50 1
Pred CF 450 ʅL of CB 1800 ʅL of medium* 10 1
Pred CG 220 ʅL of CB 1980 ʅL of medium* 10 1
Pred CH 200 ʅL of CB 1800 ʅL of medium* 0.1 1
* Medium contained 1 % EtOH
Stock solutions containing the conjugates were prepared in ethanol at 0.1 M in
prednisolone, according to Table. III.9.
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Table. III.9. Stock solution preparation of PEG-prednisolone conjugates for
cytotoxicity assays
Prednisolone
conjugate
MW
Da
Number of
prednisolone per
molecule of PEG
Mass for stock
solution
mg
Volume of EtOH
for 0.1 M
solution µL
PP28 2459 1 13.32 54
PP29 2801 2 15.27 109
PP31 4079 2 10.87 53
PP33 1700 2 8.10 95
The solutions were serially diluted (1/10) in ethanol (solution CA to CG). Each
working solution was freshly prepared by adding 10 ʅL of ethanol solution (CA to
CG) in 990 ʅL of serum free medium, so that the final ethanol concentration in all
working solutions was 1%. The equivalent prednisolone concentrations tested
ranged from 1000 ʅM to 0.0001 ʅM (8 solutions), according to Table. III.10.
Table. III.10. Dilutions for conjugate solution preparation for cytotoxicity
assay
Solution
Volume of
standard (ʅL)
Volume of
ethanol (ʅL)
[Prednisolone]
(mM) in
ethanol
Actual
[prednisolone]
(ʅM) in medium
Conjugate
Stock
NA NA 100 1000
Conjugate CA 20 ʅL of Stock 180 10 100
Conjugate CB 20 ʅL of CA 180 1 10
Conjugate CC 20 ʅL of CB 180 0.1 1
Conjugate CD 20 ʅL of CC 180 0.01 0.1
Conjugate CE 20 ʅL of CD 180 0.001 0.01
Conjugate CF 20 ʅL of CE 180 0.0001 0.001
Conjugate CG 20 ʅL of CF 180 0.00001 0.0001
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temperature for 10 min, shielded from light. Twenty-five microlitres of stop
solution were then added and the fluorescence measured within an hour, after 10 s
of shaking (excitation wavelength of 560 nm and emission wavelength of 590 nm)
on an Infinite plate reader (Tecan).
Percentage of LDH release for a particular condition was calculated according to
the manufacturers instructions using the following formula (III.3):
(III.3) % ܮܦܪ = 100 × ி௟௨௢೐ೣ೛ିி௟௨௢್ೌ೎ೖതതതതതതതതതതതതതி௟௨௢೘ೌೣതതതതതതതതതതതതതିி௟௨௢್ೌ೎ೖതതതതതതതതതതതതത
Where:ܨ݈ݑ݋݁ݔ݌ is the experimental fluorescence measured for a particular wellܨ݈ݑ݋ܾܽܿ݇തതതതതതതതത is the average (n=6) fluorescence signal measured for cell culture medium
backgroundܨ݈ݑ݋݉ܽݔതതതതതതതതത is the average (n=6) fluorescence signal measured for cells exposed to lysis buffer
(100% LDH release)
III.2.4.Hydrolysis in presence of Calu-3 cells
Calu-3 cells were seeded at a density of 74 000 cells.cm-2 on 3 wells of a 6-well cell
culture plate and allowed to grow at 37°C, 5% CO2 for 5 days until confluence in
2.9 mL of maintenance medium that was changed once during growth. The medium
was then removed, the cells rinsed with warm PBS and 3 mL of warm serum-free
medium added in all the wells. The correct volume of medium was removed from
each well and replaced by the conjugate stock solution in ethanol (Table. III.11) so
that the actual concentration of prednisolone was 700 ʅM for all experiment (700
ʅM of PP28 and 350 ʅM of PP29 and PP33).
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Table. III.11. Conjugate stock solutions in ethanol for Calu-3 hydrolysis
Conjugate
MW
Da
Mass of
conjugate
mg
Volume
of
ethanol
ʅL
[Conjugate]
mM
Corresponding
[prednisolone]
mM
Volume
of
ethanol
solution
ʅL
PP29 2801 38.42 392 35 70 30
PP28 2459 35.62 413.8 35 35 60
PP33 1700 26.7 449 35 70 30
The cell culture plates were then placed on a Stuart rocker and incubated at 37°C,
5% CO2, under gentle see-saw waving (max angle 7°) and samples were withdrawn
at specific time points. The sampling procedure was as follow: 30 ʅL of medium
were mixed with 90 ʅL of cold methanol (prepared centrifuge tubes were stored at -
20´C), vortexed and stored at -80°C before being centrifuged at 13,000 g, 4°C,
upon thawing. Then the supernatant was collected and analysed using the
previously established HPLC-UV methods (III.2.1 p.125).
III.2.5.Hydrolysis rate calculations and kinetic simulations
This section illustrates the methodology used to analyse the data collected during
the two hydrolysis experiments: in buffers and in the presence of Calu-3 cells.
III.2.5.1. Simple case of mPEG-Pred
One mole of PP28 (mPEG-Pred) gave one mole of prednisolone and one mole of
oxidised PEG (Scheme.III.2). The starting material and prednisolone concentrations
were measured by previously established HPLC-UV methods. PEG was not
monitored.
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Scheme.III.2. Hydrolysis of PP28
Hydrolysis of esters in aqueous medium follows a pseudo-first order kinetics [137]
and the rate law followed by the reactant PP28 was therefore
(III.4)
ௗ[௉௉ଶ଼]ௗ௧ = െ݇ଵ[ܲܲ28]
Once integrated, the rate law for a first order kinetic expression became
(III.5) [ܲܲ28]௧ = [ܲܲ28]଴݁ି௞భ௧݈݊[ܲܲ28]௧ = ݈݊[ܲܲ28]଴ െ ݇ଵݐ
The pseudo-first order kinetic constant k1 was calculated as the slope of the plot
ln[PP28]=f(t). The logarithm transformation and linear regression were performed
using Excel.
The half-life was defined as the time needed to degrade half of the starting
concentration of PP28 and therefore
ln [PP28]௧భ/మ െ ln [ܲܲ28]଴ = െ݇ଵ. ݐଵ/ଶݐଵ/ଶ = െ ଵ௞భ ln (ଵଶ)
(III.6) ݐଵ/ଶ = ௟௡ଶ௞భ
III.2.5.2. Case of PEG-Pred2
PEG-Pred2 conjugates degraded in two steps in aqueous buffers, the first step
generating one molecule of prednisolone and one molecule of an intermediate PEG-
Pred1. This intermediate further hydrolysed to give oxidised PEG and a second
mPEG-Pred mPEGCOOH Pred
O
CH3
O
O
O
O
O
CH3
OH
H
H
OH CH3
H
n
O
CH3
O
O
OH
n
OH
O
O
CH3
OH
H
H
OH CH3
H
+
k1
140
molecule of prednisolone (Scheme.III.3). The starting material and prednisolone
concentrations were measured by previously established HPLCUV methods. The
intermediate PEG-Pred1 was visible by HPLC-UV but not quantifiable and PEG
was not monitored.
Scheme.III.3. Hydrolysis of PEG-Pred2
Pred: prednisolone
The rate law for reaction 1 was ܴܺܰ1 = ݇ଵ[ܲܧܩܲݎ݁݀ଶ] and ܴܺܰ2 =݇ଶ[ܲܧܩܲݎ݁݀ଵ] for reaction 2. PEG-Pred2 was consumed in the reaction 1,
prednisolone produced in reaction 1 and in reaction 2, PEG-Pred1 was produced in
reaction 1 and consumed in reaction 2 and oxidised PEG was produced in reaction
2. Therefore the rate laws for the four reactants were described by equation (III.7).
PEG-Pred2
PEG-Pred1
PEG-Pred1 PEGCOOH Pred
Pred
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(III.7)
The constant k1 was determined with Excel software in the manner described in
III.2.5.1 (p. 138).
In the system of differential equations (III.7), PEG-Pred2 and prednisolone were
known (measured by HPLC-UV) and by solving this system, it was possible to
simulate the concentrations of PEG and PEG-Pred1 with time and calculated k2.
Berkeley Madonna software (v.8.3.18, the University of California, Berkeley, CA,
USA), a solver of differential equations, was used to solve the system (III.7). The
method used to determine the order of magnitude of k2 and to simulate the
concentrations of the intermediate PEG-Pred1 and oxidised PEG was the following:
x The system of differential equations was written in the software
x The concentrations of prednisolone and PEG-Pred2 were used as input
(three sets of data for PEG-Pred concentrations with time (the three
replicates) and three sets of data for prednisolone concentrations with time
(the three corresponding replicates)
x The software was set to solve the equations and determine k1, k2 and the
initial concentration of PEG-Pred2.
݀[ܲܧܩܲݎ݁݀ଶ]݀ݐ = െ݇ଵ[ܲܧܩܲݎ݁݀ଶ]݀[ܲݎ݁݀]݀ݐ = ݇ଶ[ܲܧܩܲݎ݁݀ଵ] + ݇ଵ[ܲܧܩܲݎ݁݀ଶ]݀[ܲܧܩܲݎ݁݀ଵ]݀ݐ = ݇ଵ[ܲܧܩܲݎ݁݀ଶ]െ ݇ଶ[ܲܧܩܲݎ݁݀ଵ]݀[ܲܧܩ]݀ݐ = ݇ଶ[ܲܧܩܲݎ݁݀ଵ]
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The values calculated by the Berkeley-Madonna software for k1 and initial
concentration of PEG-Pred2 were compared with respectively the value calculated
for k1 (using Excel) and with the theoretical value for the initial concentration of
PEG-Pred2 (
ସଶଷଶ = 211.5 ρM, III.2.2.2).
III.2.6.Statistical significance
Statistical tests were not systematically performed as the size of the data set
generated was often too small to give meaningful statistically significant results
compared to the number of tests to be performed. The relatively high number of
groups and conditions tested meant a high probability of obtaining false positives
due to the number of tests one could perform. Rather, the analysis was conducted
using common sense and a careful examination of trends in the data. Nevertheless,
where applicable, tests for equal means (null hypothesis H0: ʅ1 = ʅ2) were applied
when the data sets were normally distributed, with equal variance. One tailed
Students t-tests were used to statistically determine the significance (H0 rejected if
p-value < 0.05) of the difference between two sets of values.
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III.3. Results and discussions
III.3.1.HPLC calibration
The linearity range for prednisolone compounds was 1 to 1000 ȝM (Table. III.12),
and 5 to 500 ȝM for salbutamol compounds (Table. III.13). These results were
sufficient for the purpose of in vitro testing where concentrations of drugs were
artificially high compared to in vivo biologically relevant experiments. The
standard solutions were used regularly to calibrate the system.
Table. III.12. HPLC characteristics of prednisolone and PEG-prednisolone
conjugates
Compound
Retention time
min
LLOQ
ʅM
ULOQ
ʅM
prednisolone 2.1 0.06 1024
PP33 4.4 2.00 256
PP28 4.0 1.07 1092
PP29 4.4 0.25 512
PP31 4.4 7.84 502
LLOQ: Lower Limit Of Quantification, ULOQ: Upper Limit Of Quantification
Table. III.13. HPLC characteristics of salbutamol and PEG-salbutamol
conjugates
Compound
Retention time
min
LLOQ
ʅM
ULOQ
ʅM
Salbutamol sulfate 1.11 4.7 601
PS60 2.40 7.3 469
PS57 2.16 5.5 707
LLOQ: Lower Limit Of Quantification, ULOQ: Upper Limit Of Quantification
III.3.2.Hydrolysis in simple buffers
This section illustrates the results obtained for hydrolysis studies in simple buffers
for prednisolone and salbutamol ester conjugates.
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III.3.2.1. PEG-prednisolone
a. Simple case of PP28
Fig.III.3 illustrates the degradation and appearance profiles of PP28 (Ÿ) and
prednisolone (Ÿ) respectively, in McIlvaine buffer at pH 7.4 and 37°C. The
degradations of the conjugate in buffers at different pH values and 37°C gave
typical pseudo-first rate kinetic degradation profiles. Other examples of hydrolysis
profiles at pH 6.2 and 8.0 are exhibited in appendices (Appendix 7, Fig.VI.50,
Fig.VI.51).
Fig.III.3. Hydrolysis profile of PP28 (mPEG2000-Pred) in McIlvaine buffer at pH
7.4
The plot of ln(PP28) vs time gave a straight line (Fig.III.4), confirming that the
degradation followed pseudo-first order kinetics and the slope of ln[PP28] = f(time)
gave the first order degradation constant k1.
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Fig.III.4. Plot of ln[PP28] vs time at pH 7.4
Logarithmic transformation and linear regression performed using Excel
Using equation (III.5), the first order degradation constant for PP28 at pH 7.4 and
37°C was determined as 0.1245 h-1. The corresponding half-life was then calculated
as ݐଵ/ଶ = ௟௡ଶ଴,ଵଶସହ (III.6)
The same methodology was repeated for all three replicates for all three pHs. The
values for calculated half-lives are consigned in Table. III.14.
ݐଵ/ଶ = 5.57 h
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b. Cases of the disubstituted PEG-Pred2
An example of a typical hydrolysis profile for PP29 (PEG2000-Pred2) at pH 7.4 and
37°C is illustrated in Fig.III.5. Similarly to PP28, a first order kinetic was deduced
from the plots of ln [PP29] = f(time) (Appendix 7, Fig.VI.52). Other degradation
profiles are displayed in Appendix 7. Half-lives were calculated according to
equation (III.6). The results for the calculated half-lives for all conjugates are
combined in Table. III.14 and illustrated in Fig.III.6
Fig.III.5. Hydrolysis profile of PP29 (PEG2000-Pred2) in McIlvaine buffer at pH
7.4
Table. III.14. Calculated half-lives, in hour, for PEG-prednisolone conjugates
in buffers of various pHs
Conjugate Type pH 6.2* pH 7.4 pH 8.0** pH 9.0**
PP33 PEG1000-Pred2 38.37 ±1.38 2.84 ±0.05* 0.91 ±0.01
PP28 mPEG2000-Pred 73.28 ±0.17 5.58 ±0.03* 2.01 ±0.03
PP29 PEG2000-Pred2
33.94 ±0.20
P2
32.30 ±0.23
P1
2.97 ±0.01*
3.35 ±0.005**
1.00 ±0.02
0.18
±0.005
P1/2
PP31 PEG3400-Pred2 40.12 ±0.60 3.02 ±0.02* 0.94 ±0.001
* Mc Ilvaine buffer, ʅ=0.5. ** Phosphate buffer, ʅ=0.5. P1/2: Protocol 1 and protocol 2
were used. Average of n=3±SD
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The hydrolysis of PP29, in McIlvaine and phosphate buffer at pH 7.4, gave half-life
values of respectively 2.97 (±0.01) and 3.35 (±0.005) h. Although statistically
significantly different, these two values were within 13% of each other and
therefore the two buffer systems provided a continuous range of pH to study the
conjugates aqueous stability. Nevertheless, this difference illustrated the limitations
of such in vitro studies where the type of buffering agent might play a role in the
hydrolysis rate.
The comparison of the two experiments for PP29 hydrolysis at pH 6.2, reveals that
stirring the solution during hydrolysis (protocol 1) statistically significantly
increased the hydrolysis rate by 5% (32.30±0.23 h with stirring and 33.94±0.20 h in
static conditions).
Fig.III.6. Half-lives of PEG-prednisolone conjugate hydrolysis in buffers at pH
6.2, 7.4 and 8.0
Data are mean of 3 ± SD
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This study also revealed that the hydrolysis rate was pH dependent. Fig.III.7
illustrates the free-energy relationship between the logarithm of hydrolysis rate
(log(k)) and the logarithm of proton concentration (-pH) for PP29, over the pH
range 6.2 to 9.0.
For each pH, the aqueous stability of the three disubstituted conjugates (PEG-
Pred2) were similar. For example at pH 7.4, the hydrolysis half-lives of PP33, PP29
and PP31 (respectively PEG1000, PEG2000 and PEG3400-Pred2) were between 6% of
each other (Table. III.14). The same was true at pH 6.2 and 8.0 where values were
respectively within 18% and 10% range (Table. III.14).
Fig.III.7. Free-energy linear relationship between log(k) and log[H+] for PP29
hydrolysis
Logarithm transformation and regressions performed using Excel
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Finally, the half-life of hydrolysis for mPEG2000-Pred (PP28) was twice the value of
those of PEG-Pred2, at pH 6.2, 7.4 and 8.0. Therefore, mPEG-Pred was twice as
stable as PEG-Pred2, over the polymer molecular weight and pH range studied.
The intermediate PEG-Pred1 was not isolated neither was it specifically produced to
measure its degradation kinetics using a HPLC-UV method. However, a low trace
signal of this intermediate compound was visible with HPLC-UV (but not
quantifiable) at a retention time similar to this of mPEG-Pred1 (4.05 min). The
release profile of prednisolone in the buffer was used to determine the value of k2,
hydrolysis rate constant of PEG-Pred1.
Fig.III.8 illustrates a comparison between a simulated and a calculated degradation
profile for PEG2000-Pred2 (PP29) at pH 7.4 and 37°C, obtained using Berkeley-
Madonna software. The simulated profile (dotted lines) was calculated under the
assumption that the hydrolysis rate constant of PEG-Pred1 would be similar to that
of mPEG-Pred1 (PP28) at pH 7.4 (t1/2 = 5.58 h, k = 0.124 h
-1). The calculated
profile (plain lines) was obtained by fitting the experimental data of PP29
hydrolysis at pH 7.4.
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Fig.III.8. Degradation profile of PEG2000-Pred2 at pH 7.4 and simulation using
mPEG-Pred1 rate constant
Meas: Measured values, Sim, plain lines: Simulated values obtained after solving the
system differential equation (III.7) using Berkeley Madonna software. Calculated k1 =
0.228651 h
-1
, k2 = 10.9662 h
-1
, initial PEG2000-Pred2 = 207 ʅM, Sim, dotted lines: Simulated
values obtained using k1 = 0.228651 h
-1
, k2 = 0.124323 h
-1
, initial PEG2000-Pred2 = 207 ʅM
By setting the value of k2 equal to that of mPEG-Pred hydrolysis rate constant, a
delay in prednisolone appearance (- - -) was observed as compared to the real, fitted
prednisolone (ʊ) profile. The hydrolysis profile of PEG-Pred2 remained obviously
unchanged since it was only described by k1. Under this assumption, the
concentration of the intermediate PEG-Pred1 (- - -) was not negligible since it went
up to 100 ȝM in this example. In this case, the calculated value for k2 was found to
be 88 times that of mPEG-Pred hydrolysis rate constant.
These simulations were repeated for all experiments (the four conjugates and the
three different pH) and the values obtained for the constants k2 were consistently
much higher than the hydrolysis rate constant of mPEG-Pred and much higher than
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k1. This meant that the concentration of PEG-Pred1 could be neglected and the
hydrolysis simplified to ܲܧܩܲݎ݁݀ଶ ௞భ՜ 2ܲݎ݁݀ + ܲܧܩ
An example of a simulation obtained for PP29 (PEG2000-Pred2) hydrolysis at pH 6.2
is displayed in Fig.III.9. The concentration of PEG-Pred1 remained always below
14 ʅM, which is negligible in comparison to the concentration of the other entities.
Fig.III.9. Simulation for PP29 hydrolysis at pH 6.2
Meas: Measured values, Sim: Simulated values obtained after solving the system
differential equation (III.7) using Berkeley Madonna software. Calculated k1 = 0.020455 h
-1
,
k2 = 0.228221 h
-1
, initial PEG2000-Pred2 = 197 ʅM.
Overall, the simulations gave meaningful results since the calculated initial
concentrations of the conjugates were those expected. Berkeley Madonna used the
degradation profile of PEG-Pred2 and the appearance profile of prednisolone to
estimate k1, k2 and the initial conjugate concentration. Whereas the simple excel
regression used only the PEG-Pred2 degradation profile to estimate k1. Berkeley
Madonna software was mainly used to determine the instability of the intermediate
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compound PEG-Pred1 and reliable simulations required good mass balance
regarding the total amount of prednisolone measured in the system. Nevertheless,
the fitted hydrolysis rate constants using both methods (excel and Berkeley
Madonna) were very close. For example, k1 for PP29 at pH 6.2 was calculated as
0.20455 h-1 with Berkeley Madonna software and 0.020423 h-1 using excel
regression.
III.3.2.2. PEG-salbutamol
The hydrolysis of PEG-salbutamol conjugates was extremely fast compared to that
of PEG-prednisolone conjugates. The optimal conditions for approximating
hydrolysis rates were found to be room temperature for pH 6.2 and 8°C for pH 7.4.
At pH 8.0, the hydrolysis was so fast, even at 8°C, that no reliable result was
obtained. Approximate values for hydrolysis half-lives were calculated using
Berkeley Madonna software, and the following equations were used to simulate
PEG-salbutamol hydrolysis rates:
(III.8) ݉ܲܧܩ݈ܾܵܽݑଵ ௞భ՜ ݈ܾܵܽݑ +݉ܲܧܩܲܧܩ݈ܾܵܽݑଶ ௞భ՜ ݈ܾܵܽݑ + ܲܧܩ݈ܾܵܽݑܲܧܩ݈ܾܵܽݑ ௞మ՜ ݈ܾܵܽݑ + ܲܧܩ
Table. III.15 summarises the calculated hydrolysis rates for PEG-salbutamol
conjugates:
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Table. III.15. Hydrolysis rate constants and corresponding half lives for PEG-
salbutamol at pH 6.2 and 7.4
pH T Type Order k1
t1/2
min
k2
t1/2
min
6.2 RT
mPEG2000-
Salbu
First 1.53 h
-1
27.2
7.4 8°C Second
22.36
h.L.nmol
-1 6.9
a
6.2 RT
PEG3400-Salbu2
First 3.21 h
-1
12.9 2.72 h
-1
15.3
b
7.4 8°C Second
91.74
h.L.nmol
-1 2.7
b 57.19
h.L.nmol
-1 16.1
c
a
Calculated using initial [mPS1] = 389 ʅM, bCalculated using initial [PS2] = 240.18 ʅM,
c
Calculated using initial [PS1] = 65.14 ʅM, RT: Room Temperature
Once again, the hydrolysis rate of the disubstituted conjugate PS60 was
approximately twice as fast as that of the monosubstituted conjugate PS57 (Table.
III.15). The intermediate PEG-Salbu1 had half-lives of 15-16 min at pH 6.2 and 7.4.
III.3.2.3. Discussion
Ester hydrolysis in aqueous solutions was described in depth by Erkki K. Euranto
[137] and is driven by three mechanisms: acid, neutral and base catalysed
hydrolyses.
The actual overall rate is described by
(III.9)
ௗ[௘௦௧௘௥]ௗ௧ = െ(݇୓ୌ[ܪܱି] + k଴ + kୌ[ܪଷܱା])[݁ݏݐ݁ݎ]
Where kOH and kH are the rate coefficients of respectively hydroxide-ion and hydrogen-ion
catalysed hydrolysis (in mol.L
-1
.h
-1
), [HO
-
] and [H3O
+
] are respectively the concentrations of
hydroxide and hydrogen ions, and k0 is the neutral hydrolysis rate constant (in h
-1
).
At any given pH, one of the three mechanisms dominates and the overall rate of
hydrolysis is considered to be pseudo first order kinetics, and is described as:
(III.10)
ௗ[௘௦௧௘௥]ௗ௧ = െ݇௧[݁ݏݐ݁ݎ]
Where kt is the pseudo first order observed rate constant, [ester] is the concentration in
ester
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For most ester compounds, kOH > kH
+ and therefore the minimum hydrolysis rate is
obtained at acidic pH and the reaction is driven by a base-catalysed mechanism.
Nowadays, an addition-elimination mechanism is used to describe the base-
catalysed ester hydrolysis [137] as shown in Scheme.III.4:
Scheme.III.4. Base-catalysed ester hydrolysis
The slower hydrolysis rate of mPEG-Pred1 compared to PEG-Pred2 can be
explained by the formation of micelles. It can indeed be hypothesised that in
aqueous buffers, the monosubstituted conjugate can easily self-assemble into
micelles, the terminal prednisolone playing the role of a lypophilic head and the
PEG chain a hydrophilic tail (Fig.III.10). On the other hand, it may be more
difficult for the the disubstituted conjugates to form micelles due to the relatively
short polymer length, and despite the polymer chain flexibility. Micelles of
methoxy-PEG3500-succinyl-(Embelin)2 were produced by Y. Huang with a diameter
of about 20 nm [138]. The protocol used to study the hydrolysis kinetics of PEG-
drug conjugates may be suitable for the formation of micelles, since it bears some
similitude with the interfacial deposition method [139] of producing nanoparticles,
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where ethanol is used as organic solvent. The ester link could therefore be protected
from hydrolysis, being isolated from hydroxyl (HO-) and hydroxonium (H3O
+) ions
in the lypophilic core of the micelles.
Fig.III.10. Possible micelle formation with mPEG-Pred
The hydrolysis of PEG-Pred2 gives a molecule of prednisolone and PEG-Pred1
which differs from mPEG-Pred1 only by the terminal group. The former possesses a
carboxylate where the later is end-capped by an unreactive methyl group.
As demonstrated in III.3.2.1 (p.151), -OOC-PEG-Pred1 is very unstable in aqueous
buffers, whereas mPEG-Pred1 is stable. This difference of stability may be
explained by the neighbouring group participation [140] of the carboxylate. This
group potentially catalyses the ester hydrolysis by intramolecular nucleophilic or
base catalysis (Scheme.III.5). The hydrolysis of acetyl salicylic acid [141] [142]
and other acyl esters of salicylic acids has been extensively studied [143] and it was
concluded that hydrolysis is mostly driven by intramolecular base catalysis [144]
[145] [146], whereas the hydrolysis of 3,5-dinitroaspirin carboxylate anion and of
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monophenyl esters of dibasic acids were catalysed by intramolecular nucleophilic
processes [147, 148]. Other mechanisms have been proposed to describe
neighbouring influence of carboxylic acids/carboxylate on the hydrolysis rate of
ester hydrolysis, such as electrophilic participation and bifunctional catalysis [137].
Scheme.III.5. Intramolecular nucleophilic (A) and intramolecular base (B)
catalysed hydrolysis of PEG-Pred1 by carboxylate
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PEG-salbutamol hydrolysis rates were much faster than those of PEG-prednisolone
and they differed from those of published experiments with prodrugs of salbutamol.
In 1994, it was reported [149] that triesters of salbutamol (acetyl, isobutyl and
pivalyl) hydrolysed at a rate of 0.2 to 0.5 days-1 at pH 7.4. The difference observed
could be explained by the fact that these esters are highly lipophilic compared to
PEG-salbutamol. Also, the three hydroxyl groups of salbutamol were conjugated
and the ester links of the resulting prodrugs were more hindered than in
฀฀฀฀฀฀฀฀฀฀฀=฀1฀7฀2฀1฀.฀8฀ ฀฀฀฀฀฀฀฀฀−฀฀฀฀฀1
same conclusions could be drawn from another study published in 2000, where
triesters of butyryl-salbutamol hydrolysed slowly in approximately 45 minutes in
lung homogenate, despite the possible presence of esterases [150]. Those two
publications lacked a kinetic study and the analytical methods did not allow any
quantification of the intermediates (diester and monoester) that led to the release of
salbutamol, at most probably different hydrolysis rates.Salbuta ol conjugates possess a secon ary amin group whereas prednisolone
conjugates do not. Inter or intramolecular catalysis could easily explain the fast
hydrolysis rate for salbutamol derived compounds. It has previously been reported
that intramolecular catalysis of ester hydrolysis by nitrogen containing groups such
as imidazole [151], amide [152], but more importantly by protonated amino groups
[153-157] can dramatically increase the hydrolysis rate (Scheme.III.6). The later
cooperative neighbouring effect is thought to be driven by an intermolecular acid-
catalysed mechanism, and then attack of a hydroxide ion, potentially involving a
hydrogen bonding with the protonated amino group and the double bonded oxygen
of the ester link [158]. The deprotonated amine group could also be involved in an
intramolecular base catalysis similar to that of carboxylate (Scheme.III.7).
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Scheme.III.6. PEG-salbutamol intramolecular acid catalysis with protonated
amine
Scheme.III.7. PEG-salbutamol intramolecular base catalysis with deprotonated
amine
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In the pH range studied, the salbutamol amino group is mostly protonated, since the
pKa for salbutamol amine group is 9.22 [111] and therefore the acid catalysed
mechanism (Scheme.III.6) is more likely. This intramolecular acid catalysis of
alkaline hydrolysis has previously been described by Deng et al. [159, 160] for
cocaine. The amine group from another conjugate molecule could potentially
catalyse the hydrolysis via intermolecular catalysis; therefore, the hydrolysis of
PEG-salbutamol was probably catalysed by both intra- and intermolecular
processes (Scheme.III.8).
Scheme.III.8. Intra (1) and intermolecular (2) catalysis of PEG-salbutamol
hydrolysis
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III.3.3.Cytotoxicity assays
This section presents the cytotoxicity study conducted with PEG-prednisolone
conjugates on the human airway epithelial cell line Calu-3. Cytotoxicity was
assessed using LDH release from the cells.
III.3.3.1. Results
Spontaneous LDH release from Calu-3 cells was used as an internal standard for
interpretation of the values obtained. The following graphs display the average %
of LDH release from Calu-3 after 20 h incubation with prednisolone and PEG-
prednisolone conjugates.
A. Prednisolone
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C. mPEG2000-Pred1 (PP28)
B. PEG1000-Pred2 (PP33)
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Fig.III.11. Cytotoxicity profiles of prednisolone and PEG-prednisolone conjugates
% LDH released by Calu-3 cells, after 20h incubation with the different compounds.
Spontaneous indicates the LDH released by untreated cells. Box Plots represent the five-
number experiments summary: maximum measured value, upper quartile, median, lower
quartile, minimum measured value. The mean is also represented (+). n=6 replicate. *
p<0.05 (one tailed t-test, equal variances, H0: µ[conjugate] = µspontaneous).
*
*
*
*
E. PEG3400-Pred2 (PP31)
D. PEG2000-Pred2 (PP29)
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The percentage of LDH released after incubation with prednisolone, PEG1000-Pred2
(PP33), mPEG2000-Pred1 (PP28) and PEG2000-Pred2 (PP29) did not exceed the
naturally occurring LDH leakage from untreated cells (spontaneous LDH release),
up to 500 and 1000 ȝM in prednisolone when using respectively prednisolone and
the conjugates. Therefore both the conjugates and prednisolone were considered not
cytotoxic in the assay up to 1000 and 500 ȝM respectively.
For PEG3400-Pred2 (PP31), the calculated LDH release values in the presence of 1 to
1000 ʅM in drug were statistically significantly higher than the spontaneous values
(one tailed t-test, equal variances). PEG3400-Pred2 was therefore considered
cytotoxic at concentrations above 1 ʅM.
III.3.3.2. Discussion
LDH assays were conducted in order to get a feel for the toxicity induced by the
conjugates and the release of oxidised PEG. The compounds to be studied did not
have a noticeable effect on Calu-3 membrane integrity apart for PEG3400-Pred2
which was not subsequently used for hydrolysis test with Calu-3 (III.3.4). It is
worth noting that this conjugate was only cytotoxic at concentrations above 1 ȝM,
way above any biologically relevant lung concentration.
In a standard inhaled administration of 200 ȝg of budesonide (MW 430.5 Da) with
Pulmicort Turbohaler® 200 mcg, the delivery efficiency is usually of about 15-35 %
[161] [162], and more than 90% of budesonide is made of particles of less than 4
ȝm [163]. The dose reaching the lungs is therefore approximately 70 - 160 nmol.
Assuming the dose is evenly distributed through the lungs (approximately 70 m2),
the ratio dose/epithelium surface area is clinically in the region of 1 - 2.3 nmol.m-2.
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For the cell culture cytotoxicity tests, the epithelium was grown on 0.32 cm2
(manufacturers specifications) and the lowest significant cytotoxic dose was 0.1
nmol (100 ȝL at 1 ȝM), giving a ratio of 3125 nmol.m-2, more than a thousand
times more concentrated than clinically possible.
It is known however that inhaled particles are not evenly distributed in the lung. In
a study published by Kim et al. in 1996 [164], the deposition pattern of inhaled
particles of 1, 3 and 5 ȝm was defined as a function of inhalation flow rate (150,
250 and 500 mL.s-1), in 11 healthy men. The surface dose was calculated as the
ratio between the local deposition fraction and the surface area. The highest value
for 3 ȝm particles (relevant particle size) in the airway, was 3.33u10-5.cm-2,
obtained for the lowest flow rate. In this study, the total deposition fraction (for 3
ȝm particles) was 37 to 59%, slightly higher than the delivery efficiency of
Turbohaler®. Lets apply this maximum experimental surface dose to budesonide.
The maximum surface dose would be 155 nmol.m-2 according to equation (III.11),
twenty times less than the highest non toxic concentration for PP31.
(III.11) 3.33. 10ିହ × ଶ଴଴.ଵ଴షలସଷ଴.ହ = 1.55. 10ିଵଵ݉݋݈. ܿ݉ିଶ = 155 ݊݉݋݈.݉ିଶ
In conclusion, the cytotoxicity observed for one conjugate was not biologically
relevant as it concerned a very high dose of compound. However, the shape of the
cytotoxicity profile observed for PEG3400-Pred2 (Fig.III.11.E) shows a relationship
between cytotoxicity and concentration above 0.1 ȝM and proves the reliability of
the assay. The other conjugates were definitely not cytotoxic.
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Although some literature is available for PEG toxicity, the route of administration
is often oral, seldom intravenous, subcutaneous or intra peritoneal, but hardly ever
inhaled. In any case, the studies are mostly concerned by the toxicity of native PEG
and in the present work, monomethoxy-monocarboxy-PEG (mPEG-COOH) or
dicarboxy-PEG (PEG-COOH2) were released from the conjugates. According to the
review by R. Webster et al. [95] native PEG is not toxic at the doses used in drug-
conjugate technologies. PEG has been used to decrease the cytotoxicity of drugs
[104] [98] [99] [165] [166] and it has been observed that PEG-conjugates did not
have obvious cytotoxicity [167] [168]. In their reviews, both Zalipsky [169] and
Greenwald [92] described PEG-conjugates as non toxic.
III.3.4.Hydrolysis in the presence of Calu-3 cells
The conjugates PEG1000-Pred2, PEG2000-Pred2 and mPEG2000-Pred were stable in
buffers of biologically relevant pH (III.3.2), and were not cytotoxic towards Calu-3
cells (III.3.3). This section illustrates the last step of in vitro testing: stability of the
conjugates in the presence of human bronchial epithelial tissue.
III.3.4.1. Results
Hydrolysis of mPEG2000-Pred1 (PP28) in serum-free medium followed a first order
degradation profile with a half life of 13.47 ±0.10 h (Fig.III.12). In the presence of
cells, the degradation was slower and the apparent half-life increased to 15.85
±0.02 h (Fig.III.12). These values are in the same order of magnitude as the
degradation rates obtained in the MacIlvaine and phosphate buffers (III.3.2.1).
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Fig.III.12. Hydrolysis half-lives of the conjugates in cell culture medium and in
the presence of Calu-3 cells
*Half lives in medium and with cells were statistically significantly different (unpaired, one
tailed Students t-test, equal variances)
The hydrolysis rate constant of the disubstituted conjugates PEG2000-Pred2 (PP29)
and PEG1000-Pred2 (PP33) were also lower in the presence of Calu-3 than in serum-
free cell culture medium (Table. III.16). Using the same simulations as in the
hydrolysis in simple buffers (III.3.2), the calculated values for the hydrolysis rate of
the intermediate PEG-Pred1 (for PP29 and PP33 hydrolysis studies), k2 were higher
than the rate of PEG-Pred2 hydrolysis (k1), but not as high as in the simple buffers
(III.3.2.1).
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Table. III.16. Spontaneous hydrolysis rate constants of the PEG-prednisolone
conjugates in cell culture medium with and without Calu-3 cells
Compound Medium
k1
h
-1
SD
%
k2
h
-1
SD
%
mPEG2000-Pred1
No cell 0.0515 ± 0.71
NA
With Calu-3 0.0437 ± 0.14
PEG1000-Pred2
No cell 0.0651 ± 0.55 0.1433 ± 0.33
With Calu-3 0.0639 ± 1.22 0.1538 ± 2.39
PEG2000-Pred2
No cell 0.0686 ± 0.68 0.2102 ± 4.05
With Calu-3 0.0643 ± 0.57 0.2157 ± 2.21
Mean of 3 measurements
III.3.4.2. Discussion
These observations ruled out any significant influence of enzymes in the system
since one would expect a much faster hydrolysis rate with significant enzymatic
activity. The overall hydrolysis rate was mainly controlled by spontaneous
hydrolysis, explaining the slower apparent hydrolysis rate with cells. The pH
indicator phenol red, had turned orange in the culture medium with the cells at the
end of the experiments, indicating a lower pH due to cell metabolism (Appendix 8,
Fig.VI.53).
The hydrolysis rates were faster in cell culture medium than in buffers at pH 7.4,
and salt effect may explain this result. Positive salt effects for acid catalysis of ethyl
acetate have been described [170]. Positive salt effect has also been described by
Hoppé and Prue [171] for the hydrolysis of half ester of dicarboxylic acids.
Particularly K+ and Na+ ions had a positive effect on the hydrolysis rates of
potassium ethyl adipate, through the formation of a chelate complex.
A similar complex (Fig.III.13) may form during hydrolysis in simple buffers and
partially explain the faster hydrolysis rate observed in cell culture medium
compared to simple buffers, by stabilising the transition state:
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Fig.III.13. Chelate complex for OOC-PEG-Pred1 hydrolysis in buffer
The ionic strength used in the buffers was fixed at 0.5, which is higher than the
physiologic ionic strength (saline is 9 g.L-1 NaCl, ȝ = 0.154) used in cell culture
medium. An estimated ionic strength for the cell culture medium was calculated at
0.14 from the more concentrated ions (NaCl, KCl, NaHCO3), using the
manufacturer product information sheet and equation (III.2). In cell culture
medium, the concentration of K+ and Na+ ions were lower than in the buffers and
because of positive salt effects, the intermediate OOC-PEG-Pred1 was less stable
in cell culture medium. However, PEG terminal carboxylate group may still be
playing an important catalytic role as the intermediate -OOC-PEG-Pred1 was less
stable than mPEG-Pred1.
OH
-
K
+
PEG
O
-
O
O
PredO
O
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III.4. Conclusion
In this chapter, the stability of the conjugates in aqueous solutions at pH 6.2, 7.4
and 8.0 was evaluated, some cytotoxicity tests were performed and the influence of
cells on the hydrolysis rate was tested. The main findings of in vitro testing were
the following:
x PEG-salbutamol conjugates were unstable under physiological pH and their
study was not pursued any further, these conjugates were clearly inappropriate for
sustained delivery of drugs to the lung.
x PEG-prednisolone conjugates achieved a sustained release of prednisolone in
vitro. Under biologically relevant pH, the conjugates hydrolysis rates were pH
dependent. mPEG-Pred1 was twice as stable as PEG-Pred2 (half lives of 3 to 6
hours at pH 7.4, 35 to 70 hours at pH 6.2) and between pH 6.2 to 8.0, the hydrolysis
rates changed by a factor 40. Such hydrolysis rates were promising and justified
further study.
x Conjugates of molecular weights 1000 and 2000 Da were not cytotoxic to
human lung tissue (Calu-3 cells) according to the membrane integrity test based on
LDH release. Therefore, the three conjugates PEG1000-Pred2, PEG2000-Pred2 and
mPEG2000-Pred were safe to use with human bronchial airway epithelial cells Calu-
3, a more biologically relevant in vitro system. However, since PEG3400-Pred2
exhibited significant cell membrane damage between 1 to 1000 ȝM, this conjugate
was not used in the next studies.
x Finally, Calu-3 cells did only marginally affect the hydrolysis rates and no
influence of Calu-3 esterases [172] was observed. These findings further confirmed
the potential suitability of the selected ester conjugates of PEG and prednisolone for
sustained drug delivery to the lungs.
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x After in vitro studies, out of the seven ester conjugates tested, three
candidates remained. Their stability under physiological conditions and in the
presence of Calu-3 cells along with their non-cytotoxic profiles made them suitable
candidates for an even more physiologically relevant ex vivo model: the Isolated
and Perfused Rat Lung.
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Chapter IV. Ex vivo testing
IV.1. Introduction
After successful evaluation of the drug action in vitro, the next stage in the drug
development journey requires validations in vivo, in animal models. In the case of
respiratory medicines, rats are often used and the drug pharmacokinetics studied. In
the pharmaceutical industry, the accepted ethical rule for such tests is the 3Rs 
Replacement, Refinement and Reduction  as first described in 1959 by Russel and
Burch [173]. Hence, researchers have to replace the use of living vertebrates where
possible, refine their experiments to limit animal pain and reduce the number of
animals used to gain comparable levels of information [174] [175]. Ex vivo models
have been developed to provide an intermediate between in vitro and in vivo
experiments. In respiratory work, the use of an isolated and perfused rat lung prior
to any in vivo evaluation is in line with the 3Rs guidelines.
The Isolated and Perfused Rat Lung model [176] is a useful tool to directly assess
the absorption rate of drugs in the lung [177]. Despite some limitations, mostly
around the technical difficulty, the time required to perform the procedure and the
relatively short viability (2-3 h), the IPRL has been shown to give good ex vivo/in
vivo correlation in regards to absorption half lives [178]. The IPRL, and especially
the single pass method [73], although more expensive than the recirculation
method, is therefore useful to predict in vivo pharmacokinetic profiles. It has been
used to study lung absorption properties of inhaled drugs administered by forced
instillation [179] [180], nebulisation [181] or as dry powders [182] [183] [184].
The set up used in the experiments presented in this chapter was designed to
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specifically study the influence of hydrolysis rate in the apparent absorption rate of
prednisolone from the lung. Therefore, the choice was made to administer the
compounds as nebulised solutions. Thus, any observed variation in absorption rate
would be due to hydrolysis and not dissolution rate differences between the
compounds, since the drug and conjugates were already solubilised when reaching
the lung. Out of the three remaining potential candidates, the choice was made to
use PEG2000-Pred2 and mPEG2000-Pred for this study. The rationale behind this
decision was based on economical and scientific reasons:
x the IPRL set up was quite expensive and time consuming and
x PEG1000-Pred2 was the more likely to be absorbed by the epithelium, PEG3400-
Pred2 may have been cytotoxic, and the comparison between the two selected
conjugates would be made easier since they have the same molecular weight.
Tandem mass spectrometry was used to measure the concentration of the
compounds in biological media and lung. This technique presents the advantage of
being sensitive and specific compared to HPLC-UV. Methods to measure
prednisolone by tandem mass spectrometry in cosmetic products [185] and in
human serum [186] have already been published. PEG prodrugs of resveratrol were
also studied by LC/MS [187]. The specificity of the technique ensured that the
release of native (and therefore biologically active) prednisolone was measured.
The sensitivity of the measurements allowed working with clinically relevant drug
concentrations associated with ex-vivo experiments.
The Berkeley Madonna software was used to calculate hydrolysis rates in the lung
that were not directly measurable. The profile of drug retention in the lung,
unavailable with IPRL experiments, was also simulated with the software.
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IV.2. Materials and Methods
IV.2.1.Analytical techniques
Prednisolone, PEG2000-Pred2, mPEG2000-Pred, mPEG2000COOH and
PEG2000COOH2 were analysed in perfusate and in lung tissue. Dexamethasone was
used as the internal standard. The compounds were detected by Multiple Reaction
Monitoring (MRM) as it allowed to specifically monitor a particular chemical
entity and could differentiate between two metabolites of the same compound.
IV.2.1.1. LC-MS/MS method
a. Equipment and material
For ex vivo analysis, the analytical system consisted of an HPLC (Agilent 1100
series) coupled with a CTC analytic HTC-xt autosampler robot. The mass
spectrometer was an API 4000 (Applied Biosystems), and the analysis was
performed with Analyst software (v. 1.4.2., ABSCIEX, Framingham, MA, USA).
Infusion experiments were performed using a syringe pump Model 22 (Harvard
apparatus, Edenbridge, UK) equipped with a 500 ʅL precision glass syringe
(Hamilton, Bonaduz, Switzerland). HPLC grade methanol, acetonitrile and
dichloromethane were purchased from Rathburn (Walkerburn, Scotland), analytical
grade formic acid was purchased from Riedel-de Haën, Absolute ethanol (99.5%)
was purchased from Kemetyl AB (Haninge, Sweden). Deionised and ultrapure
(18.2 Mȍ.cm-1 at 25°C) water were produced in-house by reverse osmosis, with
respectively Purelab Prima and Maxima systems (ELGA). Analytical grade
dexamethasone was purchased from Riedel-de Haën and prednisolone from Sigma.
Acetate buffer at pH 5.0 was prepared to resuspend the lung homogenates. The low
buffer pH was used to reduce the level of spontaneous hydrolysis rate of the
conjugates once extracted from the lungs. Two hundred mL of acetate buffer was
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prepared by mixing 129 mL of sodium acetate solution (0.1 M, 2.72 g of sodium
acetate in up to 200 mL of deionised water) and 71 mL of acetic acid (0.1 M, 572
ȝL of acetic acid in up to 100 mL of deionised water). The pH was adjusted with a
few extra drops of acetic acid solution.
b. HPLC conditions
Two solvent mixtures were used as mobile phases:
x Mobile phase A (aqueous): 5% acetonitrile (v/v), 0.1% (v/v) formic acid in
ultrapure water.
x Mobile phase B (organic): 4.9% ultrapure water (v/v), 0.1% formic acid in
acetonitrile.
The stationary phase was a Hypurity C18 reverse phase column (ref 22105-102130,
Thermo), 100 × 2.1 mm, 5 ʅM particle size. The flow rate was set at 825 ʅL.min-1,
the injection volume was 5 ȝL and the runtime was 3 minutes. The following
gradient was used (Fig.IV.1):
Fig.IV.1. Gradient for LC-MS/MS analyses
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A valco valve protected the ionisation source and the liquid chromatography system
was actually connected to the mass spectrometer between time 1.6 and 2 minutes.
The eluent was directed to waste for the remainder of the run.
c. Mass spectrometry conditions
Solutions of analytes at 1 ʅM were prepared in a mixture of mobile phases A/B
(50/50 v/v) and infused in the mass spectrometer at 10 ʅL.min-1 with the LC system
set at 825 ʅL.min-1, 50/50 A/B (v/v). A full scan for primary ions (Q1) was
obtained between 300 and 3000 m/z for 2 minutes in positive mode. The stability of
the maximum ion was assessed in Q1M1 mode for 2 minutes. Identification and
parameter optimisation of a unique precursor ion was performed in quantitative
optimisation mode for each individual compound.
d. Calibrations
Concentrated stock solutions of the compounds were freshly prepared in methanol
and the following sets of calibration solutions were prepared:
x Prednisolone and dexamethasone: the stock solutions were prepared in
methanol at 80 ʅM of each compound. The first calibration solution was prepared
by diluting by 100 fold the stock solution (methanol solution) in perfusate or lung
homogenate suspension and further diluting 2 fold sequentially up to 10 points
(800, 400, 200, ... to 1.5625 nM).
x PP28 and dexamethasone: stock solutions were prepared in a similar way but
the serial dilution was 3 fold between each solution and 8 solutions were prepared
on ice (800, 267, ... to 0.3657 nM).
x The same procedure was repeated for PP32, mPEG2000COOH and
PEG2000COOH2.
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The compounds were then extracted and resuspended in a mobile phases A/B
(50/50) according to the extraction procedures described in IV.2.1.2.
Quadratic regressions with 1/(analyte concentration)2 weighting were performed
with Analyst software, and a new set of calibration solutions was prepared fresh for
each batch of samples. The calibrations were validated as follow: the calculated
concentration of each standard had to fall within 15% of the actual standard
concentration, otherwise the invalid point was discarded and the regression
performed again. At least two thirds of the standards had to fall within 15% of their
nominal value (e.g. at least 6 over an 8 point calibration curve or 7 over a 10 point
calibration curve) otherwise the calibration was repeated. Standards were randomly
analysed throughout the batch of injections.
IV.2.1.2. Sample work up
a. Samples from perfusate
At the end of the experiment, 430 ʅL of perfusate from selected collection tubes,
was sampled and added to 20 ʅL of spiked solution of perfusate containing 1126.5
ʅM of dexamethasone in 2 mL centrifugation tubes. For prednisolone experiments,
the samples collected at time points around the maximum perfusate concentration
(Cmax) were diluted 3 fold in perfusate prior to mixing with dexamethasone spike.
The samples were stored at -20°C for up to a week before being thawed on ice and
extracted twice with 900 ʅL of HPLC grade dichloromethane, the solvent was then
dried under nitrogen. The samples were then resuspended in 450 ʅL of mobile
phases A/B (50/50, v/v), centrifuged at 15,000 g, 4°C and 150 ʅL of the
supernatant transferred to a 96 well microplate (Nunc) for LC-MS/MS analysis.
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b. Samples from lungs
To measure the amount of drug remaining in the lungs at the end of the absorption
studies, the tissues were firstly frozen in liquid nitrogen and homogenised with a
tissue tube impactor (Covaris), the operation was repeated three times. The
resulting crushed lungs were resuspended in 4 mL of acetate buffer at pH 5 and
homogenised for three minutes at 37°C in a focused ultrasonicator (Covaris). A 200
ʅL sample of the resulting homogenate was then mixed with 250 ʅL of buffer
containing 9u10-8 M of dexamethasone. This solution was extracted twice with 900
ȝL of HPLC grade dichloromethane, and the solvent dried under nitrogen. The
samples were resuspended in 450 ʅL of mobile phases A/B (50/50), vortexed and
centrifuged at 15,000 g for 10 min at 4°C. A 150 ȝL sample of the supernatant was
transferred in a 96 microplate and 5 ʅL analysed by the LC-MS/MS method
previously established (IV.2.1).
IV.2.2.Isolated Perfused Rat Lung
IV.2.2.1. Solution preparation and administration to the IPRL
Solutions of prednisolone and PEG-prednisolone conjugates in 25% ethanol for
nebulisation were prepared at a final concentration of 2 mg.mL-1 in prednisolone,
according to Table. IV.1. To maintain similar osmotic properties, the prednisolone
solutions were complemented with the same amount of PEG used for the
conjugates. In detail, prednisolone was dissolved in ethanol to reach a concentration
of 8 mg.mL-1 and then diluted four fold in a PEG2000 (7.4 g.L
-1) water solution. The
conjugate solutions were prepared by dissolving the compounds in ethanol at 8
mg.mL-1 in prednisolone and then, just before nebulisation, diluting four fold in
water.
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Table. IV.1.Composition of the solutions for nebulisation
Compound
V EtOH
solution
V water /
PEG solution
[Prednisolone] [PEG]
mL mL mg.mL
-1
mM mM
prednisolone 0.75 2.25 2 5.55 2.77
mPEG2000-Pred
(PP28)
0.3 0.9 2 5.55 5.55
PEG2000-Pred2
(PP32)
0.3 0.9 2 5.55 2.77
IV.2.2.2. Nebulisation to the IPRL
a. IPRL set-up
The isolated and perfused rat lung is a well established model used to study
pharmacokinetic properties of inhaled drugs and is routinely used at AstraZeneca,
Mölndal. Dr Pär Ewing kindly conducted the surgery and IPRL set up (Fig.IV.2),
the experiments were approved by the local ethics committee. The procedure has
been described in details elsewhere [188]. Briefly, male Wistar rats were
administered an overdose of sodium pentobarbital (0.8 mL at 100 mg.mL-1,
intraperitoneal). The animal were bled to death and heparin was injected in the
heart. The pulmonary artery was cannulated and the lung perfused at approximately
20 mL.min-1 with Krebs-Ringer buffer (4% Bovine Serum Albumin w/v) [188]
(Appendix 9, Table. VI.7), maintained at 37°C and pH 7.4 by bubbling CO2. The
pulmonary vein was cannulated and the silicon tubing exiting the apex of the heart
was connected to an autosampler. Finally, the trachea was also cannulated and the
isolated lung and heart were placed in an artificial thorax with a negative pressure
of -0.4 kPa and maintained at 37°C. The lung was ventilated using a rodent
ventilator at a tidal volume of 2 mL and 75 rpm. A single-pass perfusion method
was used and the perfusate was initially directed to waste. Pulmonary resistance,
dynamic compliance and examination for oedema were used to assess the lung
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integrity for 15 minutes before the experiment started. Only IPRL that met our
preset criteria were proceeded to the next step.
b. Inhalation to IPRL
For each experiment, 1 mL of solution for inhalation was transferred to an Aeroneb
Lab nebuliser (control module AG-AL7000, 2.5-4.0 ȝm mesh size, nebuliser head
AG-AL 1100) and nebulised into a 500 mL polyethylene terephthalate spacer. The
nebuliser was left running for approximately 2-3 minutes to prime the spacer. The
spacer was connected upstream to the exposure line. The exposure line was
comprised by a flow-split which was connected to the tracheal cannula of the IPRL
and to an upstream vacuum source operating at a constant negative pressure,
resulting in a flow rate of 0.4 L.min-1. The exposure cycle of the IPRL was initiated
by manually opening a valve between the spacer and the exposure line and the
produced aerosol was pulled through the exposure line using the negative pressure
produced by the ventilator and the upstream vacuum source. Using this approach, at
an average negative aerosol flow rate of approximately 0.4 L.min-1, it took between
7 to 10 minutes to nebulise 1 mL of solution and empty the spacer. Hence, with the
default respiratory rates and applied vacuum, during inspiration one third of total
flow rate was inspired. The exposure cycle and perfusate sampling were started
simultaneously (the autosampler changed tube every 30 s), the nebulisation
apparatus was removed when the reservoir was empty. The perfusion and
ventilation of the IPRL were allowed to continue for one hour. After that, the
experiment was finished, the lung was removed from the chamber, collected and
placed in an individual tissue tube (Covaris). The tissues were immediately frozen
and stored at -80°C.
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Fig.IV.2. Schematic of the IPRL set up
IV.2.3.Pharmacokinetic calculations
The cumulative amount of prednisolone that had been absorbed across the air blood
barrier was calculated according to the method described below, inspired from
Eulers method of estimating the area under the curve:
At anytime, n(t) was the sum of the amount of prednisolone recovered in all the
fractions between time 0 and t:
(IV.1)
The amount of prednisolone in a fraction i was calculated as the product of the
concentration in prednisolone (ci), determined by LC-MS/MS, multiplied by the
corresponding volume of perfusate, determined by the measured perfusion rate ( పܸሶ )
and the time elapsed between two consecutive measurements (οݐ) (Fig.IV.3). At
any time i:
݊(ݐ) =෍݊௜௜ୀ௧௜ୀ଴
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(IV.2) ݊௜ = ܿ௜.οݐ. పܸሶ
The total administered dose was calculated using equation (IV.3), as the sum of
prednisolone remaining in the lungs (Nlung) and the total amount of prednisolone
recovered in the perfusate (σ ݊௜ஶ௜ୀ଴ ).
(IV.3)
Fig.IV.3. Calculation of the total dose recovered in perfusate
The flow rate పܸሶ was measured on line, ci was determined by LC-MS/MS analysis, the blue
histograms represent the Area Under the Curve [Pred] = f(t)
The normalised pharmacokinetic profiles were obtained by dividing the
concentration of prednisolone in perfusate (ci) by the total dose delivered.
The apparent lung absorption rate k was calculated as the slope of the straight line
obtained when plotting ln ci = f(t), assuming an apparent first order absorption. The
half life was calculated as ݐଵ/ଶ = ௟௡ଶ௞ .
పܸሶ
ci ȟ
ܦ݋ݏ݁ = ௟ܰ௨௡௚ +෍݊௜ஶ௜ୀ଴
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IV.2.4.Pharmacokinetic simulations
The model described in Fig.IV.4 was used to simulate the fate of the compounds
after administration to the IPRL.
Fig.IV.4. Model of Isolated Perfused Rat Lung experiments
kin: 0 order rate constant of drug administration, kout: 1
st
order permeation rate constant of
prednisolone from the lung, k1: pseudo first order hydrolysis rate constant of mPEG-Pred,
k2: pseudo first order hydrolysis rate constant of PEG-Pred2
The methodology used was to fit the cumulative amount of prednisolone recovered
in perfusate with the model. The experiments conducted with prednisolone were
used to determine kout. Berkeley-Madonna software calculated the duration of
administration and kout, being given the total dose as input. This was repeated for
the three replicates. The average value for the permeation rate of prednisolone from
the lung, kout was then used as fixed input to determine the hydrolysis rates in the
lung for the conjugates, assuming a pseudo or apparent first order hydrolysis rate.
Thus, the cumulative amount of prednisolone in perfusate (obtained experimentally
for each conjugate) was kinetically fitted, with kout and the total dose as fixed input
in the system, and the administration time and k1 or k2 calculated. The equations
used are in Appendix 9, (VI.1).
NEBULISER LUNG PERFUSATE
kin kout
mPEG-Pred Pred + PEG-COOH
LUNG
k1
PEG-Pred2 2 Pred + PEG-COOH2
LUNG
k2
183
IV.2.5. Statistical analysis
Where applicable, tests for equal means (null hypothesis H0: ʅ1 = ʅ2) were applied
when the data sets were normally distributed, with equal variance. One tailed
Students t-tests were used to statistically determine the significance (H0 rejected if
p-value < 0.05) of the difference between two sets of values.
IV.3. Results and discussions
IV.3.1.Analytical method
Table. IV.2 illustrates the retention times and the different optimised conditions for
all the compounds used in the ex-vivo study, the entrance potential was 10 V
(Appendix 10, Fig.VI.54).
Table. IV.2.Parameters for MRM and turbo spray ionisation
Compound
Retention time
(min)
Q1
(m/z)
Q3
(m/z)
DP
(V)
CE
(V)
CXP
(V)
prednisolone 1.70 361.3 147.1 41 29 10
dexamethasone 1.77 393.1 373.1 41 13 12
mPEG2000COOH 1.72
635.4 103 61 47 6
PEG2000COOH2 1.70
PP28 1.81 749.5 147.1 46 41 10
PP32 1.87 892.9 147.1 51 77 10
Q1: precursor ion, Q3: product ion, DP: Declustering Potential, CE: Collision Energy,
CXP: Collision Cell exit Potential.
The system was calibrated over the concentration range 1.6-200 nM for
prednisolone and dexamethasone and 0.37-89 nM for polymer based compounds.
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IV.3.2.Prednisolone absorption profile in the IPRL
IV.3.2.1. Nebulisation, doses delivered and fraction remaining in the
lungs
The nebulisation procedure was similar for all the tested compounds. However, it
was difficult to initiate the nebuliser with the conjugates, but this was not the case
for prednisolone. The dose precision and accuracy of nebulisers are dependent upon
many interrelated factors beyond the scope of this thesis (e.g. compound physico-
chemical properties, ambient conditions, compound concentration, physiological
profile) [189]. This variability didnt have a significant impact on the interpretation
of the experiments since the measurements were normalised to the actual dose
delivered to the lung. Table. IV.3 illustrates the doses delivered and remaining
fractions in the lungs for the IPRL experiments conducted.
Table. IV.3.Doses of prednisolone delivered to the lungs and remaining in the
tissue at the end of the experiments
Experiment Compounds
Total
dose
nmol
Total
remaining in
lungs %
Conjugate* in
lungs %
%
delivered**
PredRA prednisolone 154.0 0.35 NA 2.8
PredRB prednisolone 94.2 0.42 NA 1.7
PredRC prednisolone 72.1 0.08 NA 1.3
PP28RA mPEG-Pred1 11.9 0.62 0.30 0.2
PP28RB
2
mPEG-Pred1 Too low
PP28RC
1
mPEG-Pred1 46.4 5.96 1.69 0.8
PP28RD mPEG-Pred1 10.1 3.25 0.93 0.2
PP28RE mPEG-Pred1 10.1 0.76 0.27 0.2
PP32RA PEG-Pred2 141.4 2.21 0.37 2.5
PP32RB PEG-Pred2 93.6 2.01 0.39 1.7
PP32RC PEG-Pred2 36.6 1.90 0.26 0.7
*PEG-Pred1, **amount of prednisolone nebulised was 5.55 ȝmol, 1the lung integrity was
compromised as it was the only experiment where some polymeric products (mPEG-Pred1
and mPEGCOOH) were measured in the perfusate,
2
the dose delivered was too low to give
exploitable readings
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For prednisolone experiments, less than 0.5% of the administered dose was
detected in the lungs at the end of the experiment (Table. IV.3), about 2% for the
disubstituted conjugate PEG-Pred2 and less than 1% for the monosubstituted
conjugate mPEG-Pred1, with the exception of experiments PP28RC and PP28RD,
for which 5.96 and 3.25 % of drug remained in the lungs respectively. No PEG-
Pred2 was recovered in the lungs, and the calibration for mPEG-Pred1 was used to
quantify the remaining intermediate PEG-Pred1, which was always less than 1% of
the delivered dose (Table. IV.3).
IV.3.2.2. Normalised pharmacokinetic profiles and outliers
The normalised, averaged pharmacokinetic profiles obtained for the free drug and
the conjugates are presented in Fig.IV.5, the individual normalised plots are in
Appendix 10, Fig.VI.55.
Fig.IV.5. Normalised absorption profiles of prednisolone in the IPRL obtained
with prednisolone alone, mPEG-Pred1 and PEG-Pred2
Each individual measured concentration (nmol.L
-1
) was divided by the total dose
administered during the experiment (nmol) to give relative fractions of prednisolone in
perfusate (L
-1
). Data are presented as average of n=3 ±SD.
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For all the experiments, there was an initial infusion period of about 7-10 minutes
corresponding to the administration of the drug. After administration, the
concentration of prednisolone in perfusate decreased instantly when using only
prednisolone (x), and the drug was not detected in the perfusate after 20 minutes of
experiment. With the conjugates, prednisolone was still detected in the perfusate
after 40 minutes (x,x). There was neither PEG nor conjugate recovered in the
perfusate that could be quantified during the experiments except for PP28RC.
PP28RC displayed a completely different pattern (Appendix 10, Fig.VI.55.) as
21.8% of the total dose was recovered in the form of the intact conjugate in the
perfusate and 1.70% in the lung, the lung was probably leaky. This experiment was
not considered further in the next analysis as it clearly was an outlier. The delivery
efficiency during PP28RB experiment was not sufficient to obtain a concentration
high enough in the perfusate to give exploitable results.
IV.3.2.3. Effect of PEG conjugation on Cmax and tmax
The maximum concentration of prednisolone in perfusate divided by the total
administered dose, relative Cmax (maximum fraction of prednisolone in perfusate),
was 9.13 ±1.37 L-1 for prednisolone, 4.22 ±0.20 L-1 for mPEG-Pred1 (PP28) and
3.08 ±0.22 L-1 for PEG-Pred2 (PP32). The relative Cmax was statistically
significantly lower for the conjugates and statistically significantly lower for PEG-
Pred2 than for mPEG-Pred1 (one tail Students t-test assuming equal variances,
p<0.05).
The conjugates clearly reduced the relative Cmax by 2.2 and 3.0 for respectively
mPEG-Pred1 (PP28) and PEG-Pred2 (PP32).
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The time to reach Cmax, so called tmax, was difficult to measure with precision due to
the variability in administration times (7 to 10 minutes) and therefore tmax was not
visibly modified by the use of conjugates.
IV.3.2.4. Effect of PEG conjugation on the apparent lung absorption
rate
The apparent rate of prednisolone absorption from the lungs was calculated as
described in IV.2.3. The fitted datasets are available in Fig.IV.6. The conjugates
also decreased the absorption rates in the IPRL, and the differences were
statistically significant (one tail Students t-test assuming equal variances, p<0.05).
Absorption half lives were found to be 1.02 ± 0.17 min for prednisolone, 4.30 ±
0.70 min for mPEG-Pred1 and 7.81 ± 0.88 min for PEG-Pred2 (Table. IV.4). The
drug residence time was therefore 4.2 times longer with mPEG-Pred1 than with
prednisolone alone and 7.7 times longer with PEG-Pred2 than with prednisolone.
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Fig.IV.6. Plots of ln (prednisolone fraction) as a function of time for prednisolone
(A), PP28 (B) and PP32 (C) and fitted absorption rates for IPRL experiments
The slopes were individually calculated with a linear regression for ln (Pred)=f(t), using
Excel. The straight lines represent the average absorption rate for (A) prednisolone, (B)
mPEG-Pred1 and (C) PEG-Pred2 IPRL experiments, after the initial administration period.
B.
C.
A.
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Table. IV.4.Observed pharmacokinetic parameters for prednisolone, mPEG-Pred1
and PEG-Pred2
Compound Experiment
Relative
Cmax
Average
Cmax (±SD)
Absorption
rate
t1/2 (±SD)
L
-1
min
-1
min
prednisolone
PredRA 7.22
9.13 (±1.37)
0.7476
1.02
(± 0.17)
PredRB 9.22 0.7646
PredRC 10.45 0.5705
mPEG-
Pred1
PP28RA 4.08
4.22 (± 0.20)
0.1376
4.30
(± 0.70)
PP28RD 4.11 0.1643
PP28RE 4.44 0.1897
PEG-Pred2
PP32RA 5.5
3.08 (± 0.22)
0.0888
7.81
(± 0.88)
PP32RB 7.5 0.0798
PP32RC 7.5 0.1001
IV.3.2.5. Discussion
Results in this section demonstrated clearly that the conjugation of PEG to
prednisolone increased the pulmonary residence time. Since prednisolone was
rapidly absorbed by the epithelium, a sustained delivery of the drug was achieved
by a controlled hydrolysis of the PEG-conjugates. Consequently, the relative Cmax
was also decreased when using the conjugates compared to prednisolone.
Apart from one outlier experiment (PP28RC), PEG was not detected in the
perfusate. This is consistent with the findings published in 2009 by Nektar
Therapeutics [97]. In this study, the authors covalently conjugated PEG (0.55-20
kDa) to fluorescein isothiocyanate via a non hydrolysable linker. Fluorescent PEG
was administered by intratracheal instillation to rats and the elimination rate from
bronchoalveolar lavages was followed over time. The elimination rate of the
conjugated PEG2000 was 0.097 h
-1. In other words, it took 1 h (ݐଵ଴ = െ ଵ଴.଴ଽ଻ ×
ln (
ଽଵ଴)) to eliminate 10% of the administered PEG. In our study, the conjugates
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may have crossed the epithelium but because the absorption rates of the polymers
were certainly so much lower than that of prednisolone, we did not detect any
polymer in the perfusate.
The observed half lives of the conjugates in buffers at pH 7.4 were 3.0 and 5.6
hours for respectively PEG2000-Pred2 and mPEG2000-Pred1 (III.3.2.1). In the IPRL
model, the apparent absorption half lives measured were between 4 and 8 minutes.
A spontaneous hydrolysis could not explain such rapid degradations in
physiological conditions. The scale of the hydrolysis rate was different here and
could only be justified by enzymatic activity. There were distinct activities of the
enzymes towards mPEG-Pred1 and PEG-Pred2, since the apparent half life was
twice as long for the latter.
IV.3.3.Pharmacokinetic modelling and simulations
IV.3.3.1. Prednisolone permeation rate from the lung
The permeation rate of prednisolone from the lung, kout was estimated at 0.485
(±11% SD) min-1 using Berkeley Madonna software (Appendix 10, Table. VI.8).
IV.3.3.2. Hydrolysis rates in the lung
As suggested in IV.3.2.4, the conjugates were most probably substrates of lung
esterases. To further illustrate the role of enzymatic degradation of the conjugates,
the following simulations based on Michaelis-Menten kinetics, were performed.
In 1913, Michaelis and Menten [190] published a now classic paper, modelling the
enzymatic activity of invertase, their findings were refined by Briggs and Haldane
[191] when they introduced the steady state approximation.
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Nowadays, under the assumption that the concentration of substrate is greater than
that of enzymes, the rate of product formation is defined as:
(IV.4)
][
].[][ max
SK
SV
dt
Pd
m 
 
In the present study, the rate of absorption of prednisolone from the lungs was fast
and the limiting step was most likely the hydrolysis rate. Since the log plots of the
concentration of prednisolone in perfusate with time obtained with the two
conjugates were straight lines (Fig.IV.6), then the hydrolysis rate was independent
of concentration of substrate. Therefore one could assume that the concentration of
conjugate (substrate) was much lower than the Michaelis constant Km. In this case,
the hydrolysis rate followed an apparent first order kinetic, since equation (IV.4)
could be simplified to:
(IV.5) ].[
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Rate of product formation of a Michaelis-Menten kinetic, when [S]<<Km
Berkeley Madonna software was used to calculate the hydrolysis rate of the
conjugates in lung, using the cumulative plots of prednisolone appearance in
perfusate (Appendix 10, Fig.VI.56), and the value obtained in IV.3.3.1 for the
permeability rate of prednisolone from the lung, kout (Fig.IV.4). mPEG-Pred was
found to hydrolyse at a rate constant of k1 = 0.157 (± 1.5%) min
-1 and PEG-Pred2 at
a rate constant of k2 = 0.101 (± 13.3%) min
-1.
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IV.3.3.3. Simulation using the fitted degradation and permeation
rates
Simulations were performed with Berkeley Madonna, using the model illustrated in
IV.2.4 and the calculated dissociation (k1 = 0.157 min
-1, k2 = 0.101 min
-1) and
permeation (kout = 0.485 min
-1) rate constants. An administration of 100 nmol of
prednisolone (or equivalent with the conjugates) in 5 minutes was used to generate
the simulations presented in Fig.IV.7.
Fig.IV.7. Simulated and measured cumulative amount of prednisolone in
perfusate
A. Simulations of cumulative prednisolone appearance in perfusate, following a 5 minutes
administration time of 100 nmol of prednisolone or equivalent with the conjugates, using a
prednisolone permeation rate constant of 0.485 min
-1
and dissociation rate constants of k1
= 0.157 min
-1
for PP28 and k2 = 0.101 min
-1
for PP32. B. Experimental cumulative
prednisolone appearance in perfusate obtained with prednisolone, PP28 and PP32.
A
B
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The fitted model (A) described very closely the experimental data (B) obtained with
IPRL for the three compounds despite the experimental variability in administration
times (Fig.IV.7).
The corresponding prednisolone profile in lung is displayed in Fig.IV.8. This graph
looks very similar to the normalised prednisolone concentration in perfusate profile
(Fig.IV.5) since prednisolone permeation rate from the lung is very high. This
visualisation is very useful to get an estimate of the actual amount of drug at the site
of action: the lung. The sustained retention of prednisolone in lungs obtained with
the conjugates is clear.
Fig.IV.8. Simulated profile of prednisolone amount in lung
Simulations of the amount of prednisolone in lung tissue, following a 5 minutes
administration time of 100 nmol of prednisolone or equivalent with the conjugates, using a
prednisolone permeation rate constant of 0.485 min
-1
and dissociation rate constants of k1
= 0.157 min
-1
for PP28 and k2 = 0.101 min
-1
for PP32.
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Fig.IV.9. Simulated profile of the fraction of prednisolone in perfusate
Simulations of the fraction of prednisolone in perfusate (concentration of prednisolone
divided by total dose), following a 5 minutes administration time of 100 nmol of
prednisolone or equivalent with the conjugates, using a prednisolone permeation rate
constant of 0.485 min
-1
and dissociation rate constants of k1 = 0.157 min
-1
for PP28 and k2
= 0.101 min
-1
for PP32.
The simulation confirmed that the relative Cmax was lowered when using the
conjugates and providing that the administration time was the same for all
compounds, the tmax was also theoretically increased with the conjugates: from 5
min with the drug alone to 6.6 min with mPEG-Pred1 and 7.25 min with PEG-
Pred2.
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IV.3.3.4. Discussion
This section confirmed that the use of ester conjugates of PEG and prednisolone
successfully improved the prednisolone pharmacokinetic profile in the IPRL model.
Compared to prednisolone alone, Cmax was decreased by a factor 2.8 and 2.1 and
tmax was increased by 45 and 32% with PEG-Pred2 and mPEG-Pred respectively.
The lung esterase activity towards PEG-prednisolone conjugates, observed in the
IPRL was also confirmed. The simulations clearly identified distinct enzymatic
activities towards the mono and disubstituted conjugates: esterase activity towards
mPEG-Pred (t1/2=4.30 min) was superior compared to the activity towards PEG-
Pred2 (t1/2=7.81 min). This could be explained by a lower affinity of the esterases
towards the disubstituted PEG-Pred2 compared to the monosubstituted mPEG-Pred.
This esterase activity of the lungs has previously been reported in rabbit [192],
mouse [193], rat [194], human [80] and is known to play a key role in the
metabolism and activity of inhaled corticosteroids such as budesonide [195],
beclomethasone [196] [197] or ciclesonide [198] [199], the latter two being
administered as fatty acid ester prodrugs and then metabolised in the lung tissue to
release the active drugs. Budesonide is converted into fatty acid ester and
hydrolysed back to active drugs, in tissues and lung.
It was previously reported that ester prodrugs of inhaled corticosteroid and fatty
acid could generate a sustained release of the drug to the peripheral parts of the
lungs. The strategy employed was to reduce the drug aqueous solubility (with fatty
acid chain) to achieve a longer lung residence time [55].
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The model used for simulating IPRL experiments was simple and yet, allowed to
generate normalised prednisolone profiles in perfusate that were very close to the
experimental ones. Simulated relative Cmax were within 4% of the average
experimental values (Table. IV.4, Fig.IV.9). The model also provided a clear
determination of tmax, which was impossible with the experimental data due to
variability in administration times.
One limitation of the isolated and perfused rat lung is the difference between
human and rat metabolic activities [81]. Liver and blood esterase activities towards
fluazifop-butyl, paraoxon and phenylacetate were different in human liver and
blood, and overall lower in human than rat tissues [200]. Paranitrophenyl acetate
and ester prodrugs of propanolol were found to hydrolyse quicker in the cytosol of
intestinal mucosal cells from rats than that of humans but slower in microsomes of
rat intestinal mucosa as compared to humans [201]. Plasma stability of cyclic
prodrugs of opioid peptides was lower in rat plasma than in human plasma [202].
Moreover, cholinesterase activity in human blood is more important than
carboxylesterase whereas in rat blood, carboxylesterase is dominant [203]. Novartis
published a comparison of the biotransformation of a methylcarbonate derivative of
cyclosporin A and the metabolism by esterases was about 8 times greater in rat than
human lung slices [204]. Despite a similar expression profile for carboxylesterase 1
in rat and human lungs [205], there are interspecies differences in metabolic
activity of the lung. Therefore, an IPRL model can only show that the conjugates
are likely to improve the pharmacokinetic parameters Cmax and tmax, but it does not
predict to what extent these parameters would be improved in humans.
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Further experiments could help predict the human situation. Firstly, a comparison
between the conjugate hydrolysis rates in rat and human lung homogenates would
give a good indication of the conjugate stability in human lung tissues. Secondly, in
vivo rat pharmacokinetic profiles could be used to predict the human situation,
using advanced simulation packages based on a 2 compartmental approach [35].
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IV.4. Conclusion
In this section, a comparison was drawn between the pharmacokinetic profiles of
prednisolone and two ester conjugates, in the isolated and perfused rat lung, after
nebulisation administration of the compounds.
The conjugates decreased the relative maximum perfusate concentration (Cmax) by a
factor of 2.2 and 3.0 for mPEG2000-Pred2 and PEG2000-Pred2 respectively, compared
to prednisolone. According to simulations, tmax was also increased by 26 and 45%
for mPEG2000-Pred2 and PEG2000-Pred2 respectively, compared to prednisolone. The
improved pharmacokinetic parameters (longer tmax, lower Cmax for the same dose)
observed with the conjugates would significantly decrease the systemic exposure to
the drug and potentially lower the associated side effects.
There are two marketed inhaled corticosteroids that are activated by esterase: 17-
beclomethasone dipropionate and ciclesonide. Both prodrugs are administered as
inactive compounds and cleaved to generate the active molecule. PEG-prednisolone
conjugates were retained in the lung during the time frame of the experiment (one
hour), whereas beclomethasone dipropionate [197] and ciclesonide [206] are both
rapidly found in blood after inhalation. The two prodrugs are rapidly activated
(cleaved) in lung and plasma [196] [207] and then conjugated to fatty acid to
accumulate in the lung. In comparison to existing prodrugs, the conjugation to a
large hydrophilic polymer such as PEG, provides a sustained release of the drug in
lung tissue, by accumulation of the inactive conjugate in the airways.
Metabolised PEG conjugates were only hydrolysed in the lung to release
prednisolone that then crossed the airway epithelium, since neither PEG nor the
conjugates were recovered in perfusate.
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Chapter V. General conclusion
V.1. An improved pharmacokinetic profile
The development of ester conjugates of PEG and inhaled drugs was illustrated in
this thesis and ended up with the production of a lead model compound: a diester of
PEG (2000 Da) and prednisolone (PEG2000-Pred2). The aim of the project was to
improve the pharmacokinetic profile of a drug after inhalation administration, and
this was successfully achieved. The rationale for the conjugate design was based on
a rapid passive diffusion of small molecules through the lung epithelium. The
conjugation of such a drug to a large hydrophilic polymer did ensure that the
inactive conjugate stayed in lung fluids before hydrolysis occurred and released the
free, active ingredient.
V.2. A drug development journey
A large number of conjugates could have been designed in silico by changing the
four parameters that characterised the conjugates. The type of polymer, the
molecular weight, the linker, and the drug could be varied, expanding the design
space. The actual production of drug conjugates was narrowed to one polymer
(PEG), one type of linker (ester), two well known drugs (prednisolone, and
salbutamol) and three or four polymer molecular weights and end groups for
respectively PEG-salbutamol and PEG-prednisolone. After the successful
production of seven drug ester conjugates (Chapter II), the number of potential
candidates was down to the four PEG-prednisolone since PEG-salbutamol were
unstable at biological pHs (III.3.2). After a basic cytotoxicity screening, the number
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of potential candidates was reduced to three since PEG3400-Pred2 induced some cell
membrane damage (III.3.3, p. 160). According to the pharmacokinetic profiles
obtained with the Isolated and Perfused Rat Lung, the best candidate was PEG2000-
Pred2 since it considerably decreased Cmax and increased tmax.
V.3. Further work
Safety and efficacy of the conjugates have to be assessed in vivo to ensure an
efficient and safe disposition of the oxidised polymer after cleavage and the
functionality of the released drug. The drug safety could be studied by examining
slices of fixed rat lung after single exposure (acute toxicology) and repeated
exposure (chronic exposure) to the conjugates. The efficacy could be assessed with
the Sephadex-induced rat lung injury. This model has been developed to study lung
inflammation of rats following intravenous injection or intratracheal instillation of
suspension of saline containing Sephadex particles. The resulting inflamed lungs
are characterised by granulomas, presence of neutrophils and eosinophils, and local
increase in TNF-Į (Tumor necrosis factor alpha). It has been used to illustrate the
anti inflammatory properties of various compounds such as coumarin derivatives.
[208, 209]. The drug effect has to be assessed following administration of the
conjugates, and the correlation between prolonged delivery of the active drug in the
lung and prolonged effect must be ascertained. The delivery of such conjugates has
to be studied too. Although nebulisation was the more relevant mode of inhalation
for the purpose of this work, the shelf life of such conjugates in aqueous solution,
even at low pH, is too short and the use of nebulisation devices is not convenient
for the patients. Therefore, solid formulations should be considered. The production
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of solid particles of PEG-conjugates and lactose may be troublesome since PEG is a
sticky polymer with a low melting point [210], but this could be overcome with the
use of copolymer as excipients, or because the polymer is conjugated to a high
melting point drug [211]. Suspension or solution of PEG conjugates in
hydrofluoroalkane (HFA) could be studied for pressurised metered dose inhalers,
since PEG1000 is currently used as a valve lubricant in the formulation of Symbicort
[27].
V.4. Room for improvements
The project proved the concept and illustrated the benefits of polymer-drug
conjugation for inhaled delivery of drugs. Despite the promising results for PEG-
prednisolone conjugates, the other investigated molecule, salbutamol, did not
provide conjugates stable enough for the purpose of this work. The drug properties
appeared to be of primary importance for the stability of the conjugates, especially
the amine group of salbutamol was responsible for catalysing ester hydrolysis, and
the resulting conjugates were highly unstable. Thus, such amine containing
compounds could benefit from other types of linker such as amide or carbamate.
Such conjugations would result in more stable compounds, with similar hydrolysis
pathways of ester [212, 213]. Depending on the drug chemical structure, other
linkers such as carbonate ester [214], acetal or orthoester [215, 216] could
potentially be of interest. The stability of these linkers in physiological condition is
unpredictable but they can undergo hydrolysis and release the active drug. Ester or
amide bond seem the more promising linkers since carboxylesterases can hydrolyse
these chemical bonds [217-219], especially with the presence of carboxylesterase 1
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and 2 in the lung [205]. Particularly, small peptide chains could be used as linkers
[220] between polymer and drug, and the drug cleaved by lung proteases [221,
222], mainly produced by inflammatory cells [223].
The stability of drug conjugates towards enzymatic hydrolysis could be increased
by the addition of sterically hindered groups around the ester or amide bond [224,
225].
The relative low drug loading of the polymer could be improved by the use of
branched polymers and one molecule of hydrophilic polymer could be conjugated
to several molecules of drugs [226-228].
The use of such a conjugation strategy for compounds delivered by inhalation could
be of the greatest interest for drugs with low aqueous solubility [229]. Indeed, PEG
conjugation would improve solubility in lung fluids and limit the risk for
immunological responses [230], the drug would then be released in a controlled
manner.
Drug acting locally with systemic side effects would most definitely benefit from
PEG ester conjugation. As demonstrated with PEG-prednisolone conjugates, for a
given dose, the maximum concentration in the systemic circulation (perfusate ex
vivo, blood in vivo) was significantly lowered when using the conjugate. This
feature could benefit most inhaled locally acting drugs, especially chemotherapeutic
drugs whose effectiveness is limited by systemic side effects [231, 232].
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Chapter VI. Appendices
Appendix 1. Supplementary information for II.3.1, PEG oxidation
Fig.VI.1. IR spectra for PEG3400, PEG2000COOH and PEG1000COOH
 PEG3400OH,  PEG1000COOH,  PEG2000COOH
Fig.VI.2. 1HNMR for oxidised PEG1000COOH
Spectrum acquired on a Bruker DPX 400 spectrometer, 64 scans, in CDCl3
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Fig.VI.3. Acid titration of PEG1000COOH
-i- pH,  'pH/'NaOH
Fig.VI.4. 1HNMR for PEG2000COOH
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in CDCl3
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Fig.VI.5. Acid titration for PEG2000COOH
-i- pH,  'pH/'NaOH
Fig.VI.6. IR spectra for mPEG2000 and mPEG2000COOH
 mPEG2000OH,  mPEG2000COOH
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Fig.VI.7. 1HNMR for mPEG2000COOH
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in CDCl3
Fig.VI.8. Acid titration for mPEG2000COOH
-i- pH,  'pH/'NaOH
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Appendix 2. Supplementary information for PEG-prednisolone, acyl chloride
route
Fig.VI.9. 1HNMR spectrum for PP14 crude
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in MeOD
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Fig.VI.10. 1HNMR for PP14SF1
Spectrum acquired on a Bruker DPX 300 spectrometer, 64 scans, in MeOD
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Fig.VI.11. 1HNMR for PP14SF4
Spectrum acquired on a Bruker DPX 400 spectrometer, 64 scans, in MeOD
f_bay.PP14SF4P.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
0
0.005
0.010
0.015
0.020
0.025
0.030
N
o
rm
a
liz
e
d
In
te
n
s
it
y
6.1910.744.096.89298.983.973.792.142.240.292.14
METHANOL-d4
BHT
BHT
BHT
Diethyl ether
Triethylammonium HCl
Triethylammonium HCl
Diethyl ether
Water
0
.9
3
1
.3
0
1
.3
2
1
.4
0
1
.5
0
2
.6
6
3
.2
0
3
.2
2
3
.6
4
4
.3
0
4
.4
3
4
.9
5
4
.9
7
5
.0
1
5
.1
0
5
.1
5
6
.0
1
6
.2
4
6
.2
5
6
.2
7
6
.2
7
6
.9
3
7
.4
6
7
.4
7
7
.4
9
f_bay.PP14SF4P.esp
1.40 1.35 1.30
Chemical Shift (ppm)
0
0.01
0.02
N
o
rm
a
liz
e
d
In
te
n
s
it
y
10.742.95
BHT
210
Fig.VI.12. 1HNMR of PP14SFDC
Spectrum acquired on a Bruker DPX 300 spectrometer, 64 scans, in MeOD
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Fig.VI.13. 1HNMR of crude PP08P2
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in MeOD
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Fig.VI.14. 1HNMR of PP08DC2
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in MeOD
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Fig.VI.15. 1HNMR of PP08DC2DF1B
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in MeOD
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Fig.VI.16. 1HNMR of crude PP16S1
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in MeOD
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Fig.VI.17. 1HNMR of PP16HCl
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in MeOD
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Fig.VI.18. 1HNMR of PP16SGAp
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in CDCl3
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Fig.VI.19. 1HNMR of crude PP13S1
Spectrum acquired on a Bruker DPX 400 spectrometer, 64 scans, in MeOD
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Fig.VI.20. 1HNMR of PP13DC2
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in MeOD
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Fig.VI.21. 1HNMR of PP13DC2DFB
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in MeOD
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Fig.VI.22. 1HNMR of PP20S2
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in CDCl3
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Fig.VI.23. 1HNMR of PP21S2
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in CDCl3
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Fig.VI.24. 1HNMR of PP22S2
Spectrum acquired on a Bruker DPX 400 spectrometer, 64 scans, in MeOD
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Fig.VI.25. 1HNMR of PP23S2
Spectrum acquired on a Bruker DPX 400 spectrometer, 64 scans, in MeOD
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Fig.VI.26. 1HNMR of PP25S1
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in CDCl3
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Fig.VI.27. 1HNMR of PP26S1
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in CDCl3
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Appendix 3. Supplementary information for PEG-prednisolone, Mukaiyama
route
Fig.VI.28. 1HNMR for the crude PP01S1
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in DMSO-d6
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Fig.VI.29. 1HNMR for the crude PP24S1
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in MeOD
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Fig.VI.30. 1HNMR for the crude PP24S2
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in MeOD
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Fig.VI.31. 1HNMR for the crude PP27S1
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in MeOD
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Fig.VI.32. 1HNMR for the crude PP27S2
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in MeOD
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Fig.VI.33. 1HNMR of PP27FB
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in CDCl3
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Fig.VI.34. 1HNMR for the crude PP28S1
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in MeOD
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Fig.VI.35. 1HNMR spectrum for PP33w3 (PEG1000-Pred2)
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in MeOD
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Fig.VI.36. Mass spectrometry analyses of A. PEG1000COOH2 and B. PP33w3 (PEG1000-Pred2)
A.
B.
1037.6
1037.6 = ݉௉ாீ +݉ଵ݉௉ாீ = 1037.6െ݉ଵ
872.4 =
݉௉௉ +݉ே௔శ +݉ଵ
2݉௉௉ = 2 × 872.4െ 23 െ݉ଵ݉௉௉ = 1721.8 ܦܽ െ݉ଵο݉ܽݏݏ = ݉௉௉ െ݉௉ாீ
= 1721.8െ݉ଵ െ (1037.6െ݉ଵ)ο݉ܽݏݏ = 684.2 ܦܽ
A. MALDI ionisation of oxidised PEG1000 produced singly
charged ions (successive PEG signals 44 mass units apart),
with ion abduct of mass m1.
B. ESI ionisation of PP33 produced doubly charged ions
(successive PEG signals 22 mass units apart), with ion abducts
of sodium (23 Da) and m1.
The mass difference (ǻPDVV) between the conjugate and
oxidised PEG was therefore 684.2 Da.
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Fig.VI.37. 1HNMR spectrum for PP32D (PEG2000-Pred2)
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in MeOD
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Fig.VI.38. Mass spectrometry analyses of A. PEG2000COOH2 and B. PP32D (PEG2000-Pred2)
864.1
635.6
635.6 =
݉௉ாீ +݉ଵ
3݉௉ாீ = 1906.8െ݉ଵ
864.1 =
݉௉௉ +݉ଵ
3݉௉௉ = 2592.3െ݉ଵο݉ܽݏݏ = ݉௉௉ െ݉௉ாீ
= 2592.3െ݉ଵ െ (1906.8െ݉ଵ)ο݉ܽݏݏ = 685.5 ܦܽ
A. ESI ionisation of oxidised PEG2000 produced triply charged
ions (successive PEG signals 14.7 mass units apart), with ion
abducts of mass m1 (m1  3 amu).
B. ESI ionisation of PP32 produced mainly triply charged ions
(successive PEG signals 14.7 mass units apart), with ion
abducts of mass m1 (m1  3 amu).
The mass difference (ǻPDVV) between the conjugate and
oxidised PEG was therefore 685.5 Da.
B.A.
237
Fig.VI.39. 1HNMR spectrum for PP31P2 (PEG3400-Pred2)
Spectrum acquired on a Bruker AV(III)400 spectrometer, 64 scans, in MeOD
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Fig.VI.40. Mass spectrometry analyses of A. PEG3400COOH2 and B. PP31P2 (PEG3400-Pred2)
B.
A.
3416.2 = ݉௉ாீ +݉ଵ݉௉ாீ = 3416.2െ݉ଵ
4118.5 = ݉௣௣ +݉ଶ݉௉௉ = 4118.5െ݉ଶο݉ܽݏݏ = ݉௉௉ െ݉௉ாீ = 4118.5െ݉ଶ െ (3416.2െ݉ଵ)ο݉ܽݏݏ = 702.3െ݉ଶ +݉ଵ
ο݉ܽݏݏ = 702.3െ 18 + 1
A. MALDI ionisation of oxidised PEG3400 produced singly charged ions
(successive PEG signals 44 mass units apart), with ion abduct of mass m1.
B. MALDI ionisation of oxidised PP31 produced singly charged ions
(successive PEG signals 44 mass units apart), with ion abduct of mass m2.
Assuming that PEG ion abduct was H+ (m1 = +1 amu), and PP31 ion
abduct was NH4
+ (m2 = +18 amu), the mass difference (ǻPDVV) between
the conjugate and oxidised PEG was therefore 685.3 Da:
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Appendix 4. Supplementary information for PEG-salbutamol ester conjugation
A. Proton numbering and Carbon lettering of salbutamol sulfate
B.
1HNMR of salbutamol sulfate
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in DMSO-d6
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C.HMQC of salbutamol sulfate
Spectra acquired on a Bruker AV(III)400 spectrometer in DMSO-d6
D.HMBC of salbutamol sulfate
Spectra acquired on a Bruker AV(III)400 spectrometer in DMSO-d6
Fig.VI.41. Salbutamol sulfate 2DNMR chemical shifts assignment
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A. Proton numbering and Carbon lettering of salbutamol free base
B.
1HNMR of salbutamol free base
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in DMSO-d6
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C. HMQC of salbutamol free base
Spectra acquired on a Bruker AV(III)400 spectrometer in DMSO-d6
D. HMBC of salbutamol free base
Spectra acquired on a Bruker AV(III)400 spectrometer in DMSO-d6
Fig.VI.42. Salbutamol free base 2DNMR chemical shifts assignment
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A. Proton numbering and Carbon lettering of salbutamol dodecyl sulfate
B.
1HNMR of salbutamol dodecyl sulfate
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in DMSO-d6
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C. HMQC of salbutamol dodecyl sulfate
Spectra acquired on a Bruker AV(III)400 spectrometer in DMSO-d6
D. HMBC of salbutamol dodecyl sulfate
Spectra acquired on a Bruker AV(III)400 spectrometer in DMSO-d6
Fig.VI.43. Salbutamol dodecyl sulfate 2DNMR chemical shifts assignment
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Fig.VI.44. 1HNMR of PS62S2
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in MeOD
f_bay.PS62S2.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
N
o
rm
a
liz
e
d
In
te
n
s
it
y
15.37126.619.8553.519.40194.873.605.653.094.444.258.28
Salbu
Dodecyl sulfonate
Dodecyl sulfonate
Dodecyl sulfonate
0
.9
0
1
.2
9
1
.3
9
1
.6
5
2
.5
6
3
.0
7
3
.6
3
3
.9
8
4
.2
04
.6
6
5
.2
2
6
.8
1
6
.8
7
7
.1
8
7
.2
6
7
.3
7
7
.8
0
7
.9
0
f_bay.PS62S2.esp
5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)
0
0.05
0.10
N
o
rm
a
liz
e
d
In
te
n
s
it
y
53.529.40194.919.733.605.653.10
METHANOL-d4Methanol
THFfree Salbu
Conjugated Salbu Dodecyl sulfonate
LutidineSalbu
2
.5
6
3
.0
7
3
.6
3
3
.9
8
4
.2
0
4
.6
6
5
.2
2
f_bay.PS62S2.esp
8.1 8.0 7.9 7.8 7.7 7.6 7.5 7.4 7.3 7.2 7.1 7.0 6.9 6.8 6.7
Chemical Shift (ppm)
0
0.05
0.10
0.15
N
o
rm
a
liz
e
d
In
te
n
s
it
y
4.452.9518.320.814.258.284.10
Salbu
Salbu
Lutidine
Salbu
Lutidine
6
.8
1
6
.8
7
7
.1
8
7
.2
6
7
.3
7
7
.8
07
.9
0
246
Fig.VI.45. 1HNMR of PS62IRACl1
Spectrum acquired on a Bruker DPX 300 spectrometer, 16 scans, in MeOD
f_bay.PS62IRACl1.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
N
o
rm
a
liz
e
d
In
te
n
s
it
y
42.3929.537.49192.003.214.512.873.6616.504.88
METHANOL-d4
Methanol
Methanol
DCM
Dodecyl sulfonate
Free Salbu
Lutidine Salbu
Conjugated Salbu
Salbu
Lutidine
PEG
1
.3
9
2
.6
1
3
.0
7
3
.3
5
3
.6
3
4
.2
0
4
.6
6
5
.2
2
6
.8
1
7
.1
7
7
.3
7
7
.9
3
247
Fig.VI.46. 1HNMR of PS62X1
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in MeOD
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A. Proton numbering and carbon lettering of PEG2000-Salbu
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Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in MeOD
B. 1HNMR of purified PEG2000-Salbu
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C. HMQC NMR of purified PEG2000-Salbu
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Spectra acquired on a Bruker AV(III)400 spectrometer in MeOD
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D. HMBC NMR of purified PEG2000-Salbu
Spectra acquired on a Bruker AV(III)400 spectrometer in MeOD
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Fig.VI.47. NMR analysis of purified PEG2000-salbutamol ester
The integration values were defined such as the sum of the proton signals for PEG Į carbon (PEG-CH2-CO-O-) was 4 H. The following signals were identified
as such protons:
-Position 2 (0.90 H) was a signal for unconjugated PEG, it is correlated to an Į carbon at 69.14 ppm (B) and in HMBC, to a carbonyl at 174.90ppm
(E).
-Position 2 (2.31 H) and 2 (0.40 H) were signals for PEG conjugated to the primary hydroxyl group of salbutamol. The signals for the PEG Į carbon
(PEG-CH2-CO-O-Salbu) were respectively at 68.00 ppm (B) and 67.83 ppm (B). The corresponding carbonyl signals were measured in HMBC at 170.96
ppm (E) and 170.41 ppm (E). This carbonyl signals were also correlated to salbutamol protons in position 3, next to the primary hydroxyl group.
-Position 2 (0.40 H) was a signal for PEG conjugated to the secondary hydroxyl group of salbutamol. The signal for the PEG Į carbon (PEG-CH2-CO-
O-Salbu) was at 67.83 ppm (B), and the corresponding carbonyl signal was measured in HMBC at 169.51 ppm (E), consistent with an ester. This carbonyl
signal was not correlated with any salbutamol proton signal, making the site of esterification more difficult to identify.
The salbutamol signal in position 4 (0.23 H) was conjugated to a carbon signal at 64.25 ppm (D). This signal shares only one carbon signal in HMBC with the
proton in position 3: F at 148.55 ppm, which was dramatically shifted compared to F (127.88 ppm), correlated to the signals in positions 3 and 4.
The integral values of the proton signal in position 4 (0.23 H) was half of these of 2 and 2 (0.40 H), confirming the proposed structure.
253
Fig.VI.48. 1HNMR of purified PEG3400-salbutamol ester
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in MeOD
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Fig.VI.49. 1HNMR of purified mPEG2000-salbutamol ester
Spectrum acquired on a Bruker AV(III)400 spectrometer, 16 scans, in MeOD
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Appendix 5. Supplementary information for PEG-prednisolone HPLC-UV
calibration solutions
Table. VI.1.Calibration solution preparation for PP28
Solution
Volume of
Pred stock
Volume of
PP28 stock
Volume of
methanol
[Conjugate] [Prednisolone]
ȝL ȝL ȝL mM mM
Pred-
PP28 TA
64 64 172 6.83 6.40
Solution
Volume of Pred-PP28 TA
Volume of
methanol
[Conjugate] [Prednisolone]
ȝL ȝL mM mM
Pred-
PP28 T1
64 336 1.09 1.02
Solution
Volume of
standard
Volume of
methanol
[Conjugate] [Prednisolone]
ȝL ȝL ȝM ȝM
Pred-PP28 T2 200 ȝL of T1 200 546.02 511.94
Pred-PP28 T3 200 ȝL of T2 200 273.01 255.97
Pred-PP28 T4 200 ȝL of T3 200 136.50 127.98
Pred-PP28 T5 200 ȝL of T4 200 68.25 63.99
Pred-PP28 T6 200 ȝL of T5 200 34.13 32.00
Pred-PP28 T7 200 ȝL of T6 200 17.06 16.00
Pred-PP28 T8 200 ȝL of T7 200 8.53 8.00
Pred-PP28 T9 200 ȝL of T8 200 4.27 4.00
Pred-PP28 T10 200 ȝL of T9 200 2.13 2.00
Pred-PP28 T11
200 ȝL of
T10
200 1.07 1.00
Pred-PP28 T12
200 ȝL of
T11
200 0.53 0.50
Pred-PP28 T13
200 ȝL of
T12
200 0.27 0.25
Pred-PP28 T14
200 ȝL of
T13
200 0.13 0.12
Pred-PP28 T15
200 ȝL of
T14
200 0.07 0.06
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Table. VI.2.Calibration solution preparation for PP29
Solution
Volume of
Pred stock
Volume of
PP29 stock
Volume of
methanol
[Conjugate] [Prednisolone]
ȝL ȝL ȝL mM mM
Pred-
PP29 RA
64 64 172 3.20 6.40
Solution
Volume of Pred-PP29 RA
Volume of
methanol
[conjugate] [Prednisolone]
ȝL ȝL mM mM
Pred-
PP29 R1
32 168 0.51 1.02
Solution
Volume of
standard
Volume of
methanol
[Conjugate] [Prednisolone]
ȝL ȝL ȝM ȝM
Pred-PP29 R2 200 ȝL of R1 200 256.07 511.94
Pred-PP29 R3 200 ȝL of R2 200 128.03 255.97
Pred-PP29 R4 200 ȝL of R3 200 64.02 127.98
Pred-PP29 R5 200 ȝL of R4 200 32.01 63.99
Pred-PP29 R6 200 ȝL of R5 200 16.00 32.00
Pred-PP29 R7 200 ȝL of R6 200 8.00 16.00
Pred-PP29 R8 200 ȝL of R7 200 4.00 8.00
Pred-PP29 R9 200 ȝL of R8 200 2.00 4.00
Pred-PP29 R10 200 ȝL of R9 200 1.00 2.00
Pred-PP29 R11
200 ȝL of
R10
200
0.50 1.00
Pred-PP29 R12
200 ȝL of
R11
200
0.25 0.50
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Table. VI.3.Calibration solution preparation for PP31
Solution
Volume of
Pred stock
Volume of
PP28 stock
Volume of
methanol
[Conjugate] [Prednisolone]
ȝL ȝL ȝL mM mM
Pred-
PP31 RA
64 64 172 3.20 6.40
Solution
Volume of Pred-PP31 RA
Volume of
methanol
[Conjugate] [Prednisolone]
ȝL ȝL mM mM
Pred-
PP31 R1
32 172 0.50 1.00
Solution
Volume of
standard
Volume of
methanol
[Conjugate] [Prednisolone]
ȝL ȝL ȝM ȝM
Pred-PP31 R2 200 ȝL of R1 200 250.94 501.90
Pred-PP31 R3 200 ȝL of R2 200 125.47 250.95
Pred-PP31 R4 200 ȝL of R3 200 62.73 125.48
Pred-PP31 R5 200 ȝL of R4 200 31.37 62.74
Pred-PP31 R6 200 ȝL of R5 200 15.68 31.37
Pred-PP31 R7 200 ȝL of R6 200 7.84 15.68
Pred-PP31 R8 200 ȝL of R7 200 3.92 7.84
Pred-PP31 R9 200 ȝL of R8 200 1.96 3.92
Appendix 6. Supplementary information for PEG-salbutamol calibration
solutions
Table. VI.4.Calibration solution preparation for salbutamol sulfate
Solution Volume of standard Volume of methanol [salbutamol]
ȝL ȝL ȝM
Salbu XA 50 ȝL of stock 450 3003
Salbu X1 100 ȝL of XA 300 750.8
Salbu X2 200 ȝL of X1 200 375.4
Salbu X3 200 ȝL of X2 200 187.7
Salbu X4 200 ȝL of X3 200 93.8
Salbu X5 200 ȝL of X4 200 46.9
Salbu X6 200 ȝL of X5 200 23.5
Salbu X7 200 ȝL of X6 200 11.7
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Salbu X8 200 ȝL of X7 200 5.9
Table. VI.5.Calibration solution preparation for PS57
Solution
Volume of
salbu stock
Volume of
PS57 stock
Volume of
methanol
[conjugate] [salbutamol]
ȝL ȝL ȝL ȝM ȝM
Salbu-
PS57 QA
50 50 400 3532 3003
Solution
Volume of
standard
Volume of
methanol
[conjugate] [salbutamol]
ȝL ȝL ȝM ȝM
Salbu-PS57 Q1 100 ʅL of QA 400 706.5 600.6
Salbu-PS57 Q2 200 ȝL of Q1 200 353.2 300.3
Salbu-PS57 Q3 200 ȝL of Q2 200 176.6 150.2
Salbu-PS57 Q4 200 ȝL of Q3 200 88.3 75.1
Salbu-PS57 Q5 200 ȝL of Q4 200 44.2 37.5
Salbu-PS57 Q6 200 ȝL of Q5 200 22.1 18.8
Salbu-PS57 Q7 200 ȝL of Q6 200 11.0 9.4
Salbu-PS57 Q8 200 ȝL of Q7 200 5.5 4.7
Table. VI.6.Calibration solution preparation for PS60
Solution
Volume of standard Volume of methanol [conjugate]
ȝL ȝL ȝM
PS60 WA 50 ȝL of stock 450 1875
PS60 W1 100 ȝL of WA 300 468.8
PS60 W2 200 ȝL of W1 200 234.4
PS60 W3 200 ȝL of W2 200 117.2
PS60 W4 200 ȝL of W3 200 58.6
PS60 W5 200 ȝL of W4 200 29.3
PS60 W6 200 ȝL of W5 200 14.6
PS60 W7 200 ȝL of W6 200 7.3
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Appendix 7. Supplementary information for PEG-prednisolone in vitro
hydrolysis study
Fig.VI.50. Hydrolysis profile of PP28 (mPEG2000-Pred) at pH 6.2
Fig.VI.51. Hydrolysis profile of PP28 (mPEG2000-Pred) at pH 8.0
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Fig.VI.52. Plot of ln[PP29] vs time at pH 7.4
Logarithm transformation and linear regression performed with Excel
Appendix 8. Supplementary information for hydrolysis with Calu-3
Fig.VI.53. Cell culture plate (A) and medium after hydrolysis test in the presence
(B) or not (C) of cells
At the end of the experiments (III.3.4), the
medium were pooled together and
collected in 7 mL tubes (B and C). The
difference in colour indicated a lower pH in
the medium that contained the cells.
(A)
(B) (C)
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Appendix 9. Supplementary information for IPRL ex vivo methods
Table. VI.7.Perfusate composition: Krebs-Ringer bicarbonate buffer
Solute mM Solute mM
NaCl 118.0 KH2PO4 1.2
KCl 4.7 HEPES 12.5
CaCl2 2.5 Glucose 5.0
MgSO4 1.2 BSA, fraction V 0.3 (2%)
NaHCO3 24.9
BSA: Bovine Serum Albumin, HEPES: Hydroxyethyl Piperazineethanesulfonic acid
(VI.1) Equations used to model the fate of prednisolone in IPRL experiments,
using Berkeley Madonna terminology
a. Prednisolone݇௜௡ = ܦ݋ݏ݁ܦݑݎܽݐ݅݋݊ ȉ (1െ ݏݐ݁݌ (1,ܦݑݎܽݐ݅݋݊))݀ܲݎ݁݀௟݀ݐ = +݇௜௡ െ ݇௢௨௧ ȉ ܲݎ݁݀௟݀ܲݎ݁݀௣݀ݐ = + ݇௢௨௧ ȉ ܲݎ݁݀௟
kin (nmol.min
-1
) is the 0 order constant of prednisolone administration in the lung, Dose
(nmol) is the total administered dose, Duration (min) is the administration time, Predl (nmol)
is the amount of prednisolone in the lung, Predp (nmol) is the cumulative amount of
prednisolone in perfusate, kout (min
-1
) is the 1
st
order constant of prednisolone permeability
from the lung.
b. mPEG-Pred1݇௜௡ = ܦ݋ݏ݁ܦݑݎܽݐ݅݋݊ ȉ (1െ ݏݐ݁݌ (1,ܦݑݎܽݐ݅݋݊))݀ܲܲ1௟݀ݐ = +݇௜௡ െ ݇ଵ ȉ ܲܲ1௟݀ܲݎ݁݀௟݀ݐ = + ݇ଵ ȉ ܲܲ1௟ െ ݇௢௨௧ ȉ ܲݎ݁݀௟݀ܲݎ݁݀௣݀ݐ = + ݇௢௨௧ ȉ ܲݎ݁݀௟
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kin (nmol.min
-1
) is the 0 order constant of prednisolone administration in the lung, Dose
(nmol) is the total administered dose, Duration (min) is the administration time, PP1l (nmol)
is the amount of conjugate in the lung, k1 (min
-1
) is the first order rate constant of the
conjugate hydrolysis, Predl (nmol) is the amount of prednisolone in the lung, Predp (nmol)
is the cumulative amount of prednisolone in perfusate, kout (min
-1
) is the 1
st
order constant
of prednisolone permeability from the lung.
c. PEG-Pred2݇௜௡ = ܦ݋ݏ݁ܦݑݎܽݐ݅݋݊ ȉ (1െ ݏݐ݁݌ (1,ܦݑݎܽݐ݅݋݊))݀ܲܲ2௟݀ݐ = +݇௜௡ െ ݇ଶ ȉ ܲܲ2௟݀ܲݎ݁݀௟݀ݐ = + 2 ݇ଶ ȉ ܲܲ2௟ െ ݇௢௨௧ ȉ ܲݎ݁݀௟݀ܲݎ݁݀௣݀ݐ = + ݇௢௨௧ ȉ ܲݎ݁݀௟
kin (nmol.min
-1
) is the 0 order constant of prednisolone administration in the lung, Dose
(nmol) is the total administered dose, Duration (min) is the administration time, PP2l (nmol)
is the amount of conjugate in the lung, k2 (min
-1
) is the first order rate constant of the
conjugate hydrolysis, Predl (nmol) is the amount of prednisolone in the lung, Predp (nmol)
is the cumulative amount of prednisolone in perfusate, kout (min
-1
) is the 1
st
order constant
of prednisolone permeability from the lung.
263
Appendix 10. Supplementary information for IPRL ex vivo results
A. Prednisolone
B. Dexamethasone
264
C. mPEG2000-Pred
D. PEG2000-Pred2
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Fig.VI.54. Chromatogram of LC-MS/MS analysis of prednisolone,
dexamethasone, mPEG-Pred1, PEG-Pred2, mPEGCOOH, PEGCOOH2
F. PEG2000-COOH2
E. mPEG2000-COOH
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Fig.VI.55. Fraction of prednisolone in perfusate for prednisolone, mPEG-Pred,
PEG-Pred2
Each individual measured concentration (nmol.L
-1
) was divided by the total dose
administered during the experiment (nmol) to give relative fractions of prednisolone in
perfusate (L
-1
)
Table. VI.8.Determination of prednisolone absorption rate from the lung using
Berkeley Madonna
INPUT OUTPUT
Experiment Dose nmol
infusion time
(min)
kout
(min
-1
)
t1/2
(min)
Pred RA 153.45 2.9 0.504007 1.375273
Pred RB 93.83 1.6 0.52691 1.315494
Pred RC 72.04 1.9 0.423745 1.635765
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A.
268
B.
269
Fig.VI.56. Cumulative plots of prednisolone in perfusate for prednisolone (A),
mPEG-Pred1 (B), PEG-Pred2 (C) IPRL experiments
C.
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